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1 Introduction
Each piece, or part, of the whole of nature is always merely an approximation to
the complete truth, or the complete truth so far as we know it. In fact,
everything we know is only some kind of approximation, because we know that
we do not know all the laws as yet. Therefore, things must be learned only to
be unlearned again or, more likely, to be corrected. ... The test of all knowledge
is experiment. Experiment is the sole judge of scientific "truth".
Richard Feynman, Lectures on Physics (1964)
Nano- (from Ancient Greek νανoς – dwarf) technology enables designing and
assembling matter on atomic, molecular, and supramolecular scale, i.e. on the
dimensions ranging from 1 to 100 nanometers (10−9 meters, nm). Nowadays it
embraces a broad area of scientific research and industrial application in many
fields, starting from material development for space research [1] to cosmetics and
sunscreens [2].
The fundamental concepts of nanotechnology were first discussed in 1959 by
Nobel laureate physicist Richard Feynman in his talk "Plenty of Room at the
Bottom" [3], where he described the possibility of direct manipulation of atoms
for synthesis of matter. Fifteen years later, the term "nano-technology" was first
used by Norio Taniguchi of the Tokyo University of Science in 1974 in his paper
"On the Basic Concept of ’Nano-Technology’" [4].
The use of nanotechnology-based techniques for medical purposes, i.e. nano-
medicine, has great potential in terms of curing some world-threatening diseases
such as Alzheimer’s, Parkinson’s disease, atherosclerosis, etc., fighting multi-
ple types of cancer, and preventing infectious disease through developing novel
nanoparticles-based vaccines. In addition, the emerging field in nanomedicine,
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called "theranostics", can help to simplify many medical treatment procedures by
combining diagnostics and therapeutics in a single nanoparticulate agent. More-
over, nanomedicine is now being developed towards cell medicine, i.e. treating
and manipulating at the level of cells, subcellular compartments, and even single
molecules, thereby helping to drastically decrease the side effects of drugs, reduce
their dosage, and make medical procedures more individual-oriented.
Many diverse nanoscale structures for biomedical applications like liposomes,
dendrimers, polyplexes, conjugates, organic, inorganic, and metallic nanoparticles
[5] have been designed. By tailoring their physical and chemical features such as
size, shape, composition, surface charge, and functionalization, these structures
can have different biological functions and can be used for various purposes such
as in vitro and in vivo diagnostics, targeting and eliminating cancer cells, delivery
of therapeutic molecules inside the cells, activation of the immune system, etc.
This work deals with the synthesis, characterization, and biomedical applica-
tion of functionalized calcium phosphate nanoparticles. After being loaded with
various molecules of biological and synthetic origin, these synthesized nanopar-
ticles were tested as transport system for crossing the cell membrane barrier.
The primary focus of research was to study the cellular uptake of cargo-loaded
nanoparticles for drug delivery as well as for application as a potential vaccination
tool.
2
2 Theoretical background
2.1 Nanotechnology and nanomedicine
Nanotechnology-based techniques offer immense development opportunities for
various fields, of medicine such as pharmaceutics [6], treatment of cancer [7], in
vivo imaging and diagnostics [8,9], material for implants [10], tissue regeneration
[11], cell medicine [12], and gene therapy [13,14].
Nanomedicine can be described as the application of nanoscaled or nanostruc-
tured materials that are in size at least one dimension below 300 nm [15] for
medical or biomedical purposes. However, many earlier definitions used 100 nm
as the upper limit [16], based on the fact that quantum effects were often re-
stricted to this dimension limit [17,18]. Special physicochemical properties were
shown for nanoparticles larger than 100 nm, e.g. the plasmon-resonance in gold
nanoshells with a diameter of 150 nm, which are currently under clinical trials
for anticancer thermal therapy [19]. In the pharmaceutical and biomedical areas,
the term "nano" is not restricted to 100 nm and a number of biological effects
were obtained with particles having a size of 100-400 nm. For example, at the
tissue level, liposomes up to 200 nm in diameter remain longer in bloodstream
than those with a diameter of 70 nm [20]. Besides, the passive tumor target-
ing through the enhanced permeability and retention (EPR) effect was shown
for the particles within 100-200 nm range, and even for 400 nm particles, the
accumulation in tumor tissue was demonstrated [21]. As to the cellular uptake,
many particle properties play an important role [22], but size is a key factor. For
example, cells with no phagocytic activity are able to internalize nanoparticles up
to 200 nm in diameter [23–25]. Hardy et al. reported that a size of 50 nm is
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optimal for a high uptake efficiency [25], whereas macrophages can phagocytose
particles up to 500 nm in diameter [26].
Nanomedicine uses benefits of two general phenomena that occur at the nanosca-
le: transition in physicochemical properties and transition in physiological prop-
erties [15]. To these transition phenomena belong the high ratio of surface area
to volume as well as tunable optical, electrical, magnetic, mechanical, chemi-
cal [27–29], and biological properties. Many (if not all) biochemical processes
in living cells naturally occur at the nanoscale. For example, the oxygen-carrier
protein hemoglobin is 5.5 nm in diameter and a strand of DNA is only about
2 nm in width [27].
Table 2.1 Some examples of application of nanoparticles in medicine.
Nanoparticles Examples Application in medicine
Metallic Gold, silver, titan, iron,platinum
Thermal anticancer treatment,
MRI contrast, in vitro diagnostics
Quantum dots CdSe, CdS, CdS/ZnS Fluorescent contrast, in vitrodiagnostics
Inorganic
Silica, calcium
phosphate, barium
sulfate
Drug and gene delivery, in vivo
imaging, vaccination, X-ray
contrast agent, bone cement
additives
Carbon nano-
structures
Fullerenes, graphene,
single- and multi-wall
nanotubes,
nanodiamonds
Increasing imaging facility of
magnetic resonance (MR),
improving imaging-based
diagnosis
Polymer-based
Hydrogels, dendrimers,
nanofibers,
polymersomes
Drug and gene delivery,
anticancer treatment, antiviral
treatment
Lipid-based
vehicles
Liposmes, micelles,
solid lipid nanoparticles
Drug and gene delivery,
anticancer treatment
Nanoparticles for medical application come in a great variety [5]. They include
metallic nanoparticles [30–33], quantum dots, inorganic nanoparticles [34–37],
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carbon nanostructures [38–47], polymer-based nanoparticles [48–60], and lipid-
based vehicles [6, 61, 62]. Some prominent examples of their application in
medicine are summarized in Table 2.1.
2.1.1 Gene therapy and drug delivery with nanoparticles
One of the most promising areas of application of nanoparticles is drug delivery
and gene therapy. These techniques are generally associated with the elimina-
tion of malignant tissues and fighting widespread neurodegenerative diseases.
Nanoparticles of different kinds can help medical science to overcome these dis-
orders in human body [63], for example, by delivering some vital genes into the
cells, where these genes are inactive or absent, in the form of plasmid DNA
(pDNA). Since unprotected DNA is not able to penetrate the cell membrane and
is degraded either inside or outside the cell by nucleases, a delivery agent in the
form of nanoparticles (calcium phosphate, gold) [64–68], viral agents (retrovirus-
or adenovirus-based) [69, 70], liposomes/micells [71], or cationic polyelectrolyte
(polyethylenimine) [72–75] is needed [76].
In contrast, when some genes are overexpressed in a particular cell type or
tissue, this can also lead to serious disorders in the human body (acquired or
inherited diseases), including the development of cancer. As a result, the so-
called "gene silencing" technique is used to "silence" particular genes in terms of
protein production [77–83]. This method is similar to gene delivery, whereas the
delivered cargo is small RNA molecules, either small interfering RNA (siRNA) or
microRNA. These RNAs interfere with double-stranded RNA (dsRNA) that carries
information about the synthesis of specific protein, thus blocking the transcription
process in cytoplasm [76].
Functionalized nanoparticles are key players in the field of drug and vaccine
delivery [84–86], because they can significantly enhance the delivery efficacy,
thus dramatically decreasing overall drug toxicity [87, 88]. This can permit the
application of potentially comparable toxic drugs or compounds that are not
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able to penetrate some biological barriers. A combinational approach of using
nanomedicine with traditional clinical therapies can bring us a step forward re-
garding, e.g. the treatment of cancer. Recent studies of timed combination the-
rapy on animals where siRNA and an anticancer drug were released sequentially
from liposomal nanoparticles may help to reveal the mechanisms to overcome
chemoresistance [89].
2.1.2 Potential risks
Over the last two decades, nanotoxicologists have been studying the influence
of nanomaterials on single cell up to the whole organism. It has been found
that interactions between nanomaterials, cells, animals, humans, and the envi-
ronment are remarkably complex. The toxicity of nanoparticles can be defined as
the ability of the nanoscaled structures to adversely affect the normal physiology
and structure of tissues and organs in humans and animals [90]. It is thought
that toxicity depends on such physicochemical parameters of the nanoparticles
as particle size, shape, surface charge, chemical composition, biodegradability,
as well as clinical parameters like application routes, nanoparticle concentration
or duration of exposure [90, 91]. Recent studies suggest that cytotoxic effect is
related to the development of oxidative stress and pro-inflammatory gene activa-
tion in exposed cells and tissues, as well as the subsequent damage to proteins,
membranes and DNA [91–95]. For instance, the pro-inflammatory effect was
observed after the exposure of human endothelial cells to cobalt, silicon diox-
ide, and titanium dioxide nanoparticles through enhanced production of the IL-8
cytokine [91]. However, the exact mechanisms are yet unknown.
The adverse effects of exposure to nanoparticles are likely associated with
a range of acute and chronic effects, including inflammation, exacerbation of
asthma, metal fume fever, fibrosis, chronic inflammatory lung diseases, or car-
cinogenesis. [96–98].
Extensive research and ongoing debates on the regulation of nanomaterials are
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happening across the world [88,99,100]. The Joint Research Centre of European
Commission considers this issue at the European level [101]:
"Nanotechnology is a key enabling technology and has great potential for ad-
dressing societal challenges including energy supply and health care. Nonetheless,
the use of nanomaterials also raises safety concerns, which need to be addressed
in a Europe-wide regulatory context. ...In the past years, many new nanomaterial-
related applications have been developed. Those include a number of consumer
products such as UV-filters in sun creams and anti-odor textiles. However, many
medical and technical applications such as tumor therapies, lithium-ion batteries
for driving electric cars, or solar panels also exist. Those applications have the
potential to create major technological breakthroughs, and therefore nanomate-
rials have been identified as a key enabling technology. Products underpinned
by nanotechnology are forecast to grow from a global volume of 200€ billion in
2009 to 2€ trillion by 2015." [102]
Thus, as government and business communities continue to invest heavily in
nanotechnology, the potential toxicological effect of the developed nanomaterials
need also to be explored. Besides, nanotechnology has a lot to offer to the field
of human healthcare and medicine, improving diagnostics and paving the way to
regenerative medicine. It can provide qualitative and personalized healthcare and
yet make it more affordable.
2.2 Calcium phosphate nanoparticles
2.2.1 Hydroxyapatite
Hydroxyapatite (HAP) is the main mineral component of biological hard tis-
sues, like bone (65-70%) [103], dentin (70%) and enamel (97%) [103–106].
HAP is a mineral belonging to the family of apatites, whose general formula
is M5(ZO4)3X, where M represents an ion of rare-earth metal (Ca2+, Cd2+, Sr2+,
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Ba2+, Mg2+, Pb2+ or Zn2+); ZO4 is PO3−4 , CO2−3 or SO2−4 ; and X is OH−, F−,
Cl− or CO2−
3
[107]. HAP is, thus, described by the formula Ca10(PO4)6(OH)2 or
in a reduced form as Ca5(PO4)3OH [107, 108]. HAP is the most stable calcium
phosphate (CaP) compound in the pH range from 4.2-12.4 [107,108]. However,
in biological tissues such as human bone, HAP can undergo an extensive sub-
stitution of ions, for example (Ca, X)5(PO4 Y)3(OH, Z), where X: Na2+, Mg2+,
K+, Sr2+ and others; Y: CO2−
3
or HPO2−
3
; and Z: Cl− or F− [107,108]. As a ce-
ramic material HAP represents a chemical compound with a mixture of ionic and
covalent bonds. Depending on the stoichiometry, pH value, temperature, and
other conditions, CaP can form different phases with specific configurations and
properties [107, 108], ranging from the most water soluble monocalcium phos-
phate monohydrate (Ca(H2PO4)2·H2O) with a Ca/P ratio of 0.5, through HAP
with a Ca/P ratio of 1.67 and with the lowest water solubility, to tetracalcium
phosphate (Ca4(PO4)2O) with a Ca/P ratio of 2.0 [103].
2.2.2 Synthesis of calcium phosphate nanoparticles
There are numerous methods of synthesis of CaP particles, including reactions in
solid state [109–112], continuous precipitation from solution [113–116], hydro-
thermal processing [117, 118], electrospraying [119], electrospining [120], ultra-
sound [121], plasma deposition [122], and many others [107]. The method of
wet chemical precipitation, described previously by Sokolova et al. [123], was
used in this work to obtain the CaP core of the nanoparticles. It is a widely
used method due to its simplicity and inexpensiveness [124,125], and it involves
a rather simple reaction of precipitation of CaP nanoparticles from solutions
containing the Ca2+ and PO3−
4
salts Ca(NO3)2 and (NH4)2HPO4, respectively.
The cargo molecules (e.g. oligonucleotides and proteins), which are dissolved in
water are added subsequently to the nanoparticles’ dispersion and are adsorbed
onto the particles’ surface non-covalently due to hydrophobic or van der Waals
forces [107], as well as electrostatic interaction (Figure 2.1). Afterwards, the
8
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solution of Ca2+ and PO3−
4
containing precursors are added to form another shell
of CaP and finally the nanoparticles are stabilized with polyelectrolyte molecules
such as oligonucleotides.
Figure 2.1 The scheme of synthesis of multi-shell calcium phosphate
nanoparticles.
HAP forms sparingly soluble salt crystals in neutral and alkaline aqueous so-
lutions and is well soluble in acidic environment. The precipitation of these
crystals can occur in different morphologies (spherical, rod-like, filaments, plate-
or needle-shape particles) [126–131]. Therefore, the modulation of interaction
between growing inorganic particles, as well as their morphology by electrostatic
and steric interactions is strongly desired. For this purpose, the zeta potential of
colloidal nanoparticles can be modified by functionalizing the nanoparticles with
different cationic and anionic polyelectrolytes (Figure 2.2).
A hydrated layer comprising relatively mobile ions is assumed to be present
9
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on the surface of the nanoparticles in the dispersion. The composition of this
layer depends on the pH value of the solution as well as the ionic content of the
medium. The ratio of Ca2+ to PO3−
4
ions in the solution is also important as it
triggers the precipitation of a specific phase combination [107].
Figure 2.2 Different polyelectrolytes to functionalize and stabilize calcium phos-
phate nanoparticles in dispersion.
2.2.3 Calcium phosphate nanoparticles as a colloid system
The synthesized CaP nanoparticles are present in aqueous dispersion, thereby
forming a colloid dispersion. In colloids, particles continuously experience the in-
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fluence of Brownian motion, gravity, convection, and other forces. If two particles
are brought together too closely, they attract to each other due to the van der
Waals forces. In the absence of repulsion counterforce, the particles will collide
and form the agglomerates, which results in destabilization of the colloidal sys-
tem and the eventual sedimentation of the particles from the solution. Hence,
to achieve stable colloid dispersions, the forces of repulsion and attraction should
be balanced.
There are two mechanisms that counteract the van der Waals forces of at-
traction in colloids: electrostatic and polymeric stabilization. Owing to the first
mechanism, the attraction of the particles is balanced by the Coulomb force of
electrostatic repulsion of the electrical double-layer of the particles with the same
charge [132,133].
The electrical double layer is a layer of oppositely charged ions from the dis-
persion medium surrounding the particle (Figure 2.3). The electrical double layer
has no charge (electrically neutral). This layer comprises the following parts: the
surface charge is presented by the charged ions of the particles on its surface;
the stern layer is the layer of the counter ions from the dispersion medium that
are closely attached to the surface of the nanoparticles by the electrostatic force;
the diffuse layer is a film of the solvent molecules that immediately surrounds the
particle and contains free ions, mostly of the opposite charge (these ions are also
affected by the electrostatic force of the charged particle but to a much lower
extent); the slipping plane (or shear plane) is the outer boundary of the layer that
remains along with the moving in the medium particle.
The electric potential (zeta potential) of the double layer has its maximum on
the surface plane and then drops exponentially with the increase in the distance
from the particle surface (Figure 2.3) reaching zero in the bulk solution. The
zeta potential of the particles in the dispersion is measured on the stern plane.
The mechanism of electrostatic balance between the electrical double-layer of
the particles and the van der Waals attraction force is described by the DLVO
11
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Figure 2.3 The structure of electrical double-layer of a particle in the colloid.
theory which was developed in the 1940s by Derjaguin, Landau, Verwey, and
Overbeek. There are, however, some assumptions that need to be considered
while applying this theory: 1) the dispersion is dilute; 2) the electrical charge
and other properties are uniformly distributed over the surface of the particles;
3) only van der Waals and electrostatic forces act on the dispersed particles;
4) the distribution on the ions in the dispersion is determined by Brownian motion,
electrostatic force, and entropic dispersion [132].
The DLVO theory states that the colloidal stability of the particles is determined
by the total energy (GT ) of interaction between two particles, represented by the
sum of the energy of attractive interaction because of van der Waals forces (GA)
and repulsive electrostatic energy (GR):
GT = GA + GR
For the spherical particles, van der Waals potential energy (GA) and repulsive
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electrostatic potential energy (GR) values are calculated as follows:
GA =
−Ar
12x
with A: Hamaker constant; r : radius of the particles; x : distance between the
surfaces of two particles.
GR = 2pi""0rζ2e−kx
with ": dielectric constant of the solvent; "0: vacuum permittivity; ζ: zeta
potential; k : a function of the ionic concentration (k−1 is the characteristic
thickness of the electric double layer, Debye length).
Figure 2.4 The mechanism of the DLVO theory.
The potential energy of interaction between two spherical particles is depicted
and described in Figure 2.4. GR decays exponentially with increasing distance,
approaching zero at large x , whereas GA shows inverse power law and tends to
zero. The GT curve shows two minima and one maximum peaks. The maximum
peak (Gmax) refers to the energy maximum barrier and is dependent on the
13
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zeta potential, the electrolyte concentration, and the ion charge [133]. This
maximum barrier has to be much larger than the thermal energy of the particles
in order to obtain a stable colloid. This is achieved by a high zeta potential
(>40 mV) and a low electrolyte concentration (<10−2 mol L−1). The primary
minimum corresponds to the distance by which the particles undergo coagulation
when they are able to overcome the energy barrier (Gmax) [133]. The secondary
minimum corresponds to the distance between two particles where they are in
a stable equilibrium and may undergo a loose aggregation but can be easily
redispersed [132].
Polymeric stabilization of colloids involves the addition of the polymer molecules
to the dispersion in order to prevent the particle’s agglomeration. This occurs due
to the repulsive force created by polymeric molecules that counteract the attrac-
tive van der Waals forces between two particles. The polymeric stabilization can
be performed in two ways: by steric stabilization, where the polymer molecules
are directly attached to the particle surface and form a coating that creates a
repulsive force and separates the particles from one another, and by depletion sta-
bilization, which involves dissolved (free) polymeric molecules in the dispersion
medium, creating repulsive forces between nearing particles (Figure 2.5) [132].
Figure 2.5 Polymeric stabilization of colloids.
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2.2.4 Application in bio- and nanomedicine
Materials from CaP are widely used in medicine for substituting damaged or
impaired hard tissues. However, the application of CaP is not limited to this.
For example, it is used in chromatography for separating of proteins and DNA
[134,135]. Colloidal CaP was shown to stabilize casein micelles in milk [136]. It
has also been used as a nutrition supplement, a growth and fertilization agent
in the food and agricultural industry [137]. But with the developments in the
field of nanomedicine, CaP as a form of colloidally stabilized nanoparticles has
drawn big attention as a potential agent for drug delivery, in vivo imaging, gene
therapy, vaccination, etc. Additionally, there are several other reasons why CaP
nanoparticles (NPs) have such potential:
• The synthesis is scalable, easy, time-saving, and inexpensive. The encapsu-
lation of various components of synthetic and biological nature is possible.
The binding affinity to DNA molecules was shown [138].
• The synthesis is performed under ambient conditions. Various morphologies
and sizes of the NPs can be obtained [139–142].
• The active compounds are protected inside the multi-shell structure of the
NPs [64].
• The NPs can penetrate the cell membrane and, are thus able to deliver
molecules across the membrane barrier [12,143].
• The material is non-toxic. The degradation of CaP NPs occurs in lysosomes
under low pH and does not produce any toxic components. The over-
concentrated Ca2+ ions are pumped out of the cell through ion channels
[144].
• Good biocompatibility. Compounds of CaP NPs are naturally found in
biological hard tissues (bone, dentin, and enamel) in amorphous and crystal
phases. It is not a foreign compound in living cells and the human body in
general. The human blood contains Ca2+ and PO3−
4
ions in concentrations
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1-5 mM [103,107].
• NPs are stable in blood and other biological solutions where pH>6. They
are not prone to enzymatic degradation [103].
• Good storage abilities (in colloidal form for two weeks under 4 ◦C, in
lyophilized form for many months).
The main drawback of using CaP nanoparticles in vivo is, however, the risk
of possible atherosclerotic complications associated with undesirable sediments
along the arterial walls [145,146].
Nonetheless, examples of CaP nanoparticles application for bio- and nano-
medicine include the following: encapsulation of antibiotics gatifloxacine [147],
ciprofloxacin [148], as well as gentamicin and vancomycin [149]; loading with
DNA, encoded vascular endothelial growth factor (VEGF-A) and protein BMP-7
for induction of the new bone and vascular tissues formation [150]; encapsulating
immunostimulatory molecules and viral peptides to stimulate specific antiviral
immune responses [151–154].
2.3 The mechanism of nanoparticle uptake by
cells
2.3.1 Plasma membrane
The cell membrane is a crucial structure of a living cell. The plasma membrane
in eukaryotic cells is a thin interface that encloses the cell and maintains the
essential differences between the cytosol and the extracellular environment. The
plasma membrane consists of a lipid bilayer (about 5 nm thick [155]), mostly of
phospholipids (phosphoglycerides and sphingomyelin), cholesterol, and membrane
proteins. The organization of this film is mostly due to a non-covalent interaction
between the lipid molecules. The lipid bilayer provides the membrane with its fluid
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structure and relatively impermeable barrier function for water-soluble molecules
while proteins provide the rigidness to the structure. The fluidity of the membrane
is directly dependent on its composition and the temperature (the higher the
temperature, the more fluid the membrane becomes). Cholesterol and proteins,
on the contrary, can modulate the stability and permeability in the specific place
of the membrane. When a molecule of cholesterol is inserted near the backbone
of a phospholipid, it decreases the permeability of this region of the membrane
through the decreasing mobility of the first CH2-groups of the phospholipid. Thus,
the lipid bilayer becomes more rigid and less permeable for small water-soluble
molecules.
Membrane proteins play more than a structural role. They are responsible for
transporting specific molecules across the membrane (ion channels and receptor-
mediated endocytosis), membrane-associated enzymatic processes (e.g. synthesis
of ATP), and interconnection of membrane body with the cytoskeleton inside the
cell (lipoproteins, G proteins). They also function as transmembrane receptors
for different regulative molecules, hormones, and cytokines, through which the
cellular metabolism and gene machinery are orchestrated.
Another important property of the plasma membrane is asymmetry. First of
all, this refers to the lipid composition. The outer monolayer comprises mostly
choline-bearing phospholipids that carry overall neutral charge. In the inner mono-
layer, the phospholipids containing terminal primary amino groups, the phosphate
moieties, and the carboxy groups with overall negative charge are located. As
a result, there is significant difference in the charge between two monolayers in
the membrane. In the live cells, this asymmetry is constantly maintained and
serves as an indicator for live cells in the animal or human body [155]. A more
extreme asymmetry is observed in the glycosylation of lipids and membrane pro-
teins. These glycosylated molecules are almost exclusively presented in the outer
monolayer, thus forming the negatively charged network of proteoglycans, glyco-
proteins, and glycolipids [156]. Denoted as glycocalyx, this network covers the
whole surface of the living cell and functions in cell-cell recognition, communica-
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tion, and interaction [157].
2.3.2 Mechanisms of endocytosis
Being a dynamic structure, the plasma membrane not only segregates the inner
milieu of the cell from the extracellular environment, but also provides the selec-
tive transport of small and large molecules between the cytosol and extracellular
compartments. Ions and small molecules such as amino acids, sugars, small signal
molecules and water can traverse the membrane through channels or by means
of special membrane transport proteins. Macromolecules can be internalized only
inside the membrane-bound vesicles derived by invagination and pinching off the
pieces of plasma membrane. This process is called "endocytosis" [158].
Endocytosis can be accomplished by various mechanisms, depending on the
cell type and the internalized cargo [153, 159]. Typically, the mechanisms of
endocytosis are categorized in the following manner (Table 2.2).
Phagocytosis is generally restricted to specialized mammalian cells, while pinocy-
tosis occurs in all cell types in four major classes: macropinocytosis, clathrin-
mediated endocytosis (CME), caveolin-mediated endocytosis, and clathrin- and
caveolin-independent endocytosis. The endocytosis, performed in these five major
forms, plays a key role in such complex physiological and biochemical processes,
as antigen-presentation, hormone-mediated signal transduction, immune surveil-
lance, cellular metabolism, and homeostasis [158].
Phagocytosis is mainly conducted by specialized mammalian cells such as mono-
cytes, macrophages (MΦ), dendritic cells (DCs), and neutrophils. It is involved
in the clearance of pathogens, e.g. bacteria or fungi, as well as of necrotic cell
debris, apoptotic cells, [160] and foreign objects of comparable size (latex beads,
nanoparticles, etc.). This highly regulated process is activated through specific
cell-surface receptors such as the complement or phosphatidiylserine receptor that
recognizes damaged or dead cells, and through signaling cascades mediated by
Rho-family GTPases [161].
18
2.3 The mechanism of nanoparticle uptake by cells
Table 2.2 Morphological and molecular characteristics of endocytotic mech-
anisms. FPM: Fluid phase markers, GPI: Glycosylphosphatidylinisitol,
GPSR: G protein-coupled receptors, MHC: major histocompatibilty complex,
RTK: receptor tyrosine kinase, SV40: simian virus 40.
Mecha-
nism
Phago-
cytosis
Pinocytosis
Macro-
pino-
cytosis
Clathrin-
mediated
endocy-
tosis
Caveolin-
mediated
endocy-
tosis
Clathrin-
and
caveolin-
indipendent
Size of
cargo 1-5 µm >1 µm 120 nm 60 nm 90 nm
Impli-
cated
cargoes
Pathogens,
apoptotic
remnants
FPM,
RTK
RTK,
GPSR,
transferrin
receptor
GPI-linked
proteins,
SV40,
FPM,
GPI-linked
proteins,
cytokine
receptors,
MHC I
proteins,
proteoglycans,
CD59
Morpho-
logy
Cargo
shaped
Highly
ruﬄed Vesicular
Vesicular
/ tubulo-
vesicular
Tubular,
ring-like,
vesicular
Similarly to the phagocytosis, macropinocytosis is induced by Rho-family GTPas-
es, which trigger the formation of membrane protrusions by actin filaments. These
protrusions collapse onto and fuse with the cell membrane, unlike in phagocytosis.
This type of endocytosis is involved in the following events: cell migration [162],
immune surveillance [163], and uptake of some bacteria [164].
Caveolin-mediated endocytosis is performed through flask-shaped invaginations
of the membrane, called caveolae. These are usually formed in the cholesterol-
and sphingolipid-rich regions of the plasma membrane, where various membrane
transporters and signaling molecules are concentrated [165]. Caveolin is a dimeric
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protein that conducts the formation of the caveolae in the following way. It binds
to the cholesterol, inserts a loop into the inner leaflet of the membrane and
builds a caveolin coating by self-association on the surface of the membrane
invagination [158]. The most important processes that are regulated by this type
of endocytosis are lipid homeostasis (through intracellular cholesterol trafficking),
vasodilatation (through regulation of endothelial nitric oxide synthase) [165,166],
and transcellular transport (e.g. of serum albumin) [166].
Clathrin-mediated endocytosis is not cell type-specific and occurs in all mam-
malian cells, providing continuous uptake of nutrients such as iron-laden transfer-
rin and cholesterol-laden low-density lipoproteins [167, 168]. This type of endo-
cytosis is mediated through clathrin protein "triskelions", comprising three heavy
and three light chains. These clathrin triskelions assemble into a polygonal lattice
on the inner layer of the membrane. This deforms the overlying plasma membrane
into a vesicle-like form and finally pitches off the clathrin-coated vesicle [158].
Clathrin-mediated endocytosis was shown to be involved in numerous cellular
processes, namely intracellular communication during tissue and organ develop-
ment [169, 170], maintaining cell and serum homeostasis [158], controlling the
strength of synaptic transmission in neurons, which might have a role in learning
and memory [171], and efficient recycling of synaptic vesicle membrane proteins
after neurotransmission [172].
Clathrin- and caveolin-independent endocytosis refers to the internalization of
the macromolecules that are promoted by mechanisms other than those described
above. This was, for example, shown for lipid rafts (small structures of 40-50 nm
in diameter on the cell surface [158]). The internalization of IL-2 receptors on lym-
phocytes associated with lipid rafts or rapid endocytosis in neurons was detected
to perform in clathrin- and caveolin-independent manner [173,174]. Other mecha-
nisms of clathrin- and caveolin-independent endocytosis include Arf6-dependent,
Flotilin-dependent, Cdc42-dependent, and RhoA-dependent mechanisms [175].
In general it must be stated that the mechanisms of endocytosis are still poorly
understood and described.
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2.3.3 Internalization on the nanoparticles
With rising interest in nanomedicine in recent years, a lot of research has been
done to understand the internalization of nanoparticles for purposes like drug
delivery and imaging in vitro as well as in vivo [176–181]. It has been, however,
stated that such a complex process as endocytosis of nanoparticles cannot be
generalized: the efficiency and results of cellular uptake are clearly dependent
on the properties of both nanoparticles and cells [182]. Such physicochemical
parameters of nanoparticles like size, shape, geometry, surface charge, chemical
composition influence the uptake efficiency [175]. Some examples are summarized
in Table 2.3.
One should also notice that initially colloidally stable "small" nanoparticles will
often agglomerate in biological fluids such as cell culture media, supplemented
with calf serum, into "bigger" nano- or even submicroparticles, surrounded by
absorbed proteins ("protein corona") [183]. Hence, the cells in vitro and in
vivo are almost never exposed to the nanoparticles in the way they were initially
manufactured.
Nonetheless, some generalizing remarks can be made in terms of nanoparticle
size and charge. It was shown [184–186] that nanoparticles of 20-50 nm in diame-
ter are taken up faster and better by the cells than bigger particles. It is also gen-
erally believed that positively charged nanoparticles are better internalized by cells
due to the electrostatic interaction between the positive charge of nanoparticles
and the negative charge of the plasma membrane of the cells [153,159,187,188],
namely through interaction with heparan sulfate proteoglycans on the cell sur-
face [183, 189]. Nazarenus et al. describe in their work [183] main issues on the
nanoparticles internalization and the colloid-chemical parameters that strongly in-
fluence the cellular uptake of the nanoparticulate matter. The following summary
statement can be made based on this publication: small, charged, and elongated
nanoparticles are taken up better than big, neutral, and flat ones.
In contrast, the uptake efficiency is strongly influenced by cell-type, origin of
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cells, cell density, concentration of the nanoparticles, exposure scenarios, and the
presence of serum supplement in the cell medium [182, 183]. For the influence
of cell type, one can look at the two independent studies by Harush-Frenkel et
al. [190] and Zhang et al. [191] who tested positively and negatively charged
nanoparticles of equal size. In fact, the studies on HeLa cells showed a two times
more efficient uptake of positively charged nanoparticles [190].
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Table 2.3 Dependence of internalization results in vitro from physicochemical
parameters of applied nanomaterials.
Physico-
chemical
parameter
Description of the
particles
Results of the uptake Cell type
Geometry
Polystyrene, elliptic, size
1-10 µm
MΦ internalized particles fast when they were
attached to its sharper side, whereas attachment
from the dull side of the particle resulted in no
uptake at all
Alveolar
macrophages
(MΦ) [192,193]
Charge
PEG-co-PLA, anionic vs.
PEG-co-PLA +
stearylamine, cationic;
100 nm
Uptake of cationic NPs was better than anionic in
both cell types. MDCK cells used CME for both
NPs types: cationic NPs were routed to
transcytosis, anionic NPs to lysosomes. HeLa used
CME + caveolin-mediated endocytosis for anionic
NPs and CME + micropinositosys for cationic NPs
Fibroblasts and
epithelial cells
(polarized MDCK
and non-polarized
HeLa) [194–197]
Surface
modifica-
tions
Quantum dots (QD),
functionalized with
Transferrin (Tf) (50 nm), or
Shiga toxin (ST) (30 nm)
QD + Tf were internalized by CME, but they
resided in perinuclear endosomes. Tf alone was
taken up by CME but ended up in the lysosome.
QD + ST were internalized by and ended up in
endosomes. ST alone accumulated in the Golgi
apparatus
HeLa [198]
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Shape
Cross-linked PEG-based
hydrogels, cationic; cubic
(2-5 µm), cylindrical
microparticles (MPs)(0.5-1 x
1 µm) and cylindrical NPs
(100-200 x 200-450 nm)
All particles were taken up by CME,
caveoline-mediated and macropinocytosis. NPs
were internalized faster than MPs. Cylinders of
150 x 450 nm were internalized faster than
cylinders 200 x 200 nm and 100 x 300 nm
HeLa [199,200]
Size
Polysiloxane NPs, anionic
43 nm vs. 24 nm
43 nm NPs entered with CME and ended up in
endolysosomal compartment. 24 nm NPs entered
with clathrin- and caveolin-independent pathway
bypassed the lysosomes and ended up in
perinuclear space
HeLa [201]
Dendrimer
generation
PAMAM dendrimers,
amine-modified G2 vs. G4
generations
G2 dendrimers entered primarily by CME, G4
utilized multiple routes
Caco-2
B16f10 [202,203]
Structure
Branched PEI (bPEI) vs.
linear PEI (lPEI) in
polyplexes with DNA
bPEI polyplexes predominantly used CME in
COS-7 and both CME and caveoline-mediated
pathways in HeLa; lPEI utilized CME
independently from cell types. lPEI polyplexes
utilized both CME and caveolin-dependent
pathways
COS-7,
HeLa [203–205]
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In contrast, the results of experiments reported by Zhang et al. revealed an
opposite effect on the HEK cell line. Whereas, non-adherent (suspension) cell
lines were reported to show no significant uptake of the nanoparticles at all
[183,206].
Thus, in light of the controversial information, research should pay more atten-
tion to the mechanisms of the endocytosis in different cell types. So far, most of
the uptake studies have focused on non-polarized cells (cells with a homogeneous
morphology). However, it has been reported that polarized and non-polarized
cells utilize different uptake mechanisms [207] (see also Table 2.3).
Based on our research [14, 151, 153, 208] and the knowledge gained from the
literature [209, 210], we propose the following scheme of cellular uptake and
intracellular fate of multi-shell calcium phosphate nanoparticles on the exam-
ple of nanoparticles, functionalized with DNA and PEI for transfection of cells
(Figure 2.6). Positively charged functionalized calcium phosphate nanoparticles
interact with the negatively charged cell membrane via electrostatic interaction
and enter the cell by macropinocytosis [12,153,211,212]. The protonated amine
groups in the PEI molecules increase the osmotic pressure in the endosome, thus
leading to the disruption of the endosomal membrane and releasing the PEI/DNA
complexes into the cytoplasm.
It has been also reported recently about the role of Ca2+ ions in promoting gene
vector transportation into the nucleus. First, calcium ions, along with other ions,
play an important role in endosomal escape by triggering an osmotic imbalance
and preventing the vector’s degradation in lysosome. Secondly, after release in
the cytosol, Ca2+ ions stabilize the gene vector (this is important, especially when
no PEI or other cationic polyelectrolyte is used) and protect it from degradation in
the cytoplasm [150,213]. This happens due to the high affinity of the negatively
charged nucleic acid backbone, containing phosphate groups, towards positively
charged calcium ions in CaP nanoparticles, resulting in gene vector condensation
and packing [214–216]. Thirdly, calcium ions were shown to facilitate the nuclear
internalization of the gene vector through nuclear pore complexes (NPCs) [159].
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Figure 2.6 The internalization pathway of multi-shell calcium phosphate
nanoparticles, functionalized with DNA for transfection. I: Nanoparticles inter-
act with the cell membrane; nucleases cannot degrade DNA molecules as they
are protected with the second shell of calcium phosphate. II: Nanoparticles are
internalized by endocytosis. III: Fusion of the lysosome with enzymes and endo-
some containing nanoparticles; formation of the endolysosome. IV: Formation of
secondary lysosome, activation of v-ATPase, lowering pH, phosphate groups are
neutralizing free protons through formation of hydrogen phosphate ions; increase
in osmotic pressure by pumping Cl−, Na+/K+ ions and water molecules inside
the lysosome. V: Rupture of lysosome, the DNA-PEI complexes are released
into the cytoplasm and moving toward nucleus where the DNA will be processed;
lysosomal enzymes are inactivated due to neutral pH value in the cytosol. VI:
Excessive Ca2+ ions are pumped out of the cell via ion channels.
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2.3.4 Inhibition of endocytosis
To study which specific mechanism is responsible for the uptake of particular
nanoparticles or other cargoes, the inhibitors in endocytosis are used. As of now,
a certain number of pharmacological inhibitors are available on the market and
proved to inhibit one or another endocytotic pathway. The summarized data with
the description of the inhibitors that are now widely used in uptake studies are
presented in Table 2.4.
As can be seen from the table, the approach "one inhibitor, one pathway" is
often far away from reality. It especially concerns the depletion of cholesterol,
as many mechanisms of endocytosis are cholesterol-dependent [159, 221–224].
Moreover, Nystatin was shown to be cytotoxic and methyl-β-cyclodextrin could
destroy the plasma membrane and induce ion leakage [221]. Recently, it was
also reported that the efficacy of such inhibitors as genestein and methyl-β-
cyclodextrin on the uptake of transferrin and lactosylceramide was highly cell
line-dependend [226].
The complexity of interaction of nanoparticles with plasma membrane and the
endocytotic pathways is still far beyond our full understanding. There are many
studies on specific cell lines or on particular endocytotic pathway, or only with a
few nanoparticles having different parameters. Thus, a general picture still needs
to be created. A close collaboration between the experts with different scientific
backgrounds may help to resolve this puzzle in the future.
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Table
2.4
Description
of
endocytotic
pathways
inhibitors
[182].
CM
E:
clathrin-m
ediated
endocytosis,
CIE:clathrin-independentendocytosis.
Inhibitor
Inhibited
m
echanism
Effect
Com
m
ents
A
m
iloride
and
its
derivatives
(EIPA
and
H
O
E-694)
M
acropinocytosis
BlocksRac1
and
Cdc42
signaling
pathways[217,218]by
lowering
subm
em
braneouspH
Chlorprom
azine
CM
E
[219]
InhibitsRho
GTPase
Noteffi
cientin
som
e
celllines
Cytochalasin
D
,
Latrunculin
A
M
ainly
m
acropinocytosis
Inhibitsactin
polym
erization
and
m
ay
lead
to
actin
disassem
bly
[220]
Notalwayseffi
cientin
adherentcells[220]
Jasplakinolide
M
acropinocytosis
Stabilize
actin
filam
entsand
prom
otes
actin
assem
bly
[220]
D
ynasore
Caveolin/lipid
raft-dependent,
RhoA-dependent,phagocytosis
Inhibitsfunction
ofdynam
in
protein
M
ethyl-β-
cyclodextrin
M
acropinocytosis,
CM
E
[221,222]and
CIE
[159,223,224]
Cholesteroldepletion/extraction
The
possible
leakage
ofK
+
ionsshould
be
taken
into
consideration
Filipin
Caveolin-m
ediated,
m
acropinocytosis[159,223,224],
CM
E
[221,222]
Interactswith
cholesterol
N
ystatin
Caveolin-m
ediated,
m
acropinocytosis[159,223,224],
CM
E
[221,222]
Interactswith
cholesterol
Toxic
Lovastatin
Influence
on
all
cholesterol-dependent
m
echanism
s
Inhibitssynthesisofcholesterol,thus
lowering
itscontentin
m
em
brane
Uncertain
action
G
enistein
Inhibitsseveraltyrosine
kinases
Inhibitscaveolae
form
ation
[225]
Affectsseveral
processesata
tim
e.
Notspecific
W
ortm
annin
and
LY
94002
M
acropinocytosisand
RhoA-m
ediated
endocytosis
Inhibitphosphatidylinositol3-kinase
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2.4 Vaccination and immune response
2.4.1 Organization of the immune system
The immune system is a complex network consisting of organs, cells (Table 2.5),
and molecules with specialized roles that defend the living organism from infec-
tions. It is also responsible for destroying malignant cells within the body.
The organs of immune system are divided into primary or central lymphoid or-
gans (bone marrow and thymus) and peripheral lymphoid organs (spleen, lymph
nodes, and mucosa-associated lymphoid tissues (MALT)). Anatomical and phys-
iological barriers such as epithelia, mucosa, tears, respiratory tract, oral cavity,
stomach, and small and large intestines also play an important role in the defense
from pathogenic infection [227].
All cells of the immune system are derived from bone marrow stem cells as
a result of a process called hematopoiesis. During this multi-stage process,
stem cells undergo differentiation either into mature cells (B cells, natural killer
cells, granulocytes) under the stimulation of specific cytokines, called colony-
stimulating factors, or into precursors of cells (immature thymocytes) that leave
bone marrow for thymus to continue their maturation. Red blood cells and
platelets are also formed during the hematopoiesis.
In the thymus, the maturation and final selection of T cells take place. About
95-98% of all lymphocytes do not pass this selection and are sequestered in
thymus [228]. Mature lymphocytes then migrate through the peripheral blood
circulation into secondary lymphoid organs such as spleen, lymph nodes, Peyer’s
patches, and others.
Lymph nodes in the form of clusters are widely distributed throughout the
body, mainly in places of major blood vessel pathways, and along with the lym-
phatic liquid form the lymphatic system in the body. Lymph is drained from
blood stream through the lymph node and filtered for possible foreign bodies,
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microorganisms, cancer cells, inflammatory cytokines, or antigens. Lymph nodes
themselves represent highly structured organs, containing, among others, B cells,
follicular dendritic cells, macrophages, plasma cells, and T cells (mainly T helper
cells) [229].
The spleen is the largest single lymphoid organ in the human body. It comprises
two tissue types: red pulp and white pulp. Red pulp contains large number of
erythrocytes, resident macrophages, dendritic cells, granulocytes, plasma cells,
and lymphocytes. This is the place where aged red blood cells and platelets
are destroyed. The white pulp contains lymphoid tissue, consisting of mainly T
lymphocytes, 75% of which are CD4+ T cells (T helper cells). The spleen filters
the blood and is the main organ where the antibodies are being synthesized and
released into the blood stream. In addition, dendritic cells and macrophages
catch the foreign antigens from the blood stream passing through the spleen.
People who lack this organ (e.g. through splenectomy) are highly susceptible to
bacterial infections such as pneumococci and memingococci.
Mucosa-associated lymphoid tissue (MALT) makes up more than 50% of lym-
phoid tissue in the body. It incorporates lymphoid tissue associated with gut,
bronchus, and genitourinary tracts. The major function of these organs is to
provide local immunity through the production of IgE and IgA. These structures
contain a number of different immune cells: CD4+ and CD8+ T cells, B cells,
plasma cells, dendritic cells, macrophages, eosinophils, and mast cells.
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Table 2.5 Description of the cells of the immune system.
Origin Morpho-logy Function
Cell
Type Description
Ly
m
ph
oid
Mononuclear
Cytotoxicity NK cells
Make up 15% of human blood lymphocytes
(HBL); express no Ag-specific receptors; kill
cells with low expression of MHC Class I (in-
dicator for abnormality); are effective during
early stages of viral infection; are activated by
IFNα and IL-2; produce IFNγ [230]
CD8+
T cells
Express MHC Class II molecules; are cyto-
toxic T cells (TC cells); produce perforins and
granzymes to eliminate malignant or infected
cells [230]
Regulation
CD4+
T cells
Along with CD8+ T cells make up 70% of all
HBL; express MHC Class I molecules; secret
cytokines to promote cell-mediated immunity
(TH1) and Ab-mediated immunity (TH2) [230]
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γβ-T cells
Represent 10-15% of human blood T cells;
abundant in epithelia of gut, lung, and skin;
secrete cytokines to promote Ab-mediated im-
munity [230]
Ab
production,
Ag
presentation
B cells
Make up 5-15% of human blood lymphocytes
(HBL); require help from TH cells for activa-
tion; produce Igs [230]
M
ye
loi
d
Ag presen-
tation
Dendritic
cells
Are bone marrow-derived and located
throughout the body; are the most efficient
APCs; induce primary activation of CD4+
and CD8+ T cells; provide "self-tolerance"
against body’s own cells [230]
Ag presen-
tation,
phagocyto-
sis
Mono-
cytes /
macro-
phages
Make up 5-10% of blood mononuclear leuco-
cytes; differentiate into MΦ when migrate into
tissues; contain granules with lysozyme, acid
hydrolases, and mieloperoxidases; destroy par-
ticulate material, pathogens, and dead cells;
are activated through IFNγ, prostaglandins,
and leucotrienes [230]
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Polymorpho-
nuclear
leucocytes /
Granulo-
cytes
Neu-
trophils
Make up 60-70% of white blood cells (WBC);
short-living (2-3 days); migrate into tissues
and involved in acute response to bacterial in-
fection; contain granules like in MΦ + antimi-
crobial proteins (defensins and serprocidins)
[230]
Extracellular
digestion Eosinophils
Represent 2-5% of WBC; secrete their gran-
ules (include among others, ROS) for extra-
cellular digestion of big infectious pathogens
(e.g. parasitic worms); produce cytokines,
prostaglandins, and leucotrienes [230]
Inflammation
Basophils
Make up <1% of WBC; are activated by ana-
phylatoxins (C3a and C5a peptides) or by Ag
binding to IgE antibody on the cell surface;
release inflammatory mediators (heparin, his-
tamine, etc.) to attract lymphocytes, mono-
cytes, and granulocytes to the site of inflam-
mation [230]Mast cells
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2.4.2 Mechanisms of immune response
Immunity is provided by two parts of the immune system that closely cooperate
with each other and can be distinguished by a number of specifications (see
Table 2.6), two of these being the time of reaction and its specificity.
The cells of the innate immunity are represented by neutrophils, macrophages,
eosinophils, basophils, and mast cells. Their short description and functions are
given in Table 2.5. The innate immune response is developed mainly by recruiting
neutrophils at the site of infection to eradicate pathogens [231]. During early
stages of infection, the activated macrophages release cytokines (among them
are various colony-stimulating factors) that drive the division of myeloid precursor
cells in bone marrow, resulting in a dramatic increase of lymphocytes in the
blood circulation (neutrophils leucocytosis). Transported to the site of infection,
the recruited neutrophils eliminate the pathogen by phagocytosis, involving the
production of reactive oxygen species (ROS) [228].
The complement system, consisting of about 20 serum glycoproteins, also plays
an important role in the innate immunity. This system is activated by three major
pathways: antigen-antibody reaction (classical way), polysaccharides from yeast
and gram negative bacteria (alternative way), and presence of foreign substance.
This activation happens in a cascade sequence with amplification stages, which
means that activation of a single molecule leads to the generation of thousands
of other molecules. All three pathways have a common point where they act
in a similar manner, i.e. the activation of C3 component on the surface of
the cell with further activation of C5-C9 components, resulting in a formation
of transmembrane pores and death of the cell by osmotic lysis [228]. Normal
cells of the body carry inhibitory proteins on the surface that stop this cascade
process, thus avoiding lysis. Microorganisms or unhealthy cells, however, lack
this inhibitory system and are highly susceptible to the complement system.
The main feature of the adaptive immunity is the use of antigen-specific re-
ceptors on the surface of T and B cells to promote a targeted response against
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the pathogen. This process takes place in two stages. The first stage happens
in the following manner. The antigen is taken up either in the lymphoid tissue
or on the site of the infection by the dendritic cell (or another antigen-presenting
cell), which then migrates to the nearest lymph node and presents the processed
antigen in a complex with MHC molecules to the CD4+ (MHC Class II) and
CD8+ (MHC Class I) T cells, leading to the priming, activation, and proliferation
of the cells. This process is called activation of primary naive T cells. The func-
tions of these cell types are described in Table 2.5. After the activation, some
T cells remain in the lymph node as central memory cells and are responsible for
accelerated activation of the immune response after the subsequent exposure to
the same pathogen. This type of cells stays active in the body up to 10 years or
more [228]. The second stage, the response itself, is mediated through activated
T cells leaving the lymphoid tissue, and activated B cells (plasma cells) releasing
the antibodies into the blood stream and tissue fluids. In particular, CD4+ T cells
(T helper cells) are responsible for orchestrating the cell-mediated part of immune
response by activating other immune cells, e.g. B cells. CD8+ T cells (cytotoxic
cells) are involved in the elimination of virus-infected and malignant cells of the
body.
B cells, while performing an antigen-presenting activity, are mostly responsible
for producing antibodies. These proteins (immunoglobulins or Ig), among other
things, neutralize toxins in the blood stream; opsonize bacteria, protozoa, and
other pathogens; prevent adherence of microorganisms onto the mucosa surfaces;
and activate the complement system [228]. There are five classes of antibody
molecules known: IgA, IgD, IgE, IgG, and IgM. Igs of G Class are the main
antibodies found in the blood and tissue, and are responsible for a majority of
antibody-mediated clearance of pathogens [232]. IgM plays an important role
in providing the humoral immune response in earlier stages of B cell-mediated
immunity [232,233]. Immunoglobulins of E Class trigger the release of histamine
from mast cells and basophils during the development of allergic reaction, and are
also involved in protection against parasitic worms [232]. IgD has been shown to
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activate the production of antimicrobial factors in mast cells and basophils [234].
Table 2.6 Comparison of innate and adaptive immune responses.
Immune System
Innate (nonspecific)
immune response
Adaptive (specific)
immune response
Responses occur to the same extent,
regardless of the frequency of infection
by the same pathogen.
Responses improve on repeated expo-
sure to a given infection agent.
Function through phagocytic cells
(neutrophils, monocytes, and
macrophages), cells that induce
inflammation (basophils, mast cells,
and eosinophils), and natural killer
cells (NK cells).
Involve APCs (dendritic cells, mono-
cytes, and macrophages) to display
the Ag to lymphocytes and collabo-
rate with them to induce the response.
Involve the proliferation of antigen-
specific B and T cells, through binding
their surface receptors to antigen.
Molecular components include pep-
tides of complement system, acute-
phase proteins, and cytokines such as
interferons.
B cells secrete immunoglobulins, the
Ag-specific Ab responsible for elimi-
nating extracellular pathogen. T cells
help B cells to produce Ab and can
eliminate intracellular pathogens by
activating MΦ and by killing infected
cells.
Physical, chemical, and microbiologi-
cal barriers [228], including skin, gut,
stomach juice, etc.
Responses are generated in the lymph
nodes, spleen, and mucosa-associated
lymphoid tissue (MALT).
The innate immune response takes
place within minutes but lacks speci-
ficity [228]. Is determined for life by
the genetic information.
Adaptive response is precise but takes
several days or weeks to develop. It
has memory, provided by specific an-
tibodies, and memory cells that re-
main life-long in the body after infec-
tion [228].
The cooperation between innate and acquired responses is essential for
eliminating pathogens
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B cells function in mucosal areas, associated with gut, respiratory and urogenital
tract, where they prevent the reproduction of the pathogen microflora through
producing IgA [235]. Interestingly, the immune response generated at one site of
mucosa-associated tissue will activate the response to the same pathogen at other
sites. This fact can be used for achieving the therapeutic effect by vaccination
at one mucosal site to induce generalized mucosal immunity [236].
2.4.3 Nanotechnology for vaccination
The immune system represents a major target for the development of treatment
strategies for fighting against tumors, infectious and autoimmune diseases [228].
Among other things, these approaches include prophylactic and therapeutic vac-
cination with immunogenic adjuvants and pathogen proteins (or part of these
proteins) to drive a pathogen-specific immune response [237].
A vaccination’s main goal is to induce a specific immune response and an im-
munological memory in the recipient towards a pathogen, ideally with minimal
or no side effects and long-lasting protection [154]. Modern vaccination tech-
nology dates back to the 18th century when Edward Jenner discovered immu-
nization with non-pathogenic smallpox virus from animals (cows) against highly
fatal human smallpox virus. In the 20th century, with the help of recombinant
DNA technologies, vaccines against influenza, hepatitis A virus (HAV), hepati-
tis B virus (HBV), and the human papillomavirus (HPV) were developed and
produced world-wide [154].
Today, there are various vaccine types, used in both prophylactic and therapeu-
tic vaccinations. They can be categorized as follows: attenuated virus, inacti-
vated (killed) virus, virus subunits, virus-like particles (VLPs), and DNA vaccines.
Although these vaccines possess high immunogenicity, they are also sometimes
associated with serious risks of virulence reversion, immunotoxicity, immunocom-
promising of patients, and complex and expensive production [238–241].
In this regard, application of nanometric materials (1-1000 nm) [242] offers
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tremendous opportunities for the development of new immunization strategies,
immunomodulatory agents, and vaccination tools. Over the decades, numerous
nanoparticulate systems of different sizes and origins have been tested as poten-
tial tools for immunization against various infections [154,242]. For example, one
can name dendrimers (<5 nm) [243,244], polymers (10-20 nm) [245,246], virus-
like particles (15-30 nm) [247, 248], DNA-polyplexes (50-100 nm) [249–251],
liposomes (>150 nm) [246, 252], nanoparticles (150-250 nm) [30, 154, 253], and
nanoemulsions (400 nm) [254, 255], all of which have been tested as novel im-
munostimulatory vaccines.
These nanomedical approaches posses some potential advantages over conven-
tional antiviral therapies. They include high stability, well-defined composition,
and the possibility of large-scale production [154,256]. Moreover, it is possible to
tailor the nanoparticulate system by incorporating, encapsulating, or conjugating
various immunomodulating molecules, targeting antibodies, drugs, or vaccines to
address specific cell populations and tuning drug or vaccine release [257–259].
This multiplicity of molecules can be incorporated into one set on the produced
nanoparticles, thus providing multifunctional tool to achieve better immunization
results. Biodegradable multi-shell functionalized calcium phosphate nanoparti-
cles developed by Sokolova et al. [123] and further studied and described in this
work can serve as a prominent example of such systems. These nanoparticles
can encapsulate antigens and adjuvants in their core that APCs can process and
then present to CD4+ and CD8+ T cells (Figure 2.7). The application of such
functionalized nanoparticles showed a significant improvement in antigen deliv-
ery efficiency and enhancement of the immune response compared to soluble
immunoactive ligands and proteins [152].
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Figure 2.7 The scheme of induction of antigen-specific immune response via
immunization with functionalized calcium phosphate nanoparticles.
Additionally, we have demonstrated that the treatment of chronic viral infection
on the Friend virus model with such calcium phosphate nanoparticles, loaded with
virus-derived proteins and CpG adjuvant could significantly improve the antivi-
ral immune response and effectively suppress the viral replication. As currently
available treatments of chronic viral infections like HCV, HBV, or HIV are still
far from satisfactory level, new therapeutic strategies are highly desirable. Thus,
biodegradable, non-toxic, and effective nanoparticles, based on calcium phos-
phate, can serve as an excellent example of a novel vaccination tool.
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3.1 Synthesis of calcium phosphate nanoparticles
3.1.1 Preparation of single- and multi-shell calcium
phosphate nanoparticles
All calcium phosphate nanoparticles used for the experiments were prepared using
a method of continuous rapid precipitation in water at room temperature (RT),
developed by Sokolova et al. [123,151] in the following manner (Figure 3.1). An
aqueous solution of diammonium hydrogen phosphate (3.74 mM, pH=9, Merck,
p.a.) and an aqueous solution of calcium nitrate (6.25 mM, pH=9, Merck, p.a.)
were mixed rapidly by pumping into a glass vessel with a constant maximum
speed and constant stirring with a magnetic bar. The pH value of the diammo-
nium hydrogen phosphate and the calcium nitrate solutions were adjusted be-
forehand with 0.1 M NaOH (Merck, p.a.). The required amount of the calcium
phosphate nanoparticle dispersion was transferred by a pipette into an Eppen-
dorf tube, followed by functionalization with polyelectrolyte molecules to prevent
aggregation and to stabilize the nanoparticles in solution. Due to the selected
concentrations and the equal amount of pumped Ca2+ and PO3−
4
-ions containing
solutions in the reaction vessel, the core of calcium phosphate nanoparticles was
presumably formed in stoichiometric Ca/P-proportion, referred as hydroxyapatite
(Ca10(PO4)6(OH)2). By the functionalization with polyelectrolyte, which can be
at the same time the molecule of interest if it possesses a strongly negative or
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positive charge, the first shell is constructed.
Figure 3.1 Schematic representation of synthesis of functionalized single-shell
calcium phosphate nanoparticles.
Triple-shell nanoparticles were prepared by adding the same amount of diammo-
nium hydrogen phosphate and the calcium nitrate solutions directly into the Ep-
pendorf tube, in such a way that the total volume of added solutions was equal to
the volume of dispersion of calcium phosphate nanoparticles taken directly after
the preparation from the reaction vessel. Thus, a layer of calcium phosphate
was formed. This layer protects the inner molecules from degradation. Finally,
the nanoparticles were functionalized with the polyelectrolyte solution for a steric
stabilization, forming a third shell. After each step of addition, the nanoparti-
cle colloid was mixed thoroughly by a Vortex shaker (Vortex-Genie 2, Scientific
Industries Inc., USA).
41
Materials and Methods
3.1.2 Preparation of single-shell calcium phosphate
nanoparticles for the transport of various molecules
PEI-carrying nanoparticles were prepared in the following way: aqueous solutions
of calcium lactate (18 mM) and diammonium hydrogen phosphate (10.8 mM)
were rapidly pumped into a glass vessel. Within one minute 200 µL of the calcium
phosphate nanoparticle dispersion were taken with a syringe and rapidly mixed
with 720 µL of rhodamine-labeled PEI (1.08 g L−1; pH 10, adjusted with ammo-
nia solution). This dispersion was stored for two days at room temperature and
afterwards purified by centrifugation and redispersion by ultrasonication (UP50H,
Hielscher, Ultrasound Technology; sonotrode 3, cycle 0.8, amplitude 50%, 45 s)
in 360 µL water.
Because pTHPP porphyrin molecules are not water-soluble and hence unable
to stabilize the calcium phosphate nanoparticles, they were firstly functionalized
either with polycationalic PEI or polyanionic polymer PSS (polystyrene sulfonate).
The PEI-stabilized porphyrin-carrying nanoparticles were prepared in the following
manner: aqueous solutions of calcium lactate (18 mM), diammonium hydrogen
phosphate (10.8 mM), and PEI (2 g L−1) were simultaneously pumped into a
stirred glass vessel in a volume ratio of 5:5:7 mL containing 20 mL of ultrapure
water for 1 min at room temperature. After 1 min of stirring, 1 mL of pTHPP
(1 g L−1 in ethanol) was added to the dispersion. This obtained nanoparticle
dispersion was stored at room temperature for 2 days. Then 25 mL of this
dispersion was centrifuged and redispersed by ultrasonication (UP50H, Hielscher,
Ultrasound Technology; sonotrode 7, cycle 0.8, amplitude 50%, 90 s) in 20 mL
water.
PSS-stabilized anionic porphyrin-carrying calcium phosphate nanoparticles were
synthesized by simultaneously pumping aqueous solutions of calcium lactate (18 mM,
pH 10), diammonium hydrogen phosphate (10.8 mM, pH 10), and PSS (2 g L−1,
pH 10) in a volume ratio of 5:5:10 mL into a stirred glass vessel containing 20 mL
of ultrapure water for 1 min at room temperature. After stirring for 1 min, 1 mL
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of pTHPP (1 g L−1 in ethanol) was added to the nanoparticle dispersion. For 4
days this dispersion was stored at room temperature. After that 25 mL of this
dispersion was centrifuged and redispersed by ultrasonication (UP50H, Hielscher,
Ultrasound Technology; sonotrode 7, cycle 0.8, amplitude 30%, 90 s) in 20 mL
of pure water.
Peptide-carrying nanoparticles were synthesized in the following manner: PEI-
stabilized CaP nanoparticles were prepared as described before for the pTHPP-
carrying nanoparticles synthesis. After ultrasonic redispersion in pure water
100 µL of a fluorescing peptide solution (FITC-Pep, 1 g L−1) was added to
1 mL of this dispersion and left for 30 min. The dispersion was centrifuged
and redispersed by ultrasonication (UP50H, Hielscher, Ultrasound Technology;
sonotrode 3, cycle 0.8, amplitude 50%, 45 s) in 1 mL of pure water.
The nanoparticles carrying rhodamine-labeled PEI, pTHPP, and synthetic pep-
tide were synthesized by Dr Jan Klesing.
3.1.3 Purification of functionalized calcium phosphate
nanoparticles
Freshly synthesized dispersions of nanoparticles were purified by centrifugation
(Heraeus Fresco 21 centrifuge, Thermo Scientific) at 21,000 g for 30 min, and
subsequent redispersion of the nanoparticles’ pellet in pure water by ultrasound
finger (USF) (UP50H, Hielscher, Ultrasound technology; Sonotrode 2) with the
following settings: amplitude 60%; cycle 0.8; time 10 s (for all nucleic acid-
carrying nanoparticles) or 30 s (for nanoparticles carrying not ultrasound-sensitive
molecules).
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3.1.4 Calculation of the number of fluorescently-labeled
molecules and calcium phosphate nanoparticles in
the dispersion
After the synthesis, CaP nanoparticles, functionalized with various fluorescent
molecules, were sedimented by centrifugation. The supernatant was collected to
quantify the number of non-adsorbed fluorescent molecules by quantitative UV-
Vis spectroscopy using the calibration curve of the particular fluorescent molecule.
The precipitate containing nanoparticles was redispersed in the original volume
of ultrapure water and analyzed using atomic absorption spectroscopy (AAS). The
obtained concentration of calcium in the sample was converted into the mass of
calcium phosphate in the whole sample with regard to the hydroxyapatite phase
of the obtained nanoparticles (Ca10(PO4)6(OH)2):
m(CaP) = c(Ca) ·M(Ca10(PO4)6(OH)2)
10M(Ca)
The nanoparticle concentration was calculated by taking the mass of calcium
phosphate in the dispersion and assuming spherical nanoparticles with a diameter
obtained by SEM. Thus, the number of nanoparticles per m3 can be calculated
in the following manner:
N(NP) = m(CaP)
m(NP) =
3m(CaP)
4pir (NP)3ρ(CaP)
where N(NP): the number of nanoparticles per m3; m(CaP): the mass of syn-
thesized calcium phosphate nanoparticles per m3; r (NP): the average radius of
one nanoparticle; ρ(CaP): the density of hydroxyapatite phase of calcium phos-
phate (3140 kg m−3).
The concentration of adsorbed molecules was calculated by the subtraction of
the value, measured in the supernatant, from the theoretical concentration of
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the molecule in the nanoparticle dispersion. The number of fluorescent molecules
can thus be, determined in the following manner:
N(molecule) = c(molecule) · NA
where N(molecule): the number of fluorescent molecules per m3; c(molecule):
the concentration of the fluorescent molecules in the nanoparticle dispersion; NA:
Avogadro constant (6.022·1023 mol−1).
The number of molecules per nanoparticle was obtained by dividing of the total
number of molecules by the total number of nanoparticles per m3. The number of
functionalized nanoparticles per cell in the cell culture experiments was calculated
accordingly.
3.2 Physicochemical methods
3.2.1 Dynamic light scattering (DLS)
Dynamic light scattering is a physical method that allows to determine the hydro-
dynamic radius of particles in colloids. This technique is based on the principle
that the particles move randomly in the liquid phase, i.e. undergo Brownian mo-
tion, and on the assumption that the measured particles have a spherical shape.
Thus, the movement of these particles can be described by the Stokes-Einstein
equation:
D =
kBT
6piηRh
where D: the diffusion coefficient, kB : the Boltzmann’s constant, T : the
temperature in Kelvin degrees, η: the solvent viscosity, Rh: the hydrodynamic
radius of the particle.
The larger the particles, the slower their velocity. Hence, they will have smaller
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coefficient of diffusion compared to smaller particles. In most DLS systems, a
laser of known wavelength shines onto a cuvette with a sample solution, and
the intensity of the scattered light (with a changed wavelength due to a Doppler
shift when the light hits the moving particle) is collected by a detector, and
the particle size distribution of the sample is determined by software algorithms.
The amount of collected scattered light depends on such particle properties as
molecular weight, size, and shape, as well as the refractive index of the solvent
and the particle itself. Before reaching the detector, the scattered light from
individual particles interfere with each other, thus leading to a fluctuation in the
scattering intensity. With the help of an autocorrelation function, the diffusion
velocity is calculated with regard to the correlation between time and scattering
intensity.
The zeta potential can be described as an electrical potential of a particle, that
exists in some small distance from its surface. Through measurement of this
characteristic, the prediction of the long-term stability of the nanoparticle disper-
sion is possible. The zeta potential is derived from measuring the electrophoretic
mobility of charged particles in dispersion when they are subjected to an electric
field. By applying the Smoluchowski approximation to the measured mobilities
of the particles, the zeta potential can be determined.
ζ =
3ηµ
2εf (kHr)
where ζ: zeta potential, η: viscosity, µ: electrophoretic mobility, ε: dielectric
constant, r : radius of the particle, kH : Debye-Hückel parameter, f (kHr): Henry
function.
The Henry function depends on the radius of the spherical particle (r ), the
Debye-Hückel parameter (kH), and according to the Hückel-Smoluchowski ap-
proximation, has either the value 1.0 or 1.5.
The measurements for the computation of the zeta potential as well as the
determination of the hydrodynamic diameter were accomplished with a Malvern
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Zetasizer NanoZS instrument (λ=532 nm).
3.2.2 Nanoparticles tracking analysis (NTA)
Nanoparticle Tracking Analysis (NTA) uses two properties, i.e. light scattering
and Brownian motion, in order to determine the particle size distribution of sam-
ples in suspension. A laser beam is passed through the sample chamber, and the
particles in suspension that are located in the path of this beam scatter the light
so that they can be easily visualized through a microscope with 20x magnifica-
tion. A video camera, mounted on the microscope, generates a video file of the
particles that move due to the Brownian motion in the suspension. The soft-
ware keeps track of many particles simultaneously and, using the Stokes-Einstein
equation, calculates their hydrodynamic diameter.
The measurements of the nanoparticles’ hydrodynamic diameter were performed
with a Nanosight LM10 HS (Malvern Instruments Ltd).
3.2.3 Scanning electron microscopy (SEM)
The scanning electron microscope (SEM) is a type of electron microscope that
uses a focused beam of high-energy electrons to generate high-resolution images
of a solid sample surface. With the help of the signals derived from electron-
sample interactions, information about the sample, including external morphology
(texture) of the sample, its chemical composition, as well as crystalline structure
and orientation of materials can be revealed.
The principle of the SEM imaging is as follows. Accelerated electrons carrying
significant amounts of kinetic energy are focused by magnetic field lenses into
a narrow beam that scans the surface area of a sample. The image resolution
is determined by the diameter of this electron beam. When the electrons reach
the surface of the solid sample, their kinetic energy is transformed into a variety
of signals. These signals include secondary electrons, back-scattered electrons
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(BSE), diffracted back-scattered electrons (EBSD that are used to determine
crystal structures and orientations of minerals), photons (characteristic X-rays
that are used for elemental analysis), visible light (cathodoluminescence), and
heat. Secondary electrons are responsible for the formation of the actual contrast
of the 3D image, showing the morphology and topography of the scattered sample
[260].
SEM imaging was performed with ESEM Quanta 400 instrument (FEI) after
gold-palladium sputtering of the samples.
3.2.4 Ultraviolet-visible (UV-Vis) spectroscopy
UV-Vis spectroscopy is a physical method for the quantitative determination of
a species concentration in solution through the absorbance of this substance in
visible and near-UV as well as near-infrared ranges, i.e. in the wavelength range
of 200-800 nm. The correlation between concentration of the species of interest
and the intensity of light before and after passing the cuvette with the solution
(absorption) is described by the Lambert-Beer law:
A = log10
(
I0
I
)
= εcL,
where A: measured absorbance in Absorbance Units (AU), I0: the intensity
of the irradiated light at a given wavelength, I : transmitted intensity, L: path
length through the sample, c : concentration of the absorbing species. ε: constant
extinction coefficient (depends on the species and wavelength).
UV-Vis spectroscopic studies were performed on a Varian Cary Bio 300 spec-
trometer. The samples were measured in a quartz micro cuvette. To exclude the
influence of the dispersant or solvent on the absorbance of the samples, reference
measurements of pure dispersant or solvent were carried out. For a qualitative
conversion of the absorbance of the measured samples into the mg mL−1 units,
the calibration curve, obtained under the same measurement conditions with the
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known concentration of the molecule of interest, was used.
3.2.5 Atomic absorption spectroscopy (AAS)
Atomic absorption spectroscopy (AAS) is an analytical method used to identify
the presence and concentration of chemical elements by analyzing the absorption
of light by free atoms when they are vaporized and absorb certain frequencies of
light. The atoms are brought to the excitation state by absorbing ultraviolet or
visible light in a defined quantity for a short period of time (nanoseconds). This
amount of energy and wavelength corresponds specifically to a particular element.
Besides, the characteristic absorption lines are very narrow, which gives AAS its
elemental selectivity. The amount of the analyte is directly correlated with the
absorption value. Therefore, the concentration can be determined from a working
curve after calibrating the instrument with standards of known concentration.
The measurement of samples was performed with an M series atom absorption
spectrometer (Thermo electron corporation, Schwerte).
3.2.6 Lyophilization (freeze-drying)
Often biological materials must be dehydrated to keep them stable for a long
term. Drying always causes some loss of activity or other damage of biomolecules.
Lyophilization is a method of dehydratation that significantly reduces such da-
mage [261].
Lyophilization is the process where water (or another solvent) is removed from
a frozen material by sublimation at low temperature and reduced pressure (va-
cuum). It occurs when a liquid sample is frozen and the pressure in lyophilization
chamber is lowered below the triple point of the substance, so the frozen water
from the sample undergoes sublimation. This means a direct transition of water
molecules from the solid state to the gaseous state.
Immediately after the synthesis, the dispersions of nanoparticles were frozen in
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liquid nitrogen (-196 ◦C) in the presence of trehalose (20 mg mL−1, Fluka), to
build a sugar matrix for the nanoparticles. The lyophilization was carried out in
Alpha 2-4 LSC (Martin Christ, Osterode, Germany) at -7 ◦C, 31 Pa, 48-72 h,
and stored at -20 ◦C until they were redispersed in pure water directly before the
application.
3.3 Applied molecules
3.3.1 Antigenic viral peptides
The influenza protein hemagglutinin (HA) is a major viral surface antigen. This
strain-specific glycoprotein consists of two polypeptide chains (H1 and H2). In
the form of a trimer, HA is responsible for the attachment of the virus to the
host cell [262].
It is well known that CD4+ T helper (TH) lymphocytes recognize peptides along
with Class II MHC-encoded molecules, whereas CD8+ T cytotoxic cells react to
the peptides in association with Class I MHC-encoded molecules expressed on the
surface of antigen-presenting cells (APCs). These peptides with a length of 10-15
residues are generated during the processing of the native protein by APCs [263].
Studies with a T cell clone from BALB/c and CBA mice immunized with the
whole influenza virus with a single substitution on the amino acid sequence in
HA have revealed the importance of certain residues in the sequence, wherein
the changes dramatically affect reactivity. Thus, these conservative residues were
shown to play a major role in antigen-presenting process [263].
For our studies on the influenza virus, the following residues of immunogenic
peptides of the influenza virus A/PR/8/34 were used: HA512−520 (MHC Class
I-restricted, sequence YQILAIYSTVASSLVLL, 1 mg mL−1, Intavis AG, Cologne,
Germany) and HA110−120 (for MHC Class II-restricted, sequence SVSSFERFER-
FEIFPKESS, 1 mg mL−1, Intavis AG, Cologne, Germany).
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For our studies on the Friend virus, the following residues of immunogenic pep-
tides of the Friend virus were used: GagL85−93 (MHC Class I-restricted, sequence
CCLCLTVFL, 1 mg mL−1, JPT Peptide Technologies GmbH, Berlin Germany)
and the surface protein gp70123−141 (MHC Class II-restricted, sequence EPLT-
SLTPRCNTAWNRLKL, 1 mg mL−1, JPT Peptide Technologies GmbH, Berlin
Germany).
3.3.2 Bioactive peptides (LxVPc1)
LxVPc1 peptide is a synthetic molecule that can block the phosphorylation activ-
ity of calcineurin towards the NFAT signal molecule, thus inhibiting the activation
of the proinflammatory pathway in macrophages. This is an interesting approach
to fight inflammation-related transplantation failures.
The LxVPc1 peptide was synthesized along with its mutant type LxVPc1mut
by the company Pepscan R© in the following sequences:
LxVPc1 (FITC-Ahx-DQYLAVPQHPYQWAK-OH, Mw=1844.04 g mol−1,
1 mg mL−1);
LxVPc1mut (FITC-Ahx-DQYAAAAQHPYQWAK-OH, Mw=1747.87 g mol−1,
1 mg mL−1).
3.3.3 Bovine serum albumin (BSA)
BSA is a ubiquitous globular protein derived from bovine serum. It is often used
as a standard protein in many biological applications and methods. It consists of
583 amino acidic residues and has a molecular weight of 66.5 kDa.
For our experiments we used BSA, labeled with fluorescein isothiocyanate (FITC)
or tetramethylrhodamine isothiocyanate (TRITC) (Sigma-Aldrich, Germany,
1 mg mL−1).
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3.3.4 Calixarene dimer
This new calixarene dimer with 4-6 positive charges (see Figure 3.2) is able to
specifically bind to the major groove of the DNA duplex due to its chemical and
topological characteristics. It is currently examined with respect to its potential
to prevent cell proliferation and to induce apoptosis in cancer cells [264].
Figure 3.2 The chemical structure of calixarene dimer.
The calixarene dimer compound was synthesized in the group of Prof. Thomas
Schrader (Institute for Organic Chemistry, University of Duisburg-Essen, Ger-
many, Mw=1859.03 g mol−1, 1 mg mL−1).
3.3.5 Carboxymethyl cellulose (CMC)
Carboxymethyl cellulose (CMC) is a water-soluble polyanionic polymeric deriva-
tive of cellulose with carboxymethyl groups (-CH2-COOH) bound to some of the
hydroxyl groups of the glucopyranose monomers in the cellulose backbone. Due
to its nontoxic and hypoallergenic properties, CMC is widely used in the food
industry under the label E466 as a viscosity modifier or thickener and stabilizer.
It is also a constituent of many non-food products such as toothpaste, diet pills,
water-based paints, detergents, and various paper products.
For our experiments, we used a solution of sodium carboxymethyl cellulose
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(Mw=262 g mol−1, Sigma-Aldrich, 2 mg mL−1).
3.3.6 CpG: Toll-like receptor 9 (TLR9) ligand
CpG oligodeoxynucleotides (CpG ODN) are short (6-30 nucleotides [265]), single-
stranded DNA molecules containing a CpG dinucleotide motif (Cytosine-phospho-
diester bond-Guanine), which in unmethylated state can act as an immuno-
stimulant [266]. Owing to their high abundance in microbial genomes and
rareness in genomes of vertebrates, CpG motifs are considered to be pathogen-
associated molecular patterns (PAMPs) [267]. The unmethylated CpG PAMP is
recognized by the intracellular pattern recognition receptor (PRR) Toll-like recep-
tor 9 (TLR9), which is constitutively expressed in cells of the innate and adaptive
immune system, including plasmacytoid dendritic cells, monocytes, natural killer
(NK) cells, and B cells in humans and higher primates [268, 269]. This mecha-
nism is used to detect viral, fungal, and bacterial infection through recognition
of pathogen DNA motifs.
The reported effect of immunostimulation with CpG ODN include cytokine se-
cretion and upregulation of costimulatory molecules of macrophages and dendritic
cells (DC) [270–272]; activation, polyclonal proliferation, and immunoglobulin se-
cretion of B cells [273]; direct and indirect costimulatory effects for T cells [274];
as well as enhancing effects on haemopoiesis [275]. These mentioned effects make
CpG a powerful adjuvant in activation of adaptive immune response [276, 277].
Moreover, it has been shown that CpG strongly supports the induction of cyto-
toxic T cell responses that are crucial for eliminating the infected cells, carrying
intracellular pathogens [278]. Furthermore, CpG has the capacity to induce T
helper type 1 (TH1)-dominated immune responses [277, 279] and can redirect
ongoing TH1 responses [279]. Thus, CpG ODN have been recognized as a new
and effective class of adjuvants that can be used for vaccination against allergies,
infectious diseases, and tumors [276,280].
For our studies, we used B-type CpG 1826 with the following sequence
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5’-TCCATGACGTTCCTGACGTT-3’ (Eurofins MWG Operon, Ebersberg, Ger-
many, 0.4 mg mL−1).
3.3.7 High temperature requirement A1 (HTRA1) protein
The high temperature requirement A (HtrA) family of serine proteases belongs
to a highly conserved set of proteases found in single and multicellular organisms.
HtrAs differ from other serine proteases in sequence homology in the presence
of a catalytic domain and one or two C-terminal PDZ domains that mediate
specific protein-protein interactions. The key functions of HtrA family members
are related to protein quality control.
HTRA1 is one of the most studied members of HtrA family in human, which
is known to be involved in various biological processes from tumor suppression
and control of proliferation to cell migration and neurodegeneration [281]. It
was shown that overexpression of HTRA1 inhibited tumor growth in vitro and in
vivo [282]. This data suggests that HTRA1 might function as a tumor suppressor.
In the extracellular matrix, HTRA1 cleaves numerous secreted proteins such as
fibronectin, fibromodulin, aggrecan, Type II collagen, biglycan, clusterin, and
others. It is suggested that HTRA1 has cellular (20% of protein) as well as
extracellular (80% of protein) localization [283]. The regulation of the cellular
distribution of HTRA1 is, however, unknown.
For our experiments, we used HTRA1 that was produced according to the liter-
ature [282], labeled with Alexa488 (Invitrogen, USA) according to the manufac-
turer’s manual, and purified by gel electrophoresis in the group of Prof. Michael
Ehrmann (Centre for Medical Biotechnology (ZMB), University of Duisburg-
Essen). The final concentration of Alexa488-labeled HTRA1 and HTRA1∆PDZ
(HTRA1 without PDZ domains) was 1 mg mL−1; Mw (HTRA1)=37 kDa,
Mw (HTRA1∆PDZ)=25 kDa.
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3.3.8 High temperature requirement A2 (HTRA2) protein
HTRA2 is a human serine protease located in the intermembrane compartment
[284] of mitochondria. It is known to be involved in mitochondrial quality control,
namely through interactions with antiapoptotic protein HAX-1 [285]. The degra-
dation of this protein by HTRA2 induces autophagy, resulting in the clearance
of damaged mitochondria. The functional unit of HTRA2 structurally appears
as a trimer molecule with central protease domains and a PDZ domain, located
on the C-terminus, which is characteristic for the HtrA family. The PDZ domain
preferentially binds to the C-terminus of the target-protein and modulates the
proteolytic activity of the trypsin-like protease domain [286]. A normal protease
activity of HTRA2 is required for mitochondrial homeostasis in mice and humans.
It was shown that mice with the inactivated (muted) form of HTRA2 display
phenotypes similar to Parkinson’s disease [287], which is associated with amy-
loid precursor protein metabolism [288]. Neurodegenerative disorders are strongly
associated with the aggregation of proteins or protein fragments as well as the
accumulation of unfolded proteins in mitochondria. This implies that HTRA2
protease plays a significant role in maintaining cellular homeostasis by means of
protein quality control.
For our experiments, we used HTRA2 that was produced according to the litera-
ture [282], labeled with Alexa488 (Invitrogen, USA) according to the manufacturer’s
manual, and purified by gel electrophoresis in the group of Prof. Michael Ehrmann
(Centre for Medical Biotechnology (ZMB), University of Duisburg-Essen). The
final concentration of Alexa488-labeled HTRA2 was 1 mg mL−1 (Mw=49 kDa).
3.3.9 Lysozyme-inhibiting polymer
A polyfunctional anionic copolymer was developed for the selective inhibition
of lysozyme as a supramolecular enzyme inhibition model. The activity of this
polymer is provided by cooperative interaction of selected binding co-monomers
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with critical amino acid residues on the protein surface, specifically exploiting
electrostatic interactions, hydrophobic forces, and substrate mimicry [289–292].
Its functional parts are as follows: bisphosphonates as molecular tweezers for
arginine and lysine residues; unipolar dodecyl tails for aliphatic and aromatic
amino acids; glucosamine moieties, which imitate the lysozyme’s natural substrate
(bacterial cell walls); dansyl molecule as fluorescent label (see Figure 3.3).
The polymer was synthesized in the group of Prof. Thomas Schrader (Insti-
tute for Organic Chemistry, University of Duisburg-Essen, Germany, 1 mg mL−1,
Mw=181.5 kg mol−1).
Figure 3.3 The chemical structure of the lysozyme-inhibiting polymer.
3.3.10 Molecular tweezers
The pathological misfolding and self-assembly of key proteins inside and out-
side the nerve cells are the hallmarks of severe neurological disorders, the so-
called amyloidosis. Prominent examples of such disorders are Alzheimer’s disease,
Parkinson’s disease, Creutzfeldt-Jakob and related prion diseases, senile systemic
amyloidosis, dialysis-related amyloidosis, and Type-II diabetes. Any prevention
strategy that has the potential to treat amyloidosis by inhibition or modulation
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of these processes is thus of great significance.
Of late, molecular tweezers have been discovered and demonstrated to inhibit
specific protein-protein interactions that lead to the formation of amyloidogenic
aggregates inside cells. These amphiphilic compounds carrying 2-4 negative
charges (Figure 3.4) hold great promise for the development of disease-modifying
therapies if they can be transported across cell membranes and inhibit aberrant
protein misfolding [293].
Figure 3.4 The chemical structure of molecular tweezers.
The molecular tweezers were synthesized in the group of Prof. Thomas Schrader
(Institute for Organic Chemistry, University of Duisburg-Essen, Germany,
Mw=814.57 g mol−1, 1 mg mL−1).
3.3.11 Plasmid DNA
Plasmid is an extrachromosomal circular double-stranded single DNA molecule
found in bacteria, which encodes a sequence of a specific protein (or proteins)
and may autonomously replicate. Vectors are small, engineered plasmids that
are widely used for transfection of eukaryotic cells to delivery non-hosting gene
for production of a specific protein. They are usually derived by replication in
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transformed prokaryotic cells such as Escherichia Coli (E.Coli) and then purifying
with the help of plasmid DNA purification kits.
For our transfection experiments, the plasmid DNA that encoded the synthesis
of enhanced green fluorescence protein (EGFP) was obtained by transforming
E.Coli (Dh5α subtype) with a pcDNA3EGFP plasmid according to standard pro-
tocol and purified with NucleoBond R© PC 10000 EF endotoxin-free plasmid DNA
purification kit (Macherey-Nagel R© , Dueren, Germany), according to the manu-
facturer’s manual (Mw=4.0·106 g mol−1, 6160 base pairs).
3.3.12 Polyethylenimine (PEI)
Polyethylenimine (PEI) is a polycationic polymer comprising of repeating units
of amine groups and two carbon aliphatic CH2-CH2 spacers. In its linear form,
PEI contains only secondary amines, whereas branched PEI contains primary,
secondary, and tertiary amino groups. It is a commercially available compound,
produced on industrial scale for many applications [294]. It is widely known as
polymeric transfection agent. PEI is able to condense negatively charged DNA
molecules into positively charged polyplexes, which have high affinity towards
negatively charged cell membrane and is internalized by cells via endocytosis.
PEI is reported to be highly effective and also cytotoxic to some degree [295].
It implies two different mechanisms [296] causing the cell death either by necro-
sis, damaging the cell membrane followed by cytosol leakage, or by apoptosis,
disrupting the mitochondrial membrane after internalization.
For our experiments, we used branched PEI (Mw=25 kg mol−1, Sigma-Aldrich,
2 mg mL−1).
3.3.13 Protamine
Protamine is the member of a small arginine-rich proteins family. It is a naturally
occurring polypeptide with membrane-translocating and nuclear-localizing activity
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[297–300]. It is generally recognized as being safe by the Food and Drug Ad-
ministration (FDA) [301]. Protamine is found to be a prominent compound
as it can facilitate the entrance of DNA into the nucleus by efficient binding
to negatively charged DNA molecules and providing its highly compact config-
uration [300, 302, 303]. Protamine carries four nuclear localization sequences
(NLSs), which facilitate the translocation of the protamine-DNA complex into
the nucleus [297,304–306].
For our studies, we used protamine sulfate (Merck, Darmstadt, Germany;
Mw=4-10 kDa, 10 mg mL−1).
3.4 Applied materials and methods for cell cul-
ture experiments
3.4.1 Cell lines and applied chemicals
In Table 3.1, the cell lines and primary cell cultures used along with the corre-
sponding cell media are listed. The cells were used in a particular cell line range
of cell passages (number of cell divisions), freshly defrosted and cultivated 10-14
days prior to being taken into the experiment. The adherent cell lines, which get
attached to the bottom of the cell culture flask, were passaged every 3-4 days
when their confluency (cell density) reached 80-90%. The non-adherent cells,
which live and proliferate in the cell medium as suspension, were passaged once
a week when their concentration reached 1-2·106 cells per mL of cell medium.
Cell culture medium is a basal liquid nutrient essential for cultivating the cells
outside the living organisms (in vitro) for different purposes. Basal cell culture
medium contains a mixture of defined nutrients (amino acids, inorganic salts,
glucose, vitamins and other organic nutrients) dissolved in a buffered physiological
saline solution (see Table 4.12). Most culture media also contain pH-indicators
like Phenol Red, which signals on the pH changes in the cell culture medium
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during the cultivation process. Basal media can be modified by the addition of
various supplements to generate a complete growth medium for a specific cell
line.
For cultivation of the above mentioned cell lines and primary cells, the follow-
ing cell culture media and chemicals, purchased from Gibco R© , Life Technolo-
gies, USA (if not stated otherwise), were used: DMEM-Dulbecco’s Modified
Eagle’s Medium; RPMI-1640 medium-Roswell Park Memorial Institute medium;
MSCGM-Mesenchymal Stem Cell Growth Medium (MSCGM R© , Lonza); HEPES
buffer (5mM); L-glutamine (5mM); penicillin/streptomycin (P/S) (antibiotics
for prevention of bacterial contamination) and fetal calf serum (FCS) containing
growth factors, as serum supplement.
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Table 3.1 List of all cell lines used in the biological experiments. FCS: fetal calf
serum.
Cell
type Description
Cell
morphology
and
properties
Range
of
passage
number
Cell medium
HeLa
Human epithelial
cervical cancer
cell line
Epithelial,
adherent P8-50
DMEM + 100 U mL−1
penicillin/streptomycin
+ 10% FCS
MG-63
Human
osteosarcoma
cell line
Fibroblasts,
adherent P37-50
DMEM + 100 U mL−1
penicillin/streptomycin
+ 10% FCS
THP-1
Human acute
monocytic
leukemia cell line
Monocytes/
Macrophages,
suspension
P45-50
RPMI-1640 +
100 U mL−1 penicillin/
streptomycin + 10%
FCS + 5mM HEPES
+ 5mM L-glutamine
hMSC
Normal human
bone marrow
derived
mesenchymal
stem cells
Multipotent
stromal cells,
adherent
P5-7
MSCGM +
100 U mL−1 penicillin/
streptomycin + 10%
FCS
3.4.2 Light and fluorescence microscopy
Fluorescence is a form of luminescence by which a substance emits light with
longer wavelength (less energy) per photon after absorption of light with shorter
wavelength (more energy). This phenomenon lies in the basis of fluorescence
microscopy. A typical fluorescence microscope consist of (but is not limited to) a
light source (usually a mercury-vapor lamp or a xenon arc lamp), the excitation
filter, the dichroic mirror, collector lens, the emission filter and objective. The
light source emits white light, which while passing through the excitation filter
selects the specific wavelength for the excitation of a fluorophore. The specimen
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previously stained with a fluorescent dye (DAPI, Cell mask R© , Alexa488, Cy5,
etc.) is illuminated with this light which the fluorescent molecules absorb. This
causes them to emits light with longer wavelength (less energy per photon) and,
thus, another color. The emitted light then goes through spectral emission filters
separating it from other residual unspecific fluorescence and giving one bright
color of lower wavelength, which can be observed by naked eye. The filters and
the dichroic mirror are chosen to match the spectral excitation and emission
characteristics of the fluorophore used to label the specimen [307].
The light and fluorescence microscopy was performed with a Zeiss Axiovert 40
CFL (Carl Zeiss, Goettingen, Germany) and a Keyence Biorevo BZ-9000 (Osaka,
Japan) equipped with filters for TRITC (excitation: 540 nm, emission: 605 nm),
GFP BP (excitation: 470 nm, emission: 535 nm) and DAPI (excitation: 360 nm,
emission: 460 nm) channels under 40x and 100x magnification.
3.4.3 Confocal laser scanning microscopy (CLSM)
Confocal laser scanning microscopy (CLSM) is one of the light microscopic tech-
niques that allows to obtain high-resolution optical images of micrometer or sub-
micrometer range objects, including fixed and living cells or cell compartments,
tissues, as well as colloidal dispersions [308].
This technique has become an essential tool in biomedical sciences and related
fields, owing to the possibilities offered compared to traditional optical fluores-
cence microscopy. In a conventional microscope, the entire fluorescently labeled
specimen is irradiated with the emitted light, often resulting in a blurred image,
because the fluorophores on all levels of the sample are exited simultaneously and
overlay one another. Besides, it could lead to photo bleaching of fluorophores,
causing a loss of image quality. In contrast, in confocal microscopy only one
selected depth level of the specimen is irradiated at a time. The images of
the specimen, labeled with multiply fluorophores, are acquired via point-by-point
scanning of selected plane, while scattered fluorescent light outside of the focal
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plane is shielded through a pinhole. This process can be repeated within selected
sample depth and then the obtained serial of images could be reconstructed in a
three-dimensional object. This process is called optical sectioning or Z-stack.
Investigations of cells were performed on a Leica SP5 confocal inverse CLSM
in the group of Prof. Perihan Nalbant at the University of Duisburg-Essen, as
well as on a Zeiss LSM 510, Axiovert 200 in the group of Prof. Eric Metzen at
Essen University Hospital.
3.4.4 Fluorescence-activated cell sorting (FACS) analysis
Fluorescence-activated cell sorting (FACS) is a specialized form of flow cytometry
that enables sorting a heterogeneous mixture of cells into two or more fractions,
one cell at a time, according to the specific light scattering and fluorescent char-
acteristics of each cell. Using this method, the fluorescent signals from individual
cells in cell mixture can be quickly and easily quantified and the cells of particular
interest can be collected into separate vessel.
The mechanism of FACS is described as follows. The cell suspension is cen-
tered in a narrow, rapidly flowing stream of liquid in a narrow needle. The flow
undergoes vibration to achieve large separation distances between cells. This
flow passes between the laser (or lasers) with a specific wavelength to excite the
cell, and the detectors, which detect the cell fluorescence intensity, its size and
granularity, depending on the obtained scattered light. Depending on the chosen
characteristics, the flow receives a corresponding charge, flowing through an elec-
trical charging ring and breaks into droplets. Under the influence of electrostatic
deflectors, the charged droplets, containing one cell each are divided into test
tubes corresponding to their charge.
The FACS analysis was performed with a FACSCalibur instrument (BD Bio-
scienses, USA) in the group of Prof. Michael Ehrmann (Centre for Medical
Biotechnology, University of Duisburg-Essen).
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3.4.5 Viability test (MTT assay)
The MTT assay is a colorimetric assay for measuring the metabolic activity of
cells. This method is based on the ability of NAD(P)H-dependent cellular oxidore-
ductase to reduce MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) to insoluble formazan compound of purple color in the mitochondria of
living cells (Figure 3.5). Using this method, one can assess the viability and the
proliferation rate of cells in vitro. It can also be used to determine the cytotoxic-
ity of potential medicinal agents and toxic materials because these agents would
stimulate or inhibit cell viability and proliferation. The absorbance of the colored
solution can be quantified by measuring it at a certain wavelength (λ=570 nm)
by a spectrophotometer.
The protocol used for determining the cell viability in our experiments was as
follows. MTT (Sigma, Taufkirchen, Germany) was dissolved in PBS (5 mg mL−1)
and then diluted to 1 mg mL−1 in the cell culture medium. The cell culture
medium of the cells treated with nanoparticles or control was replaced by 300 µL
of the MTT solution and incubated for 1 h at 37 ◦C under 5% CO2 in humidified
atmosphere. Then 300 µL of DMSO was added to the cells. After 30 min,
three aliquots (100 µL) per sample were taken for spectrophotometric analysis
with a Multiscan FC instrument (Thermo Fisher scientific, Vantaa, Finland) at
λ=570 nm. The absorption of treated cells was normalized to the untreated cells
(Mock), thereby indicating the relative level of cell death.
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Figure 3.5 The reduction reaction of MTT in mitochondria.
3.4.6 Lysozyme activity assay
Lysozyme (muramidase) is a ubiquitous and well-characterized enzyme that natu-
rally occurs in different animal and plant tissues as well as secretions (e.g. saliva,
tears, serum, urine, seminal fluid, and milk). Lysozyme hydrolyzes β-(1-4)-
glucosidic bonds between N-acetylmuramic acid and N-acetyl-D-glucosamine resi-
dues presented in the mucopolysaccharide cell wall of a variety of microorganisms,
thus possesses an explicit antibacterial effect.
The EnzChek R© Lysozyme Assay Kit (Molecular Probes R© , Life Technologies,
USA) is a sensitive assay to measure levels of lysozyme activity in solution. This
fluorescence-based assay can detect lysozyme activity down to 20 U mL−1. The
assay measures lysozyme activity on Micrococcus lysodeikticus cell walls that are
labeled to such a degree that the fluorescence is quenched. Lysozyme action can
prevent this quenching, thereby yielding a dramatic increase in fluorescence that is
proportional to lysozyme activity. The fluorescence increase can be measured by
using a spectrofluorometer, mini-fluorometer, or fluorescence microplate reader
that can detect fluorescence.
The determination of lysozyme activity in THP-1 cells using this assay was car-
ried out in the following manner. THP-1 cells (1·106 cells per well) were seeded
in 12-well plates in 1 mL of RPMI-1640 medium. The cells were differentiated
by additions of PMA as described in Subsection 3.5.2. Afterwards, the cell cul-
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ture medium was removed and new medium containing lipopolysaccharides (LPS,
10 µg mL−1) and aprotinin (pancreatic trypsin inhibitor, ApplChem, 2 µg mL−1)
was added to the cells, so that the total volume of added cell medium was 1 mL.
The sample was left for incubation for 48 h. Then 100 µL of nanoparticles
suspension or soluble polymer were added to the cells and incubated for 24 h.
Afterwards, the cell medium was collected into Eppendorf tubes and centrifuged
for 10 min at 2,000 g under 4 ◦C. The cells were washed with PBS and sub-
sequently lysed with the addition of 450 µL of CelLytic R© M Cell Lysis Reagent
(Sigma-Aldrich, Steinheim, Germany) and incubation on the Shaker (Oehmen,
Labortechnik) for 5 min. This followed by collection the cell lysate into the Ep-
pendorf tube and subsequent centrifugation for 10 min by 14,000 g at 4 ◦C to
remove cellular debris. The obtained samples were then used for the EnzChek R©
assay, according to the manufacturer’s manual.
In brief, 50 µL aliquots of each sample (cell lysate and cell medium, 4 aliquots
each) were transferred into a black 96-well plate for measuring fluorescent sam-
ples (Sarstedt, USA). Along with this the lysozyme standard curve was prepared
by filling 8 wells with 50 µL of phosphate reaction buffer and adding 50 µL of the
1,000 U mL−1 stock solution of lysozyme to the first well, mixing by pipetting
and transferring 50 µL to the second well. This procedure was repeated subse-
quently for the next wells, except for discarding 50 µL from the mixture in the
seventh well and adding nothing to the eighth. Thus, the lysozyme concentra-
tion ranged from 500 U mL−1 to 0 U mL−1 in the 50 µL volumes. After the
addition of 50 µL of DQ lysozyme substrate working suspension (50 µg mL−1
stock suspension diluted in phosphate buffer) to each well, the concentration of
the substrate in each well was 25 µg mL−1 and final concentrations of lysozyme
in standard curve samples ranged from 250 U mL−1 to 0 U mL−1 in the 100 µL
volume. The mixtures were incubated for 1 h at 37 ◦C, protected from light. The
fluorescence measurements were carried out on a fluorescence microplate reader
(SpectraMax M5e, Molecular Devices, in the group of Prof. Michael Ehrmann,
Centre for Medical Biotechnology, University of Duisburg-Essen) by using filters
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for absorption (λ=485 nm) and emission (λ=538 nm). The obtained values were
then converted into lysozyme activity in U mL−1 using a calibration curve. All
samples were measured in quadruplicates. At least 3 independent experiments
were carried out. The statistical analysis of the obtained data was performed us-
ing Student’s t-test, where p-value<0.5 was accepted as statistically significant
difference.
For determining of lysozyme-inhibiting polymer efficiency in the samples with-
out cells in different milieus, the standard lysozyme solution in concentration of
1.4 nM was added to the wells containing either phosphate buffer, RPMI-1640
without FCS or RPMI-1640 + 10% FCS. The polymer was added in different con-
centrations (0.11, 1.1, 2.2, and 3.3 nM) to the lysozyme-containing solutions and
incubated for 5 min at 37 ◦C. The solution with no addition of inhibitor polymer
was used as positive control (100% lysozyme activity). Then the samples were
transferred into black 96-well plate for measuring fluorescent samples in 50 µL
aliquots and treated according to the above mentioned protocol. All samples
were measured in quadruplicates in two independent experiments.
3.5 Cell culture methods
3.5.1 Cultivation of secondary cell lines and primary cells
All cell lines and primary cells (hMSC) were cultured in the corresponding media
(see Table 3.1) at 37 ◦C under humidified atmosphere, containing 5% CO2 in
25 cm2 or 50 cm2 cell culture flasks (Sarstedt, USA) in incubator. After achieving
80-90% confluence, adherent cell lines were washed twice with PBS and then
treated with a trypsin/EDTA solution (Gibco R© , Life Technologies, USA) for
3 min at 37 ◦C to detach cells from the cell culture flask surface. After this,
the corresponding cell medium was added to the cell suspension and transferred
to the falcon tube for centrifugation (Heraeus Multifuge X1R, 900 rpm, 3 min,
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RT). Then the trypsin-containing supernatant was removed and the cells were
subsequently resuspended in fresh medium and transferred to a cell culture flask
or seeded for the experiments into corresponding well plates or slides.
The suspension cell line THP-1 was cultivated in corresponding medium (see
Table 3.1) and at the same conditions as adherent cell lines at concentration
between 1·105-1·106 cells mL−1. After reaching the concentration of 1·106 cells
mL−1, the cells were transferred into the falcon tube and collected by centrifu-
gation (Heraeus Multifuge X1R, 900 rpm, 3 min, RT). After the removal of the
supernatant, the cells were resuspended in fresh medium and transferred into a
cell culture flask, or seeded for the experiments into corresponding well plates or
slides.
The number of cells, added for further cultivation to the cell culture flask, was
adjusted so the passage of each cell line was repeated 1-2 times a week. The
cell number was determined with the help of a hemacytometer, adding 10 µL of
cell suspension (obtained after centrifugation) to the chamber of hemocytometer,
covered by cover glass, and by manually counting the cells in 4 big squares using
light microscope at 10x magnification. The cell number was calculated as follows:
the mean value from 4 squares multiplied by 104 to estimate the number of cells
per mL of cell suspension.
To estimate the number of healthy suspension cells they were treated in the
same way as the adherent, except that before adding the aliquote to the hema-
cytometer chamber, they were previously diluted in the Trypan Blue R© reagent
(Gibco R© , Life Technologies, USA) in a 1:10 ratio (10 µL of cell suspension
to 90 µL of Trypan Blue R© solution). Afterwards, a 10 µL aliquote of Trypan
Blue R© -treated suspension cells were placed into the hemacytometer chamber
and counted as mentioned above. In this case, the cells that took up the blue
dye (appear blue in light microscope) were considered non-viable and were not
counted.
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3.5.2 Differentiation of suspension cells
Before imaging the suspension cells of the THP-1 cell line with light and fluores-
cence microscopy and CLSM as well as carrying out EnzCheck R© assays, the cells
must become adherent. This can be done by stimulating the cells to differentiate
from suspension-proliferating monocytes into adherent multinuclear, non-dividing
macrophages. For this purpose, the seeded THP-1 cells were treated with PMA
(phorbol-12-myristate-13-acetate, Sigma-Aldrich, USA, 0.1 mg mL−1) solution
with the final concentration 100 nM per well (1 µL stock solution of PMA to
2 mL of cell medium) and then left to differentiate for 3 days. Then the medium
for differentiation was substituted by the same amount of fresh one and the
differentiated cells were used further in the experiments.
3.5.3 Cryoconservation and thawing of cells
In order to be able to use fresh and adequate cells for experiments, they must
be aliquoted and stored properly with minimal damage and loss of cell viability,
as well as excluding the risk of contamination and mutation of the cells. For
this reason, all cell lines and primary cells used were exposed to the process
of cryoconservation as follows. Cultured cells were washed twice with PBS,
trypsinized, and centrifuged as described previously in Subsection 3.5.1. Then
they were redispersed in the corresponding cell medium containing 10% DMSO
(100 µL in 1 mL of total cell medium for cryoconservation) with the concentration
1·106 cell mL−1 per one cryogenic vial. These vials were exposed to a slow
cooling over 24 h at -80 ◦C and then transferred into a Dewar container with
liquid nitrogen (-196 ◦C) for prolonged storage.
For thawing, the cells were rapidly taken out from the liquid nitrogen and heated
to 37 ◦C within 1 min. To avoid an osmotic shock, the cells were immediately
transferred into 10 mL preheated (37 ◦C) cell culture medium. The thawed cells
were then centrifuged (Heraeus Multifuge X1R, 900 rpm, 3 min, RT), resuspended
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in fresh medium, and transferred to the cell culture flask. In order to remove the
residues of DMSO, the medium was changed again after 18 h (overnight).
3.5.4 Cell transfection and determination of the
transfection efficiency
HeLa cells and MG-63 cells were cultivated in the corresponding medium (see Ta-
ble 3.1) at 37 ◦C under 5% CO2 atmosphere. On the day before the transfection
experiment, the cells were trypsinized and seeded in 96-well plates with a density
of 5·103 cells per well in 100 µL of cell culture medium. Approximately 24 h
later, the cell medium in all samples was removed and a fresh medium containing
functionalized nanoparticles or corresponding controls in 1:10 ratio, i.e. 10 µL of
each nanoparticle dispersion and 90 µL of cell culture medium, was added to the
cells and incubated for 7 h. Nanoparticles without protamine or PEI and poly-
plexes (DNA/Protamine/PEI) were set as control groups. After 7 h incubation,
the cell culture medium containing the transfection agents was changed and the
cells were left for another 72 h incubation.
The transfection efficiency was determined by transmission light microscopy and
fluorescence microscopy (Carl Zeiss MicroImaging, Göttingen, Germany, magnifi-
cation 100x) 72 h after transfection. The transfection efficiency of the nanopar-
ticles and corresponding controls was determined by fluorescence and light mi-
croscopy as follows:
Number of EGFP-expressing cells (green fluorescence)
Total number of cells · 100%
Dead cells (as recognized by their shape) were not included in the computation.
Each sample was performed in duplicates and imaged at three different places
within one well, giving a total of six images per sample. The statistical analysis
of obtained data was performed using Student’s t-test, where a p-value<0.5 was
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accepted as a statistically significant difference. The values are written as mean
value ± standard deviation (SD) in %.
3.5.5 Studies of uptake of nanoparticles
All cell types were cultured in corresponding cell culture media (see Subsec-
tion 3.4.1) at 37 ◦C and 5% CO2. About 18 h prior to uptake experiments,
the cells were trypsinized and seeded in cell culture well plates with the overall
density of 1·105 cells per well in 1 mL cell medium. The suspension cells were
first treated with PMA (see Subsection 3.5.2) so that they became differentiated
and adherent. For the uptake studies, the cells were treated with corresponding
nanoparticles’ colloids in ratio of 1:11 (50 µL of the particle dispersion was added
to cell culture well, containing 500 µL cell medium). The cells were incubated for
3 h or longer (depending on the experiment), after which the whole cell culture
medium was removed and cells were washed three times with PBS to remove
the cell medium and the nanoparticles that were not taken up by the cells. Af-
terwards, the cell samples were immediately imaged using light and fluorescence
microscopy (Zeiss Axiovert 40 CFL or Keyence BZ-9000 fluorescent microscope).
3.5.6 Fixation of cells for CLSM
For performing CLSM on fixated cells, they were treated as follows. Cells were
seeded into special 4- or 8-wells cell culture coverslips (Falcon R© Culture Slides,
DB Biosciences) in density 0.5·105-1·105 in 500 µL cell medium, depending on
the well size, and cultivated overnight. For fixation of suspension cells, they were
differentiated beforehand, as previously described.
After treating the cells with different samples and during various cultivation
periods they were fixated and stained in the following manner. The cell medium
was removed and the cells were washed 3 times with PBS. Then they were
treated with formaldehyde solution (2.5% dissolved in PBS) for 20 min at room
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temperature (RT). The used solution of formaldehyde was collected into a sep-
arate waste container and the cells were washed twice with PBS. Afterwards,
the cells were stained subsequently with different fluorescent dyes, labeling ei-
ther cell membrane (Cell Mask R© , Molecular ProbesTM, Life Technologies, USA),
chromatin (DAPI, 4’,6-diamidin-2-phenylindol, Molecular ProbesTM, Life Tech-
nologies, USA) or actin filaments (Actin phalloidine488, Molecular ProbesTM,
Life Technologies, USA) and incubated for 5, 7 or 15 min at 37 ◦C, respectively.
After each staining, all samples were washed twice with PBS to remove the un-
bounded dye. Finally, the slides were treated with mountain medium (Dako,
Agilent Technologies) and carefully covered with cover glass so that no air bub-
bles emerged. The cover slips were stored in aluminum foil at 4 ◦C for long-term
storage.
3.5.7 Inhibition of endocytosis
To study the role of different endocytotic pathways in the uptake of the func-
tionalized calcium phosphate nanoparticles and the HTRA1 protein a selective
inhibition of various pathways was applied. The list of the inhibitors used and the
corresponding inhibited pathways, as well as the concentrations used, are given
in Table 3.2.
The selection of the concentrations used and protocol was adjusted from the
literature [153]. Briefly, the day before the start of the experiment, MG-63
cells were seeded in 6-well plates with a density of 5·105 cells per well. On
the following day, the cell culture medium was removed by fresh cell medium
containing inhibitors, in total volume of 2 mL and cultivated for 30 min. As a
control group, the cells treated with normal cell medium with no inhibitors and left
either at 37 ◦C (positive control) or 4 ◦C (negative control) for 30 min were used.
Afterwards, the nanoparticles or the protein were added to the corresponding
cell samples and incubated for another 3 h. Then all samples were washed 3
times with PBS, detached with trypsin/EDTA complex (3 min by 37 ◦C) and
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transferred into 15 mL falcon tubes by adding to each cell sample 3 mL of cell
medium. The cells were then washed 3 times by centrifugation (1,700 g, 5 min,
4 ◦C) and subsequent resuspension in 4 mL PBS. After final centrifugation, all
samples were resuspended in 2% formaldehyde solution and incubated for 20 min
at RT. Then 0.6 mL of PBS were added to each sample and the cells were washed
3 times by centrifugation (1,700 g, 5 min, 4 ◦C) and subsequently resuspended
in 3 mL PBS. As the last washing step, each sample was resuspended in 1 mL
PBS and stored in dark at 4 ◦C. The prepared cell samples were then transferred
to FACS tubes for measurements (see Subsection 3.4.4).
Table 3.2 The list of endocytosis inhibitors used in biological experiments.
Inhibitor
Inhibited
pathway /
structure
C
(inhibitor)
in stock
solution /
µg mL−1
V
(inhibitor)
added /
µL
C
(inhibitor)
per well /
µg mL−1
Wortmannin Macropino-cytosis 10 20 0.1
LY294002 Macropino-cytosis 1000 40 20
Nystatin
Caveolin-
mediated
endocytosis /
Lipid Rafts
2000 10 10
Nocodazole Microtubules ofcytoskeleton 1000 20 10
Chlorpromazine
Clathrin-
mediated
endocytosis
100 20 1
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4.1 Transport of molecules into the cell with calcium
phosphate nanoparticles
4.1.1 DNA-, protamine- and PEI-functionalized calcium
phosphate nanoparticles for transfection
4.1.1.1 Characterization of functionalized calcium phosphate
nanoparticles
Nanoparticles for transfection experiments were prepared as described above
in Subsection 3.1.1 and were not purified. For characterization purposes the
nanoparticles were functionalized with model DNA from herring sperm (Sigma-
Aldrich, Mw=10-30 kg mol−1, 1 mg mL−1). The volume ratio of calcium phos-
phate colloid to nucleic acids solution, used for the synthesis, was 5:1. The triple-
shell structure of nanoparticles was used to protect the sensitive biomolecules
from nucleases and other risks of degradation in and outside the living cell. As
a final shell for steric and electrostatic stabilization, polyethylenimine, which is a
positively charged polyelectrolyte, was used in different amounts (see Table 4.1).
For transfection experiments, calcium phosphate nanoparticles were loaded with
functional pcDNA-EGFP. In order to increase the transfection efficacy of the
nanoparticles, they were additionally functionalized with protamine in different
configurations. Additional control samples carried either no CaP, protamine or
PEI were prepared. In Table 4.1, the final concentrations of calcium phosphate,
DNA, protamine, and PEI in the nanoparticle dispersion are shown.
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Table 4.1 The final concentrations of calcium phosphate, DNA, protamine, and
PEI in the nanoparticles dispersion.
Sample Concentration / µg mL
−1
CaP DNA Protamine PEI
A CaP/DNA/Protamine/CaP/PEI0.05 1447 107 533 80
B CaP/DNA/Protamine/CaP/PEI0.1 1391 103 513 153
C CaP/DNA/Protamine/CaP/PEI0.2 1292 95 476 286
D DNA/Protamine/PEI0.05 0 107 533 80
E DNA/Protamine/PEI0.1 0 103 513 153
F DNA/Protamine/PEI0.2 0 95 476 286
G CaP/DNA/CaP/PEI0.05 1528 113 0 108
H CaP/DNA/CaP/PEI0.1 1466 108 0 162
I CaP/DNA/CaP/PEI0.2 1356 100 0 300
J CaP/DNA/CaP/Protamine 1507 111 555 0
In Table 4.2 the colloid-chemical characterization data of the synthesized nano-
particles are shown. All samples had relatively good polydispersity index (<0.5)
and a size between 200 and 300 nm. The addition of PEI lends a strong positive
surface charge to the nanoparticles, preventing the nanoparticles from agglo-
meration, and also facilitating the uptake process and preventing the DNA from
subsequent degradation in lysosomes due to the "proton sponge effect" (see Fi-
gure 2.6).
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Table 4.2 Colloid-chemical characterization data of the synthesized nanoparti-
cles. PDI: polydispersity index from dynamic light scattering.
Sample PDI Particle size/ nm
Zeta
potential
/ mV
A CaP/DNA/Protamine/CaP/PEI0.05 0.470 207 +30
B CaP/DNA/Protamine/CaP/PEI0.1 0.407 238 +28
C CaP/DNA/Protamine/CaP/PEI0.2 0.390 247 +33
D CaP/DNA/CaP/PEI0.05 0.420 239 +20
E CaP/DNA/CaP/PEI0.1 0.306 285 +36
F CaP/DNA/CaP/PEI0.2 0.390 271 +37
G CaP/DNA/CaP/Protamine 0.496 464 +5
The scanning electron micrographs (Figure 4.1) showed spherical nanoparticles
with an actual size up to 100 nm. This value is slightly different from the
measurements obtained with DLS, indicating some agglomeration in dispersion.
Figure 4.1 Scanning electron micrographs of DNA-, protamine- and PEI-loaded
calcium phosphate nanoparticles: (A) CaP/DNA/Protamine/CaP/PEI0.05;
(B) CaP/DNA/Protamine/CaP/PEI0.1; (C) CaP/DNA/Protamine/CaP/PEI0.2.
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4.1.1.2 Results of transfection experiments
For the transfection experiments, two different cell lines of human origin were
used, namely HeLa (epithelial cell line) and MG-63 (osteoblast-like cell line). For
the transfection protocol and cell cultivation procedures, refer to Subsection 3.5.1.
The evaluated results of the transfection with multi-shell CaP/DNA/Protamine/-
CaP/PEI nanoparticles and controls, as well as the cell viability of both cell lines,
are summarized in Table 4.3. The transfection efficiency was shown to be be-
tween 39% and 54% for both cell lines, and did not have strict dependency on
the concentration of PEI (Figure 4.2 A). However, the viability of cells showed
a direct dependency on the PEI concentration in the nanoparticles’ samples: it
decreased from 94% to 73% for HeLa and, in the case of the more sensitive
MG-63 cell line, the viability decreased dramatically from 67% to 8% with an
increased concentration of PEI (Figure 4.2 B; Table 4.3, samples A, D, G). In
the control groups (Table 4.3, samples without calcium phosphate B, E, H and
without protamine C, F, I), the transfection efficiency and the cell viability were
significantly reduced. This indicated the toxic influence of PEI and the necessity
of nanoparticles and protamine for a high transfection efficiency. On the con-
trary, the control sample K without PEI showed very poor transfection efficiency
on the level of 5%, which demonstrated that the presence of PEI is still needed
for effective transfection despite its harmful effect on the cells.
In contrast, the addition of protamine into CaP/DNA/CaP/PEI nanoparticles
enhanced the transfection efficiency of both cell lines by improving the nuclear
import of the plasmid DNA. Protamine-DNA complexes are able to bind to im-
portins that attach to cytoplasmic filaments of the nuclear pore complex, resulting
in nuclear entry and subsequent transcription and translation processes through
the host cell gene expression machinery.
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Table 4.3 Results of transfection efficiency and cell viability of HeLa and MG-63
cells. Mean value ± standard deviation (SD). * p<0.05 compared to CaP/DNA-
Protamine/CaP/PEI0.05, 0.1 and 0.2 respectively. TE: Transfection efficiency,
CV: Cell viability.
Sample HeLa cells MG-63 cells
TE / % CV / % TE / % CV / %
A CaP/DNA/Protamine/CaP/PEI0.05 45 ± 8 94 ± 5 49 ± 5 67 ± 1
B DNA/Protamine/PEI0.05 26 ± 6∗ 35 ± 9∗ 17 ± 6∗ 13 ± 7∗
C CaP/DNA/CaP/PEI0.05 20 ± 7∗ 23 ± 8∗ 22 ± 7 42 ± 7∗
D CaP/DNA/Protamine/CaP/PEI0.1 39 ± 10 84 ± 6 52 ± 6 56 ± 7
E DNA/Protamine/PEI0.1 1 ± 1∗ 5 ± 4∗ 3 ± 1∗ 4 ± 3∗
F CaP/DNA/CaP/PEI0.01 33 ± 5 21 ± 6∗ 39 ± 6∗ 14 ± 6∗
G CaP/DNA/Protamine/CaP/PEI0.2 47 ± 7 73 ± 7 54 ± 8 8 ± 3
H DNA/Protamine/PEI0.2 29 ± 9∗ 5 ± 3∗ 8 ± 6∗ 4 ± 2∗
I CaP/DNA/CaP/PEI0.2 29 ± 12∗ 5 ± 3∗ 39 ± 9 5 ± 3
J CaP/DNA/CaP/Protamine 5 ± 3∗ 119 ± 8 4 ± 2∗ 77 ± 9
Figure 4.2 Comparison of transfection efficiency (A) and cell viability (B) of
HeLa and MG-63 cells. § p<0.05 compared to the untreated control.
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As can be seen from the summarized Table 4.3, CaP/DNA/Protamine/CaP-
/PEI0.05 nanoparticles (sample A) have a high transfection efficiency, combined
with good viability for both cell lines (Figure 4.2), which made them good candi-
dates for further experiments. Figure 4.3 illustrates the representative light and
fluorescent microscopy micrographs of HeLa and MG-63 cell, transfected with
CaP/DNA/Protamine/CaP/PEI0.05 nanoparticles.
Figure 4.3 Transmission light and fluorescence microscopy of HeLa and MG-63
cells, transfected with CaP/DNA/Protamine/CaP/PEI0.05 nanoparticles. Trans-
fected cells appear green on fluorescence microscopy; 100x magnification.
The next step was to check whether the amount of the nanoparticle dispersion
could influence the parameters of the transfection, i.e. efficiency and viability.
We used the same control groups for our experiments and this time varied the
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amount of the nanoparticle dispersion, which was given to the cells from 1.25 up
to 10 µL per 100 µL of cell medium. In Table 4.4, the corresponding amounts of
calcium phosphate, DNA, protamine, and PEI per well are given. The results from
the transfection experiments on both cell lines are summarized in Table 4.5. The
transfection efficiency increased significantly with the increase in the nanoparticle
concentration in cell medium for both cell lines: for HeLa from 4% to 38% and
for MG-63 from 5% to 39%. However, the viability rate of MG-63 cells decreased
almost to half from 110% to 59% with increasing concentration of the nanopar-
ticles. Interestingly, however, it remained unchanged for HeLa cells. It is also of
note that the optimal amount of CaP/DNA/Protamine/CaP/PEI0.05 nanopar-
ticle dispersion was different for each cell line. The best results of transfection,
i.e. optimal efficacy and viability for HeLa cells, were achieved with amount
nanoparticle dispersion of 10 µL to 100 µL of cell medium, whereas for MG-63
the amount was four times smaller (2.5 µL) (see Figure 4.4).
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Table 4.4 Final concentrations of CaP, DNA-EGFP, protamine, and PEI in
nanoparticle dispersions per 100 µL of cell medium.
V
(sample)
/ µL
Sample
Concentration / µg per
100 µL of cell medium
CaP DNA Pro-tamine PEI
10
CaP/DNA/Protamine/CaP/PEI0.05 14.46 1.07 5.3 0.8
DNA/Protamine/PEI0.05 0 1.07 5.3 0.8
CaP/DNA/CaP/PEI0.05 15.28 1.12 0 0.85
CaP/DNA/CaP/Protamine 15.07 1 5.6 0
5
CaP/DNA/Protamine/CaP/PEI0.05 7.23 0.54 2.6 0.4
DNA/Protamine/PEI0.05 0 0.54 2.6 0.4
CaP/DNA/CaP/PEI0.05 7.14 0.56 0 0.42
CaP/DNA/CaP/Protamine 7.53 0.5 2.8 0
2.5
CaP/DNA/Protamine/CaP/PEI0.05 3.16 0.27 1.3 0.2
DNA/Protamine/PEI0.05 0 0.27 1.3 0.2
CaP/DNA/CaP/PEI0.05 3.57 0.28 0 0.21
CaP/DNA/CaP/Protamine 3.76 0.25 1.4 0
1.25
CaP/DNA/Protamine/CaP/PEI0.05 1.86 0.13 0.65 0.1
DNA/Protamine/PEI0.05 0 0.13 0.65 0.1
CaP/DNA/CaP/PEI0.05 1.78 0.14 0 0.11
CaP/DNA/CaP/Protamine 1.88 0.13 0.7 0
In Figure 4.4, representative light and fluorescence micrographs of HeLa and
MG-63 cells after transfection with different amounts of CaP/DNA/Protamine/-
CaP/PEI0.05 nanoparticles are shown.
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Table 4.5 Transfection efficiency and cell viability of HeLa and MG-63 cells
at different concentrations of nanoparticles (per 100 µL of cell medium). Mean
value ± standard deviation (SD). * p<0.05 compared to CaP/DNA/Protamine/-
CaP/PEI0.05 nanoparticles. TE: Transfection efficiency, CV: Cell viability.
V
(sample)
/ µL
Sample HeLa cells MG-63 cells
TE / % CV / % TE / % CV / %
10
CaP/DNA/Protamine/CaP/PEI0.05 38 ± 6 91 ± 3 39 ± 4 59 ± 7
DNA/Protamine/PEI0.05 30 ± 7 12 ± 7∗ 21 ± 8∗ 11 ± 6∗
CaP/DNA/CaP/PEI0.05 28 ± 7∗ 12 ± 1∗ 30 ± 5 31 ± 7∗
CaP/DNA/CaP/Protamine 4 ± 2∗ 118 ± 9 5 ± 3∗ 78 ± 9
5
CaP/DNA/Protamine/CaP/PEI0.05 19 ± 7 121 ± 6 38 ± 6 72 ± 10
DNA/Protamine/PEI0.05 13 ± 5 91 ± 4 23 ± 7∗ 36 ± 8∗
CaP/DNA/CaP/PEI0.05 13 ± 7 34 ± 6∗ 27 ± 8∗ 42 ± 6∗
CaP/DNA/CaP/Protamine 3 ± 1∗ 116 ± 8 3 ± 1∗ 83 ± 12
2.5
CaP/DNA/Protamine/CaP/PEI0.05 12 ± 3 117 ± 8 32 ± 5 109 ± 5
DNA/Protamine/PEI0.05 13 ± 4 113 ± 9 16 ± 7∗ 97 ± 9
CaP/DNA/CaP/PEI0.05 9 ± 5 99 ± 6 7 ± 5∗ 80 ± 5∗
CaP/DNA/CaP/Protamine 2 ± 1∗ 106 ± 9 1 ± 2∗ 105 ± 11
1.25
CaP/DNA/Protamine/CaP/PEI0.05 4 ± 2 114 ± 9 5 ± 2 110 ± 8
DNA/Protamine/PEI0.05 6 ± 2 119 ± 8 4 ± 1 91 ± 8
CaP/DNA/CaP/PEI0.05 2 ± 2 111 ± 8 6 ± 4 82 ± 8
CaP/DNA/CaP/Protamine 1 ± 1∗ 115 ± 9 2 ± 1∗ 95 ± 10
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Figure 4.4 Comparison of transfection efficiency (A) and cell viability (B) of
HeLa and MG-63 cells, depending on the amount of nanoparticle dispersion added
per 100 µL of cell medium. A: * p<0.05 compared to the 10 µL group for HeLa
cells; § p<0.05 compared to 10 µL group for MG-63 cells. B: * p<0.05 compared
to the untreated control.
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Figure 4.5 Transmission light microscopy and fluorescence microscopy of HeLa
and MG-63 cells transfected with different concentrations of CaP/DNA/Pro-
tamine/CaP/PEI0.05 nanoparticles. Transfected cells appear green on fluores-
cence microscopy; 100x magnification.
4.1.1.3 Conclusions
We developed multi-shell calcium phosphate nanoparticles loaded with plasmid
DNA, protamine and PEI. The polycationic polymer PEI provided high transfec-
tion efficiency, while protamine reduced the cytotoxicity of PEI, protecting cells
from apoptosis, and at the same time improved the entry of plasmid DNA into the
nucleus. Nanoparticles with the smallest concentration of PEI (CaP/DNA/Pro-
tamine/CaP/PEI0.05) were found to be most effective, showing a good trans-
fection efficiency while preserving high viability in both cell lines.
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On the whole, the following conclusions can be drawn from these results. First,
the MG-63 cell line is more sensitive to the transfection procedure than the HeLa
cells. Second, the interaction of the nanoparticles with cells depends on the cell
type. Finally, it is important to find the optimal concentration of the transfection
agent (in our case, functionalized calcium phosphate nanoparticles) for a specific
cell line to receive the highest transfection efficiency, and at the same time the
highest viability, which often stands in contrast to each other: the higher the
transfection efficiency, the lower the viability rate.
4.1.2 Transport of various molecules across the cell
membrane with calcium phosphate nanoparticles
4.1.2.1 Synthesis and characterization of functionalized calcium
phosphate nanoparticles
For this experiment, we took molecules that were completely different by origin
and chemical structure in order to make a proof-of-principle experiment that we
can deliver any kind of molecular cargo inside the cell with calcium phosphate
nanoparticles when the cargo itself is not able to penetrate the cell membrane. We
chose eight fluorescent or fluorescently labeled molecules: oligonucleotide CpG
(labeled with Alexa488 or Alexa555), protein BSA (labeled with fluorescein isoth-
iocyanate (FITC) or with tetramethylrhodamine isothiocyanate (TRITC)), anti-
body DEC-205 (labeled with FITC), polycationic polymer PEI (labeled with rho-
damine), porphyrine pTHPP (5,10,15,20-tetrakis(4-hydroxyphenyl)-21H, 23H-
porphine; has red fluorescence), and a synthetic peptide (labeled with FITC).
For this study we designed single-shell nanoparticles. For the description of
the synthesis process of the nanoparticles loaded with labeled CpG, BSA, and
DEC-205 molecules, refer to Subsection 3.1.1. For the synthesis of CpG-carrying
nanoparticles, no addition of the stabilization agent was needed, because the
strong negative charge from phosphate groups of the oligonucleotide backbone
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was big enough to stabilize the nanoparticles. In the case of neutral big proteins
BSA and DEC-205, a polyelectrolyte in the form of DNA from herring sperm and
non-labeled CpG was added, respectively. CpG- and BSA-loaded nanoparticles
were purified by centrifugation and a subsequent redispersion in pure water. For
the DEC-205-carrying nanoparticles, this procedure could not be employed due
to the high sensitivity of the antibody molecules to ultrasonication.
The synthesis of single-shell nanoparticles carrying PEI-rhodamine, pTHPP por-
phyrin, stabilized either with PSS or PEI as well as peptide-FITC is described in
Subsection 3.1.2.
The colloid-chemical characterization of all samples, performed by DLS and
NTA methods, and the concentration of fluorescent molecules in the nanoparticle
dispersion determined by UV-Vis spectroscopy, are summarized in Table 4.6.
Table 4.6 Colloid-chemical data of calcium phosphate nanoparticles, carrying
different molecules. PDI: polydispersity index from dynamic light scattering.
Sample
Size /
nm
(DLS)
PDI
Size /
nm
(NTA)
Zeta
potential
/ mV
C (fluo-
rescing
molecules)
/ µg mL−1
1 CaP/CpG-Alexa555 240 0.295 139 -24 ± 4 58
2 CaP/CpG-Alexa488 289 0.338 147 -22 ± 7 58
3 CaP/DNA/TRITC-BSA 227 0.482 209 -21 ± 6 95
4 CaP/DNA/FITC-BSA 256 0.370 189 -20 ± 6 63
5 CaP/CpG/FITC-DEC205 243 0.650 226 -19 ± 5 40
6 CaP/PEI-rhodamine 138 0.165 185 +34 ± 6 1000
7 CaP/PEI/pTHPP 117 0.236 173 +15 ± 4 5
8 CaP/PSS/pTHPP 122 0.198 203 -18 ± 5 7
9 CaP/PEI/FITC-Pep 109 0.169 230 +12 ± 6 49
All samples are monodisperse and have a size distribution of 100-250 nm. The
zeta potential, which refers to the surface charge of the nanoparticles, completely
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corresponds to the polyelectrolyte charge used for the steric stabilization of the
nanoparticles. Moreover, the absorbed molecules did not reverse the surface
charge of the nanoparticles, resulting in the absence of agglomeration and ag-
gregation in DLS and NTA measurements. The concentration of the fluorescent
cargo molecules can be seen in the right column of Table 4.6.
A representative scanning electron microscopy image of the functionalized nano-
particles (CaP/CpG-Alexa555) is shown in Figure 4.6. The nanoparticles are
about 50 nm in diameter and have a characteristic spherical shape. It must be
noted that in SEM images the nanoparticles appear to have smaller diameter
than that determined by dynamic light scattering (DLS) or nanoparticle tracking
analysis (NTA) because of absence of hydration and organic shell around the
nanoparticles after the sample preparation for SEM, as well as some agglomera-
tion. All dispersions were stable for several days during storage at 4 ◦C.
Figure 4.6 Scanning electron micrograph of CaP/CpG-Alexa555-loaded
nanoparticles.
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4.1.2.2 Results of uptake studies
All cell culture experiments were carried out with HeLa cell line with the samples
containing fluorescent molecules adsorbed on the surface of the nanoparticles or
in dissolved form at the same concentrations (control groups). The cells were
incubated for 3 h with the samples and then washed 3 times with PBS. Afterwards,
light and fluorescent microscopy and a viability assay (MTT test) were performed.
For a more detailed protocol of cultivation, incubation, and treatment during the
above mentioned procedures, refer to Subsection 3.5.1.
Figure 4.7 illustrates the results of the MTT assay of all samples, including
calcium phosphate nanoparticles without any molecules (sample CaP). Untreated
cells were used as control. We conclude from this figure that calcium phosphate
nanoparticles alone and also loaded with different fluorescent molecules had no
harmful effect on the cells, along with the dissolved molecules. Remarkably,
sample 6C (dissolved labeled PEI) clearly showed a cytotoxic effect, whereas the
same concentration of PEI adsorbed on the nanoparticles was not harmful for
cells.
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Figure 4.7 Results of the MTT test on HeLa cells. Labels 1-9 refer to the sample
number from Table 4.6 and labels 1C-9C to their corresponding controls; CaP:
unfunctionalized CaP nanoparticles (agglomerated).
In Figure 4.8, light and fluorescent microscopy images of HeLa cells which were
treated with FITC-BSA-functionalized nanoparticles and dissolved FITC-BSA are
depicted. The uptake of BSA was detected only in cells that were treated with
functionalized nanoparticles; this was recognized by green fluorescence in the cell.
Dissolved FITC-BSA molecules were not able to penetrate the cell membrane.
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Figure 4.8 Representative light (top) and fluorescence microscopy (bottom)
images of HeLa cells, incubated with CaP/DNA/FITC-BSA-loaded nanoparticles
(sample 4) and with dissolved FITC-BSA (sample 4C). Scale bar 10 µm.
In order to prove that the fluorescent molecules are located inside the cells
confocal laser scanning microscopy (CLSM) was performed. For this purpose,
the cells were incubated with the nanoparticles and the corresponding controls,
stained with DAPI and imaged by CLSM (Figure 4.9). The nanoparticles are
necessary to transport the molecules over the cell membrane barrier, as can be
judged by the presence of fluorescence in the image near the nucleus. Only minor
amounts of CpG (samples 1 and 2) and PEI (sample 6) were internalized in a
dissolved form. The charge of the nanoparticles did not influence the uptake as
well as the charge of the dissolved molecules alone. It was assured in all cases by
three-dimensional slicing that the fluorescent molecules were present inside the
cells and not on their surface (the fluorescence from the molecules was found at
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the same Z-level as the nucleus).
Figure 4.9 Confocal laser scanning microscopy images of cells treated
with nanoparticles carrying CaP/CpG-Alexa555 (1, red), CaP/CpG-Alexa488
(2, green), CaP/DNA/TRITC-BSA (3, red), CaP/DNA/FITC-BSA (4,
green), CaP/CpG/DEC205-FITC (5, green), CaP/PEI-rhodamine (6, red),
CaP/PEI/pTHPP (7, red), CaP/PSS/pTHPP (8, red) or CaP/PEI/FITC-Pep
(9, green). The corresponding controls were the dissolved fluorescent molecules
at the same concentration as in the nanoparticles: CpG-Alexa555 (1C), CpG-
Alexa488 (2C), TRITC-BSA (3C), FITC-BSA (4C), DEC205-FITC (5C), PEI-
rhodamine (6C), pTHPP (7C), pTHPP (8C), and FITC-Pep (9C). Scale bar
5 µm.
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Moreover, we were interested in the kinetics of the internalization process. For
this purpose, we carried out a separate experiment where the cells were incubated
with CaP/CpG-Alexa555 nanoparticles for different periods of time, as shown in
Figure 4.10. After 15 min, the adsorbed nanoparticles were seen on the cell
membrane, after 60 min the nanoparticles started to be internalized, after 180
min the nanoparticles were clearly visible inside the cell, and after 300 min the
number of the nanoparticles inside the cell increased, and they could be observed
all over the cytoplasm. From this, we can conclude that 3-5 h of incubation are
needed for the nanoparticles to be taken up by the cells.
Figure 4.10 Confocal laser scanning microscopy images of HeLa cells after incu-
bation with CpG-Alexa555-loaded nanoparticles for 15 min (A), 60 min (B), 180
min (C), and 300 min (D). Note that the color of the nanoparticles was changed
from red to green by the CLSM software. The blue color represents cell nucleus
(DAPI), red: actin cytoskeleton. Scale bar 10 µm.
The general uptake mechanism schematically is illustrated in Figure 4.11. After
adsorption on the cell membrane, the nanoparticles are internalized by endocytosis
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or pinocytosis, depending on the cell type and the nanoparticle type, degraded in
the lysosome, and finally released into the cytoplasm by endosomal rupture.
Figure 4.11 Schematic model of the nanoparticles internalization stages. The
following steps can be distinguished: I. Adsorption of nanoparticles on the cell
membrane; II. Cell membrane invagination; III. Endosome formation; IV. Degra-
dation of the endosome and release of the nanoparticles and molecules into the
cytoplasm.
It is noteworthy that the biomolecules that were adsorbed onto the nanopar-
ticles surface or into a polyelectrolyte layer on the nanoparticles surface may be
susceptible to enzymatic attack, e.g. by nucleases in the case of nucleic acids.
This unwanted effect can be prevented by preparing multi-shell calcium phosphate
nanoparticles where the biomolecules are incorporated into the nanoparticles and
covered by a second shell of calcium phosphate as demonstrated in [64].
4.1.2.3 Conclusions
In this study, we demonstrated the essential role of calcium phosphate nanopar-
ticles for the transport of various molecules of interest across the cell mem-
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brane. It was clearly shown that the majority of the bio- and synthetic molecules
used in these experiments could not cross the cell membrane alone. Therefore,
the calcium phosphate nanoparticles can serve as an efficient carrier to deliver
these cargos into cells. However, it is worth noticing that a specific synthesis
method needs to be developed and optimized separately for each system and
cargo molecule. In the most favorable case, nanoparticles can be functionalized
directly with the cargo molecule, e.g. a nucleic acid or a polyelectrolyte, which
can serve at the same time as steric and electrostatic stabilizer. In other cases,
molecules that would be transported must be incorporated into a stabilizing layer
covering the nanoparticles. This layer can consist of non-encoding nucleic acid
or a polyelectrolyte polymer like PEI or CMC. Such stable and at the same time
biodegradable nanoparticles are easily taken up by cells where they can exert their
therapeutic function. Further studies are needed, however, to address in detail
the mechanisms of uptake, degradation of nanoparticles and their influence on
the metabolic activity of the living cell.
4.1.3 Transport of synthetic molecules across the cell
membrane with calcium phosphate nanoparticles
4.1.3.1 Characterization of functionalized calcium phosphate
nanoparticles
For these experiments, three different synthetic molecules were used: a poly-
anionic lysozyme-inhibiting copolymer (A), calixarene dimers (B), and molecular
tweezers (C). For a more detailed description of the molecules, their structural
formulas and properties refer to Subsection 3.3. As all these molecules are water-
soluble, the synthesis of single-shell nanoparticles and their functionalization and
purification were performed as described in Subsection 3.1.1 and 3.1.3.
As polyanionic copolymer and calixarene dimers are negatively and positively
charged molecules, respectively, no additional polyelectrolyte was necessary for
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the attachment to nanoparticles. In case of the third molecule, the polyelectrolyte
polymer PEI was added first to stabilize the nanoparticles, and subsequently
molecular tweezers were added to the outer shell, because the weak negative
charge of the tweezers was not sufficient to stabilize the nanoparticles by them-
selves. This did not, however, lead to charge reversal, and the nanoparticles
were still cationic (see Table 4.7). Additionally, all these molecules were visible
in the ultraviolet range, due to their structure (see description in Subsection 3.3)
which enabled their quantification by UV-Vis spectroscopy. For fluorescence mi-
croscopy the nanoparticles, carrying molecular tweezers were functionalized with
FITC-labeled PEI, in order to visualize the nanoparticles’ uptake by the cells.
The purified nanoparticles were first characterized by DLS and NTA to prove
their stability and monodispersity. As it can be seen from Table 4.7 all samples
had good monodispersity index (<0.4) and a hydrodynamic diameter in the range
of 140-200 nm. Relatively high positive and negative charges, depending on
the molecule used in the synthesis also proves the electrostatic stability of the
nanoparticles. According to the obtained scanning electron micrographs of the
samples (Figure 4.12), all functionalized single-shell nanoparticles had a typical
spherical shape and an actual size about 50-60 nm.
Table 4.7 Colloid-chemical data of functionalized and purified calcium phosphate
nanoparticles. PDI: Polydispersity index from dynamic light scattering.
Sample PDI Particle size(DLS) / nm
Particle size
(NTA) / nm
Zeta-
potential /
mV
CaP/polymer 0.380 377 156 ± 57 -17 ± 8
CaP/calixarene dimer 0.331 169 212 ± 63 +22 ± 2
CaP/PEI/tweezers 0.315 140 150 ± 58 +44 ± 6
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Figure 4.12 Scanning electron micrographs of calcium phosphate nanoparti-
cles, functionalized with polymer (A), calixarene dimer (B), and molecular tweez-
ers (C).
After the purification step, all non-adsorb synthetic molecules could be easily
detected in the supernatant by UV-Vis spectroscopy, using the calibration curve
for each molecule (Figure 4.13).
In Table 4.8, the amount of the adsorbed molecules on the nanoparticles is
shown. It ranges between 22% and 51% of the initially present amount of syn-
thetic molecules.
Table 4.8 The amount of synthetic molecules in the nanoparticle dispersion.
Sample
Theoretical
concentra-
tion /
µg mL−1
C (molecules)
after
purification /
µg mL−1
Present on the
nanoparticles
after purification
/ %
CaP/polymer 167 37 22
CaP/calixarene dimer 167 86 51
CaP/PEI/tweezers 143 78 46
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Figure 4.13 Calibration curves for the lysozyme-inhibiting polymer, the cali-
xarene dimer and the molecular tweezers. The fluorescence of all samples was
measured by UV-Vis spectroscopy. Absorption was determined at the correspond-
ing absorption maxima: polymer at λ=320 nm; calixarene dimer at λ=495 nm;
tweezers at λ=280 nm.
After the colloid-chemical characterization of the nanoparticles, the biological
experiments were performed.
4.1.3.2 Results of uptake studies
In all performed in vitro experiments, the HeLa cell line was used. First, we
checked whether these compounds are toxic for the cells. HeLa cells were in-
cubated with functionalized nanoparticles and dissolved molecules alone (in the
same concentration as in the nanoparticle dispersion) as a control group for 3 h.
Afterwards, the cell viability was determined by an MTT assay (see Subsec-
tion 3.4.5). The results of this experiment are shown in Figure 4.14. No toxic
effect was observed either in the nanoparticle samples or in the control samples
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with dissolved molecules. The viability level was in the range between 100% and
85%. Only for the nanoparticles which carried the calixarene dimer a mild toxicity
(20%) was found, which is in a good agreement with the purpose of this molecule
to kill tumor cells. In this case, no therapeutic effect was needed, and we chose
the low concentration of this compound only to check its uptake by the living
cells.
Figure 4.14 MTT assay after incubation of HeLa cells with functionalized cal-
cium phosphate nanoparticles.
Along with the MTT assay, uptake studies of these samples were carried out.
In Figure 4.15, one can see representative light and fluorescence microscopy mi-
crographs of the samples. HeLa cells were incubated either with the molecules in
dissolved form or absorbed on the calcium phosphate nanoparticles. The quali-
tative difference in the uptake efficiency of the fluorescent synthetic molecules
between these two groups can be clearly recognized. We conclude that calcium
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phosphate nanoparticles are necessary to transport these molecules across the cell
membrane.
Figure 4.15 Representative light microscopy (top row) and fluorescence mi-
croscopy (bottom row) images of HeLa cells after 3 h incubation with function-
alized calcium phosphate nanoparticles and with the dissolved drug molecules
(equal concentrations). The fluorescence is visualized due to the polymer, the
calixarene dimer, and the FITC-labeled PEI (in the case of molecular tweezers),
respectively.
Using conventional fluorescence microscopy, it is often difficult to show whether
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the nanoparticles are only attached to the cell membrane or already taken up in-
side the cytoplasm. Therefore, we have analyzed the cells by confocal laser scan-
ning microscopy (CLSM) after staining the nucleus and the cell membrane with
DAPI and Cell MaskTM dyes, respectively. Figure 4.16 shows the confocal laser
scanning micrographs of HeLa cells treated with functionalized CaP nanoparticles
or with the corresponding controls (the same concentration of the molecules as
in the nanoparticles). In all three cases, we saw the absence of fluorescence in the
control group, which means that no synthetic molecules could penetrate the cell
membrane in the dissolved form. In contrast, polyanionic polymer, hexacationic
calixarene dimer and molecular tweezers combined with CaP nanoparticles were
easily detectable within the cells. We also carried out three-dimensional slicing
of the cells to prove the presence of the functionalized nanoparticles inside the
cells (data not shown).
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Figure 4.16 Confocal laser scanning microscopy micrographs of HeLa cells af-
ter incubation with calcium phosphate nanoparticles functionalized with polymer,
calixarene dimer, PEI-FITC/tweezers, and the corresponding controls. Channel 1
(DAPI): cell nucleus; channel 2 (TRITC): cell membrane stained with the Cell
MaskTM; channel 3 (FITC): calixarene dimer and PEI-FITC/tweezers. The poly-
mer appears on the picture as blue dots. Scale bar 5 µm.
4.1.3.3 Conclusions
We have prepared purified calcium phosphate nanoparticles, functionalized with
a synthetic polymer, a calixarene dimer and molecular tweezers. The nanopar-
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ticles were characterized and showed a stable and monodisperse character. The
actual concentration of all three molecules after the purification was determined.
The in vitro studies showed that the compounds are not harmful to the cells
(only calixarene dimer can be toxic in a higher dose) and they could be trans-
ported into the cell with the help of calcium phosphate nanoparticles, whereas the
dissolved molecules alone were not able to penetrate the cell membrane. There-
fore, these purified functionalized calcium phosphate nanoparticles represent a
well-characterized delivery system for further in vitro and in vivo application.
4.1.4 Transport of synthetic lysozyme-inhibiting polymer
across the cell membrane with calcium phosphate
nanoparticles
4.1.4.1 Characterization of functionalized calcium phosphate
nanoparticles
The nanoparticles were synthesized as described earlier in Subsection 3.1.1, where
they were functionalized first with PEI and then with the lysozyme-inhibiting poly-
mer (in the following denoted as "polymer") or vice versa. Afterwards, both types
of the nanoparticles were purified by centrifugation and redispersed in ultrapure
water by ultrasonication. The characterization of the nanoparticles was performed
by DLS, NTA and SEM methods, and the quantification of the polymer was done
by UV-Vis spectroscopy.
In Figure 4.17, one can see the scanning electron microscopy micrographs of
the synthesized nanoparticles. The nanoparticles had an approximate size of
50 nm and a spherical morphology. The DLS and NTA measurements summarized
in Table 4.9, show that both types of the nanoparticles were stable, and no
aggregation occurred during the synthesis and purification steps. The positive
surface charge of the nanoparticles, loaded first with PEI and then with polymer,
was slightly lower compared to the second type, which could be explained by
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the negative charge of the polymer, which could partially neutralize the positive
charge of PEI.
Figure 4.17 SEM images of the polymer-functionalized calcium phosphate
nanoparticles.
Table 4.9 Colloid-chemical characterization of PEI- and polymer-functionalized
calcium phosphate nanoparticles. PDI: polydispersity index from dynamic light
scattering.
Sample PDI Particle size(DLS) / nm
Particle size
(NTA) / nm
Zeta
potential /
mV
CaP/PEI/polymer 0.368 449 169 ± 63 +18
CaP/polymer/PEI 0.379 409 197 ± 77 +37
The quantification of the polymer was performed by the fluorescent labeling
with a dansyl group (absorption maximum at λ=245 nm). After the centrifu-
gation of the nanoparticle dispersions, the supernatant was taken to determine
the amount of the polymer, which was then used to calculate a calibration curve
(Figure 4.13). The concentration of the polymer on the nanoparticles as well as
the loading efficiency for both types of the nanoparticle dispersion were calculated
(Table 4.10).
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Table 4.10 Results of UV-Vis spectroscopy measurements of PEI- and polymer-
functionalized calcium phosphate nanoparticles.
Sample
C (polymer)
before
purification
/µg mL−1
Supernatant Dispersion ofnanoparticles
Absorp-
tion
C (polymer)
/ µg mL−1
C (polymer)
/ µg mL−1
Quantity/
%
CaP/PEI/polymer 500 1.936 183 317 63
CaP/polymer/PEI 250 2.337 223 27 11
As one can see, the amount of the polymer was much higher when the calcium
phosphate nanoparticles were functionalized first with PEI: 63% of the polymer
molecules were absorbed onto the surface of the nanoparticles.
The quantification data are shown in Table 4.11, i.e. the amount of polymer
per nanoparticle and per cell.
Table 4.11 Determination of the amount of polymer and calcium phosphate
nanoparticles in the dispersion and in culture medium per cell (for 5·104 cells).
Sample
Diameter
(NP) from
SEM / nm
N (NP)
per m−3
N
(polymer
molecules)
per NP
N (NP)
per cell
N
(polymer
molecules)
per cell
CaP/PEI/polymer 49 7.442·1016 14 1.353·105 1.912·106
CaP/polymer/PEI 52 3.493·1016 3 6.351·104 1.629·105
4.1.4.2 Results of the uptake studies and viability assay
The next step was to measure the uptake of these functionalized nanoparticles
and their cytotoxicity. In Figure 4.18, representative light and fluorescent micro-
graphs of HeLa cells, incubated with the nanoparticles for 3 h, are depicted. It
is clearly seen that the CaP/PEI/polymer nanoparticles were better taken up by
the cells, and that the polymer which can be recognized by the cyan fluorescence
could be detected. Furthermore, in Figure 4.19, at 100x magnification on THP-1
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cells incubated with functionalized nanoparticles and polymer alone at the same
concentration, we showed that the polymer alone did not penetrate the cell mem-
brane. In contrast, adsorbed on the nanoparticles, the polymer was detectable
inside the lysozyme-producing THP-1 cell line.
Figure 4.18 Light and fluorescence microscopy micrographs of THP-1 cells in-
cubated with polymer-loaded CaP/PEI nanoparticles. Top row: overlay; bottom
row: fluorescence images; Cyan fluorescence represents polymer; 40x magnifica-
tion.
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Figure 4.19 Uptake of the polymer, loaded on the CaP/PEI nanoparticles and
the polymer alone on fixed THP-1 cells. Green channel: actin filaments; red
channel: cell membrane; blue channel: polymer; 100x magnification.
It was also important to check the viability of the cells after the incubation with
polymer-functionalized nanoparticles. As can be seen from Figure 4.20, no toxic
effect was detected for both types of nanoparticles, and the viability rate of HeLa
cells remained over 91%. The control group, where the cells were treated with
PEI/polymer aggregates, showed a low viability level due to the toxic effect of
the PEI.
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Figure 4.20 Results of viability assay on THP-1 cells, treated with functionalized
calcium phosphate nanoparticles and PEI/polymer polyplexes.
4.1.4.3 Studies on lysozyme activity inhibition
Our aim was then to check the inhibitory activity of the polymer inside the cells
as well as in cell medium. For these purposes, we chose the THP-1 cell line
(monocytes/macrophages) which is known to produce lysozyme and is a good
and well-defined model to study lysozyme activity. Before the cells were taken
into the experiment, they were differentiated by the addition of PMA (phorbol-
12-myristate-13-acetate) for 3 days. After this differentiation, the cells became
adherent macrophages and did not divide anymore. These PMA-induced cells
were used in all experiments for lysozyme-inhibiting studies. For the incubation
and differentiation protocol, refer to Subsection 3.5.2.
In Figure 4.21 A, the results of lysozyme activity measurements inside the cells
after the incubation with polymer-functionalized nanoparticles are presented. As
control groups, the cells were treated either only with the polymer or with calcium
phosphate nanoparticles functionalized with PEI (sample CaP). Mock represents
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untreated cells. The CaP/PEI/polymer-treated cell samples the lysozyme ac-
tivity was decreased compared to untreated cells (Mock). This is also in good
agreement with UV-Vis spectroscopy measurements and the uptake studies for
this type of nanoparticles. In addition, the sample CaP/polymer/PEI was not so
efficient as well as the polymer itself. What also needs to be noticed here is the
big standard deviation in the control group of CaP/PEI nanoparticles.
When we compared the results of the lysozyme inhibition in the cell medium,
we also got a similar picture (Fig 4.21 B). The CaP/PEI/polymer had the best
inhibiting action on lysozyme outside the cell, and the free polymer had no effect
on the lysozyme activity in the cell medium. Nevertheless, the big standard
deviations in two control groups (untreated cells and the CaP/PEI-treated cells)
were disappointing. In order to improve the outcome of these experiments, some
further ideas were pursued:
1. The cells were stimulated with lipopolysaccharides (LPS, 5 mg mL−1) for
1 h, 3 h and 24 h before the experiment to enhance the higher production
of lysozyme.
2. The incubating time with nanoparticles were increased to 24 h.
3. The nanoparticles were incubated in serum-free medium for 3-7 h.
4. The number of independent experiments for each sample was doubled.
5. The cell lysate was treated with a protease-inhibitor cocktail to prevent
possible lysozyme degradation during the preparation phase.
6. The incubation time for the EnzCheck reagent was prolonged for 1 to 2 h.
All these activities, however, did not have much impact on the results and the
outcome of the measured data set. Again, no statistically significant effect of the
polymer on the lysozyme activity was found.
It was shown earlier that the polymer itself could inhibit the lysozyme in a dose-
dependent manner in the phosphate buffer solution containing the lysozyme in the
specific concentration. For this reaction the half maximal inhibitory concentration
(IC50=0.7 µM) was determined by the group of Prof. Thomas Schrader [292].
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Figure 4.21Measurements of the lysozyme activity inside THP-1 cells (A) and in
cell medium (B) after incubation with polymer-functionalized calcium phosphate
nanoparticles and polymer alone.
Therefore, our idea was to look if the polymer itself was still stable and active
in the cell culture medium, as it was never analyzed before. For this, we took
the standard lysozyme solution from the EnzCheck kit, polymer solution, and
different milieus: phosphate buffer from the EnzCheck kit, serum-free cell culture
medium (RPMI-1640), and cell culture medium containing 10% FCS. The same
amount of lysozyme from a standard solution was added to all samples, resulting
in the concentration of 0.2 mg mL−1. The amount of added polymer solution
(concentration 1 mg mL−1) varied from 0 to 3.3 nM. Then the samples were
incubated for 5 min in a 24-well plate in the cell culture incubator at 37 ◦C
and 5% humidity to simulate the cell culture experiment conditions. Afterwards,
all samples were treated simultaneously according to the EnzChek manufacture
protocol (see Subsection 3.4.6).
The results of this set of experiment are shown in Figure 4.22. Graph A presents
the results of the experiment carried out in phosphate buffer. A clear decrease in
the lysozyme activity with increasing polymer concentration in dose-dependent
manner can be seen. At the concentration of the polymer of 3.3 nM, the lysozyme
activity was decreased by more than 50%, which proves the inhibiting ability of
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the polymer against the lysozyme. That is also in line with former studies, carried
out in the group of Prof. Thomas Schrader. Nevertheless, when we look at the
Graph B, where the reaction milieu was RPMI-1640 (without FCS), the polymer
was not capable to inhibit the lysozyme activity as efficiently as it was shown
in the phosphate buffer. There was no further concentration-dependent drop in
the lysozyme activity. It stayed at the level of 100% at the concentration of the
polymer in the sample up to 2.2 nM. Only at the highest concentration of 3.3 nM
of polymer, an inhibition by 40% was detected. Moreover, when we look at the
results with cell culture medium containing 10% FCS, an inhibiting effect of the
polymer even at the highest concentration was not detectable anymore.
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Figure 4.22 Measurements of lysozyme activity after incubation with polymer
in different milieus: (A): in phosphate buffer; (B): in RPMI-1640 without FCS;
(C): in RPMI-1640 with 10% FCS.
These results can be explained only by the influence of the reaction milieu.
When there are only the molecules of the target protein and only free polymer,
there is very efficient inhibition. However, once the polymer appears in a complex
biological medium such as cell culture medium even without FCS, its specificity
drops dramatically and, in the presence of FCS, it is completely absent. This
effect can be explained by the variety of the biological molecules other than
lysozyme present in the cell medium such as free amino acids, vitamins, etc.
(see Table 4.12), which can easily interfere with the polymer and, thus, block
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its function. When we take the FCS into account, which contains a variety of
different proteins, factors, and other components (Table 4.13), it becomes clear
that the polymer cannot keep selectivity to just one protein among thousands of
chemically similar molecules. Even if we consider that the experiment with the
cells could be carried out in serum-free media, the polymer, taken up by the cell
and eventually released in the cytoplasm, still would have to deal with a number
of different biomolecules that are presented in the cytoplasm.
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Table 4.12 RPMI-1640 medium content [309].
RPMI-1640 medium composition
Medium Component g L−1 Medium Component g L−1
Calcium Nitrate · 4H2O 0.1 L-Proline 0.02
Magnesium Sulfate
(anhydrous) 0.04884 L-Serine 0.03
Potassium Chloride 0.4 L-Threonine 0.02
L-Tryptophan 0.005 L-Valine 0.02
Sodium Chloride 6 D-Biotin 0.0002
Sodium Phosphate
Dibasic (anhydrous) 0.8 Choline Chloride 0.003
L-Arginine 0.2 Folic Acid 0.001
L-Asparagine
(anhydrous) 0.05 myo-Inositol 0.035
L-Aspartic Acid 0.02 Niacinamide 0.001
L-Cystine · 2HCl 0.0652 p-Aminobenzoic Acid 0.001
L-Glutamic Acid 0.02 D-Pantothenic Acid(hemicalcium) 0.00025
L-Glutamine 0.3 Pyridoxine · HCl 0.001
Glycine 0.01 Riboflavin 0.0002
L-Histidine 0.015 Thiamine · HCl 0.001
Hydroxy-L-Proline 0.02 L-Tyrosine · 2Na ·2H2O 0.02883
L-Isoleucine 0.05 Vitamin B12 0.000005
L-Leucine 0.05 D-Glucose 2
L-Lysine · HCl 0.04 Glutathione (reduced) 0.001
L-Methionine 0.015 L-Glutamine 0.3
L-Phenylalanine 0.015 Sodium Bicarbonate 2
Phenol Red · Na 0.0053
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Table 4.13 Composition of FCS [310].
Component Average Range
Endotoxins (ng mL−1) 0.35 0.01-10.0
Glucose (mg mL−1) 1.25 0.85-1.81
Protein (mg mL−1) 38 32-70
Albumin (mg mL−1) 23 20-36
Hemoglobine (µg mL−1) 113 24-181
Bilirubin, total (µg mL−1) 4 3-11
Bilirubin, direct (µg mL−1) 2 0-5
Urea (µg mL−1) 160 140-200
Urate (µg mL−1) 29 13-41
Creatinin (µg mL−1) 31 16-43
Insulin (µU mL−1) 10 6-14
Cortisol (ng mL−1) 0.5 0.1-23
Growth hormone (ng mL−1) 39.0 18.7-51.6
Parathormone, PTH (ng mL−1) 1.72 0.085-6.18
Triiodothyronine, T3 (ng mL−1) 1.2 0.56-2.23
Thyroxine, T4 (ng mL−1) 0.12 0.08-0.16
Thyroid-stimulating hormone, TSH (ng mL−1) 1.22 0.2-4.5
Follicle-stimulating hormone, FSH (pg mL−1) 95 20-338
Testosterone (pg mL−1) 400 210-990
Progesterone, P4 (pg mL−1) 80 3-360
Prolactin=Luteotropic hormone, LTH (pg mL−1) 176 20-500
Luteinizing hormone, LH (pg mL−1) 8 1.2-18
Prostaglandin E (ng mL−1) 5.9 0.5-30.5
Prostaglandin F (ng mL−1) 12.3 3.8-42.0
Vitamin A (ng mL−1) 90 10-350
Vitamin E (ng mL−1) 1.1 1-4.2
Cholesterol (µg mL−1) 310 120-630
Lactate-dehydrogenase, LDH (mU mL−1) 864 260-1,215
Alkaline Phosphatase (mU mL−1) 255 110-352
Aspartate-Aminotransferase, ASAT (mU mL−1) 130 20-200
Sodium, Na+ (µeq mL−1) 137 125-143
Potassium, K+(µeq mL−1) 11.2 10.0-14.0
Calcium, Ca2+ (µeq mL−1) 6.75 6.30-7.15
Chloride, Cl− (µeq mL−1) 103 98-108
Phosphate, Pi (µg mL−1) 98 43-114
Selen (µg mL−1) 0.026 0.014-0.038114
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4.1.4.4 Conclusions
Calcium phosphate nanoparticles, functionalized with a lysozyme-inhibiting poly-
mer, were synthesized and characterized by different methods. Their uptake by
THP-1 cells was shown by CLSM. Nevertheless, the expected significant inhibitory
effect of the polymer inside the living cell, as well as in the cell culture medium
was not detected. Consequently, the experiments showed a dramatic influence
of the experimental conditions. The inhibitory effect of the polymer was clearly
shown in phosphate buffer solution in a dose-dependent way. In the presence
of the cell culture medium containing various biological molecules, the inhibi-
tion of lysozyme essentially decreased and could be detected at only the highest
concentration of polymer. Furthermore, when the cell culture medium was sup-
plemented with 10% of FCS, no inhibitory effect was found. These indicates low
specificity of the inhibitory polymer to target lysozyme. The polymer molecules
can apparently interact with other biomolecules contained in large quantities in
cell culture media.
4.1.5 Uptake of HTRA1 and HTRA2 proteins: alone and
with calcium phosphate nanoparticles
4.1.5.1 Characterization of functionalized calcium phosphate
nanoparticles
For these studies, single-shell and triple-shell nanoparticles, stabilized either with
CMC or PEI and loaded with HTRA1 (with or without PDZ domain) and HTRA2
proteins (see Subsection 3.3.7 and 3.3.8), were used. The synthesis of the protein-
functionalized calcium phosphate nanoparticles was carried out as described in
Subsection 3.1.1 and purified as described in Subsection 3.1.3. The proteins
were synthesized, purified, and labeled with Alexa488 in the group of Prof.
Michael Ehrmann, Centre for Medical Biotechnology (ZMB) at the University
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of Duisburg-Essen [311]. The concentration of both proteins was 1 mg mL−1.
After the synthesis, all nanoparticles were purified with the help of centrifugation
and redispergation in ultrapure water. The supernatants were used to perform
UV-Vis spectroscopy to determine the protein concentration in the dispersion of
nanoparticles.
In Table 4.14, the characterization data of the functionalized nanoparticles are
summarized. The single-shell nanoparticles showed a hydrodynamic size between
250 and 350 nm and had a good polydispersity index (<0.5). Apparently, the
multi-shell samples contained some agglomerates that resulted in bigger size and
polydispersity. The zeta potential reflects the corresponding charge of the poly-
electrolyte polymer used for stabilization (CMC: negative, PEI: positive) that
indicates the colloidal stability of the nanoparticles in dispersion. The concentra-
tion of each protein was determined by UV-Vis spectroscopy with a calibration
curve (Figure 4.23) and labeling with Alexa488 fluorescent dye.
Figure 4.23 Calibration curves of Alexa488-labeled HTRA1 and HTRA2 proteins
(λmax=492 nm), obtained by the UV-Vis spectroscopy.
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Table 4.14 Characterization of nanoparticles by dynamic light scattering (DLS)
and UV-Vis spectroscopy. PDI: polydispersity index from dynamic light scatter-
ing.
Sample Size /nm PDI
Zeta
potential
/ mV
C (protein)
after
purification /
µg mL−1
CaP/CMC/HTRA1 247 0.321 -16 168
CaP/CMC/∆HTRA1 376 0.439 -11 168
CaP/CMC/HTRA1/PEI 958 0.837 +12 419
CaP/CMC/HTRA1/CaP/PEI 4665 1.0 +17 286
CaP/PEI/HTRA1 292 0.325 +18 410
CaP/CMC/HTRA2 696 0.565 +16 255
CaP/CMC/HTRA2/CaP/CMC 763 0.628 -10 167
CaP/PEI/HTRA2 450 0.369 +17 226
CaP/PEI/HTRA2/CaP/PEI 3514 0.323 +26 138
The quantification data for all types of functionalized nanoparticles are shown
in Table 4.15.
Table 4.15 Number of fluorescently labeled HTRA1 and calcium phosphate
nanoparticles in dispersion and in culture medium per cell (for 5·104 cells).
Sample
Diameter
(NP) from
SEM / nm
N (NP)
per m−3
N (protein
molecules)
per NP
N (NP)
per cell
N (protein
molecules)
per cell
CaP/CMC/HTRA1 77 4.9·1016 56 8.9·104 5.0·106
CaP/CMC/∆HTRA1 90 2.0·1016 197 3.7·104 7.3·106
CaP/CaP/PEI/HTRA1 37 2.9·1017 23 5.4·105 1.2·107
CaP/CMC/HTRA1/PEI 33 3.3·1017 21 6.0·105 1.3·107
CaP/CMC/HTRA1/CaP/PEI 149 7.8·1015 599 1.4·104 8.5·106
117
Results and Discussion
In Figure 4.24, representative SEM images of the protein-functionalized cal-
cium phosphate nanoparticles are depicted. The nanoparticles had a spherical
morphology, and the actual size was up to 50 nm for single-shell nanoparticles,
and 150 nm for multi-shell nanoparticles.
Figure 4.24 Scanning electron microscopy images of functionalized calcium phos-
phate nanoparticles, loaded with HTRA1 and HTRA2 proteins.
4.1.5.2 Uptake studies with different cell lines
First, we measured the uptake of the protein-loaded nanoparticles by different
cell lines. HeLa, MG-63, THP-1, and hMSCs cells were incubated with calcium
phosphate nanoparticles containing fluorescently labeled HTRA1 for 3 h. After-
wards, the cells were washed three times with PBS and imaged with light and
florescence microscopy. The detailed process of cell imaging is described in Sub-
section 3.5.5. Remarkably, all tested cell lines, including hMSCs, were able to
take up the nanoparticles in a very high number (Figure 4.25). The least-efficient
uptake of the nanoparticles was detected by HeLa cells, which points to a different
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endocytosis mechanisms of the nanoparticles uptake with this cell line.
We then went on to check whether the functional PDZ domain of HTRA1
protein plays a role in the nanoparticle uptake mechanism. We loaded HTRA1
without PDZ domain (∆HTRA1) onto the nanoparticles and again incubated
them with different cell lines. As can be seen in Figure 4.25, the absence of
the PDZ domain did not influence the uptake efficiency of the nanoparticles: it
neither increased the endocytosis by HeLa cells nor decreased it with the other
cell lines. Therefore, we can conclude that the functional PDZ domain is not
responsible for the transport of the protein across the cell membrane.
Our purpose was to deliver the HTRA1 protein into HeLa cells. It is known
from the literature that positively charged nanoparticles are usually better and
faster taken up by cells because of the electrostatic interaction of the nega-
tively charged cell membrane and the positively charged surface of the nanopar-
ticles [153, 159, 187, 188]. We prepared different nanoparticles to test which
combination would be the most effective: single-shell CaP/PEI/HTRA1, where
the protein was absorbed on the surface of the nanoparticles, and multi-shell
CaP/CMC/HTRA1/CaP/PEI and CaP/CMC/HTRA1/PEI, where HTRA1 was
encapsulated under the covering shell of CaP or covered by PEI. In all cases,
PEI was present on the nanoparticles surface which gave them a positive charge.
The colloid-chemical characterization data of the nanoparticles are summarized in
Table 4.14. HeLa cells were incubated with the nanoparticles, carrying HTRA1
protein and with dissolved HTRA1 alone in the same concentration as on the
nanoparticles. Fluorescence and light microscopic images are depicted in Fi-
gure 4.26. A very high uptake of all types of functionalized nanoparticles in
contrast to the dissolved proteins is clearly observed. This indicates a key role of
the surface charge of the nanoparticles in their uptake by cells in vitro.
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Figure 4.25 Uptake of CaP/CMC/HTRA1 (left column) and
CaP/CMC/∆HTRA1 (right column) nanoparticles by different cell lines.
Figure 4.26 Uptake of functionalized calcium phosphate nanoparticles by HeLa
cells. Left column: transmission light microscopy; right column: fluorescence
microscopy micrographs.
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We also performed similar experiments with HTRA2-loaded calcium phosphate
nanoparticles, where we incubated HeLa cells with HTRA2-functionalized nanopar-
ticles for 3 h. Figure 4.27 presents the light and fluorescent micrographs of the
cells that were treated with single- and multi-shell nanoparticles, loaded with
HTRA2-Alexa488. In all cases, the green fluorescence from the protein was de-
tected. In contrast, no uptake of the protein was detected when cells were treated
with soluble HTRA2 at the same concentrations: neither by HeLa cells, nor by
MG-63 cells (Figure 4.28).
Figure 4.27 Light and fluorescent microscopy images of HeLa cells treated with
HTRA2 functionalized calcium phosphate nanoparticles. Cells were incubated for
3 h. HTRA2, labeled with Alexa488, appears in the images as green dots.
Figure 4.28 Light and fluorescent microscopy images of HeLa and MG-63 cells,
treated with dissolved HTRA2-Alexa488.
For a more detailed investigation of the uptake of the HTRA2 that was loaded
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onto the nanoparticles, we performed CLSM imaging on two cell lines: HeLa and
MG-63 with single-shell nanoparticles. After incubation for 3 h, the cells were
washed 3 times with PBS, fixated, and stained according to the protocol (see
Subsection 3.5.6). In Figure 4.29, the overlay images from HeLa and MG-63
cells are depicted. In both cases, the green fluorescence of the Alexa488-labeled
HTRA2 was detected.
Figure 4.29 Confocal microscopy micrographs of HeLa and MG-63 cell incu-
bated with HTRA2-loaded calcium phosphate nanoparticles. Red channel: cell
membrane; blue channel: nucleus; green channel: HTRA2-Alexa488.
4.1.5.3 Studies on the uptake kinetics in MG-63 cells
To compare the uptake kinetics of the protein alone and that loaded onto the
nanoparticles, we incubated MG-63 cells with either dissolved Alexa488-labeled
HTRA1 or adsorbed on the nanoparticles at different time points: 3, 7, 24,
and 48 h. By CLSM, the kinetics of the uptake were studied. As depicted in
Figure 4.30, the amount of the internalized protein increased with time, which
can be recognized by green fluorescence in both cases. This indicates that living
cells (MG-63) are constantly internalizing HTRA1 for their metabolic needs. It
is noteworthy that HTRA1 penetrated the cell membrane alone in high amounts,
i.e. without carrier.
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Figure 4.30 Uptake of CaP/CMC/HTRA1 nanoparticles (left) and HTRA1 alone
(right) by MG-63 cells during different incubation times.
To quantify the uptake kinetics on a smaller time scale (5 min to 5 h), we
performed a similar experiment with the same samples and the same cell line,
and measured the uptake by FACS. A difference in the internalization rate of
dissolved HTRA1 and HTRA1 adsorbed onto calcium phosphate nanoparticles
was observed (Figure 4.31). One can see strong time-dependend increase in
the fluorescence from HTRA1-Alexa488, which is internalized by MG-63 cells
in both cases. Interestingly, protein alone is taken up faster, starting already
from incubation time of 15 min, and more efficiently, compared to HTRA1-
carrying nanoparticles. After 5 h of incubation with protein-loaded nanoparticles,
a comparable amount of the HTRA1 was detected as by the incubation for 1 h
with dissolved HTRA1. These findings suggest that HTRA1 is a highly mobile
protein and, in contrast to nanoparticles, it is not take up by endocytosis, which
is a time-consuming and energy-dependent process. This indicates that HTRA1
is internalized by different routes in the cells that are yet to be discovered.
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Kinetics of the uptake of HTRA1 alone and with NP
Figure 4.31 FACS measurements of the uptake of dissolved protein (HTRA1) and
protein-loaded nanoparticles (NP) by MG-63 cell line during different incubation
times.
4.1.5.4 Results of the endocytosis inhibition on MG-63 cell line
We carried out a series of experiments to find out the uptake pathways of the
nanoparticles that carry HTRA1 and the protein alone on MG-63 cell line. For
this purpose, we used inhibitors of the endocytosis that affect different pathways
(Table 4.16) in order to selectively block various types of endocytosis. We in-
cubated MG-63 cells with the inhibitors and then added either HTRA1-carrying
nanoparticles or the HTRA1 protein alone and incubated for 3 more hours. The
cells incubated by 4 ◦C before and after the addition of the samples were referred
to as the negative control group and the cell with no addition of any inhibitor were
referred to as the positive control group. We also used untreated cells (Mock) as
control for FACS measurements. For a detailed protocol of endocytosis inhibition,
see Subsection 3.5.7.
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Table 4.16 List of inhibitors and endocytotic pathways they affect.
Inhibitor Affected pathway or cellular structure
Wortmannin Macropinocytosis
LY294002 Macropinocytosis
Nystatin Caveolin-mediated endocytosis/lipid rafts
Nocodazole Polymerization of microtubules of cytoskeleton
Chlorpromazine Clathrin-mediated endocytosis
The nanoparticle uptake by MG-63 cell was strongly inhibited by Nystatin which
inhibits caveolin-mediated endocytosis, and partially by Nocodazole, an inhibitor
of microtubules cytoskeleton polymerization [312] (Figure 4.32). In contrast,
other inhibitors did not affect on the internalization process. It was shown that the
main internalization pathway for nanoparticles into HeLa cells is micropinocytosis
[153]. Thus, it could be said that the preferable endocytosis pathway differs with
different cell types.
Interestingly, the only partial inhibition effect of the HTRA1 uptake was demon-
strated by Nocodazole treatment, and other agents showed no inhibition effect
(Figure 4.32, left). This indicates that HTRA1 is not internalized by any of the
listed endocytosis pathways and that only the inhibition of microtubules poly-
merization in cytoskeleton partially affects this process. It is interesting to note
that the fluorescence intensity of the samples, treated only with HTRA1 protein,
showed significantly higher values, compared to HTRA1-functionalized nanopar-
ticles (Figure 4.32, right).
125
Results and Discussion
Figure 4.32 Uptake of CaP/CMC/HTRA1 nanoparticles (left) and dissolved
HTRA1 protein (right) by MG-63 cells in the presence of endocytosis inhibitors.
4.1.5.5 Conclusions
In this study, we used the functional natural protein HTRA1, loaded onto cal-
cium phosphate nanoparticles and in dissolved form for uptake experiments with
different cell lines. Protein-loaded nanoparticles were taken up by HeLa, MG-63,
THP-1 cell lines as well as by hMSCs. The surface charge of the nanoparticles
plays an important role in the cellular uptake process, as shown in the experi-
ments with HeLa cells. The PDZ domain of the HTRA1 protein did not play a
significant role in the internalization of the protein, because its absence did not
influence the uptake efficiency of the nanoparticles loaded with HTRA1 without
the PDZ domain.
Kinetic studies have revealed that HTRA1 is taken up constantly by MG-63
cells and the uptake speed of dissolved protein is dramatically higher than that of
HTRA1-loaded nanoparticles. This, in turn, indicates that the dissolved protein
is internalized by a mechanism other than endocytosis. Moreover, the inhibition
of the endocytosis on MG-63 cell showed fundamental differences in the uptake
mechanisms for loaded nanoparticles and dissolved HTRA1. Taken together,
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these results indicate that HTRA1 is transported to the living cells by a hitherto
unknown mechanism.
4.1.6 Transport of bioactive peptides across the cell
membrane with calcium phosphate nanoparticles
In the present study, we aimed to deliver the bioactive peptide LxVPc1 and its
non-functional mutant LxVPc1mut into macrophages. LxVPc1 peptide is a syn-
thetic molecule that can block the phosphorylation activity of calcineurin towards
the NFAT signal molecule, thus inhibiting the activation of the proinflamma-
tory pathway in macrophages. This is an interesting approach to fighting the
inflammation-related transplantation failures.
4.1.6.1 Characterization of functionalized calcium phosphate
nanoparticles
To this end, we synthesized PEI-functionalized calcium phosphate nanoparticles
and loaded them with peptide FITC-labeled LxVPc1 (in the following denoted
as "Pep") and its mutant form LxVPc1mut (in the following denoted as "Mut").
The nanoparticles were purified and redispersed by ultrasonication in ultrapure
water and subsequently characterized with DLS, NTA, and SEM methods. The
quantification of the peptides in the nanoparticles colloid after purification was
performed by UV-Vis spectroscopy. For a more detailed protocol of synthesis and
purification, refer to Subsection 3.1.1.
The colloid-chemical characterization data of obtained functionalized nanopar-
ticles are summarized in Table 4.17. Both samples showed average hydrodynamic
size of about 400 nm. By measuring these samples with NTA, the size was es-
timated in the range of 130-160 nm. This difference may occur because minor
agglomeration of smaller nanoparticles could be detected in DLS as one big par-
ticle. The zeta potential measurement by DLS showed positive values for both
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samples due to the presence of PEI molecules on the outer shell of the nanoparti-
cles. The adsorbed peptides on the surface of the nanoparticles had only a slight
effect on the surface charge values of the nanoparticles.
Table 4.17 The colloid-chemical characterization of purified peptide-
functionalized CaP/PEI nanoparticles by DLS, NTA and UV-Vis spectroscopy.
PDI: polydispersity index from dynamic light scattering.
Sample PDI
Size
(DLS)
/ nm
Size
(NTA) /
nm
Zeta
potential
/ mV
C (peptide)
in the colloid
/ µg mL−1
C (peptide)
in the
colloid / %
CaP/PEI/Pep 0.384 397 158 ± 53 +12 238 52
CaP/PEI/Mut 0.438 391 128 ± 44 +10 310 65
With the help of a calibration curve (Figure 4.33), the concentration of peptides
in the nanoparticles was determined and estimated with 52% for Pep and 65%
for Mut peptide, corresponding to 238 and 310 µg mL−1.
Figure 4.33 UV-Vis spectroscopy calibration curve (λ=492 nm) for determin-
ing the concentration of the peptide in the supernatant of purified peptide-
functionalized nanoparticles.
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With scanning electron microscopy, the actual size and morphology of the syn-
thesized peptide-loaded calcium phosphate nanoparticles was obtained. The ac-
tual diameter of the nanoparticles ranged between 50 and 100 nm and their
morphology was mostly spherical (Figure 4.34).
Figure 4.34 SEM images of the synthesized peptide-functionalized calcium phos-
phate nanoparticles.
Furthermore, we also calculated the theoretical number of the peptide molecules
on the surface of the nanoparticles based on the assumption that all nanoparticles
have more or less the same size and loading capacity (Table 4.18). For more
detailed description of the calculation procedure, see Subsection 3.1.4.
Table 4.18 Determining the number of fluorescently-labeled peptides and cal-
cium phosphate nanoparticles in the dispersion.
Peptide
Mw
(peptide) /
kg mol−1
n
(peptide)
/ mol m−3
N (peptide)
per m3
N (NP) per
m3
N (peptide)
per NP
Pep 1.844 0.129 7.771·1022 1.717·1016 4.525·106
Mut 1.747 0.178 1.069·1023 1.717·1016 6.225·106
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4.1.6.2 Transport of peptides with calcium phosphate nanoparticles
All biological experiments were carried out with the THP-1 cell line as a model
of differentiated macrophages. For differentiation protocol of these cells, refer to
Subsection 3.5.2. First, we checked whether the nanoparticles and peptides cause
any toxic damage to the living cells by an MTT assay. To do this, we incubated
differentiated THP-1 cells either with peptide-functionalized calcium phosphate
nanoparticles or with dissolved peptides (Ctrl) at the same concentrations as in
the dispersion of nanoparticles for 3 h. This was followed by an MTT assay. The
cell viability was normalized to the untreated control group (100% viability). The
results of this assay showed no harmful effect on the THP-1 cells of the tested
samples (Figure 4.35).
Figure 4.35 Results of MTT assay on THP-1 cells.
To determine the cellular uptake of the peptide-functionalized nanoparticles, the
CLSM was performed on the fixed differentiated THP-1 cells. The cells were incu-
bated with peptide-functionalized nanoparticles or with dissolved peptides as con-
trol. After 3 h the cells were washed 3 times with PBS and fixed for CLSM analysis
(detailed fixation protocol is described in Subsection 3.5.6). Figure 4.36 shows
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representative CLSM images of the nanoparticle-treated macrophages. Both pep-
tides could be clearly recognized due to the FITC labeling. Thus, the fluorescence
in green channel indicates that the peptides were taken up by the cells after 3 h
of incubation. In order to prove that the peptides were located inside the cell,
Z-stack slicing was performed (Figure 4.37).
Figure 4.36 Uptake of CaP/PEI/Pep (left) and CaP/PEI/Mut (right) nanopar-
ticles by THP-1 cells after 3 h of incubation.
It was clearly observed that the green fluorescence of both peptides was lo-
cated on the same level with the DAPI-stained nucleus, thereby proving their
internalization and cytosolic localization. In contrast, no fluorescence was found
in the samples treated only with dissolved peptides (Figure 4.38). This sug-
gests that peptides alone cannot be transported into the living cells and that an
appropriate carrier is needed. Previously we have shown that with the help of
calcium phosphate nanoparticles different cargos could be transported across the
cell membrane when it was not possible for the cargo molecule alone [143].
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Figure 4.37 Uptake of CaP/PEI/Mut nanoparticles by THP-1 cells after 3 h of
incubation. Blue channel: nucleus; red channel: cell membrane; green channel:
FITC-labeled peptides.
Figure 4.38 Uptake of dissolved peptides by THP-1 cells after 3 h of incubation.
Blue channel: nucleus; red channel: cell membrane; green channel: FITC-labeled
peptides.
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4.1.6.3 Conclusions
We synthesized FITC-labeled peptide-functionalized calcium phosphate nano-
particles and characterized them by different colloid-chemical methods (DLS,
NTA, SEM). With the help of UV-Vis spectroscopy, the amount of peptide in
the nanoparticles colloid after purification was estimated. Furthermore, we could
calculate the theoretical amount of each peptide per nanoparticle. The functio-
nalized nanoparticles as well as the peptides themselves did not show any cyto-
toxic effects, and thus their practical application in vitro and in vivo is possible.
CLSM revealed no uptake of the dissolved peptides by the cells (no fluorescence),
whereas the peptide-functionalized nanoparticles were taken up by differentiated
THP-1 cells after 3 h of incubation. Therefore, biodegradable calcium phosphate
nanoparticles represent a flexible tool in bio- and nanomedicine as a carrier of
peptides into macrophages.
4.1.7 Summary
The following conclusions can be drawn from the obtained results. First, the
transfection of HeLa and MG-63 cell lines with PEI-functionalized calcium phos-
phate nanoparticles was efficient and less toxic compared to the transfection
with pure DNA-PEI polyplexes. Moreover, an additional functionalization with
protamine increased the efficiency of nanoparticles by facilitating the nuclear lo-
calization of plasmid DNA and by decreasing the toxic effect of PEI.
Second, functionalized calcium phosphate nanoparticles were able to transport
different molecules into the cells, whereas free molecules in general were not
able to penetrate the cell membrane. The studies using inhibition of endocytosis
showed that the uptake route of nanoparticles differed from that of free protein
molecules in the example of HTRA1.
It was also shown that the biological environment strongly influenced the func-
tion of synthetic enzyme-inhibiting molecules. In terms of the example of the
133
Results and Discussion
lysozyme inhibitor-polymer, this dependence was clearly demonstrated in the pres-
ence of cell culture medium with and without FCS.
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4.2 Functionalized calcium phosphate nanoparticles
as vaccine carriers
In this section, the application of calcium phosphate nanoparticles as a novel
and flexible vaccination tool will be discussed. The results of the in vitro and
in vivo experiments of immunization against influenza and Friend viruses with
functionalized calcium phosphate nanoparticles are summarized. Several decades
of vaccine research have failed to develop protective vaccine against persistently
infecting viruses such as HCV or HIV. Protein-based vaccines or adenoviral vectors
are commonly used to induce humoral and cellular T cell responses but rarely
lead to a sufficient antiviral immunity [313, 314]. Therefore, the development
of new strategies for prophylactic or therapeutic vaccination has attracted much
attention today.
All biological experiments presented in this section were carried out at the Essen
University Hospital, Institute of Medical Microbiology, Department of Infectious
Immunology, in the group of Prof. Astrid M. Westendorf. The major part of the
experiments was carried out by Dr Torben Knuschke.
4.2.1 Functionalized calcium phosphate nanoparticles for
vaccination against the influenza virus
4.2.1.1 Synthesis and characterization of functionalized calcium
phosphate nanoparticles
The synthesis protocol and optimization experiments to produce stable and im-
monoactive calcium phosphate nanoparticles, functionalized with a TLR9 ligand
(oligonucleotide CpG) and the hemagglutinin peptide from the influenza virus
(HA) (see Subsection 3.3), was recently introduced in our group by Sokolova
et al. [151]. These CpG- and HA-loaded nanoparticles were a useful nontoxic
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tool with the ability to maturate DCs and to induce Ag-specific CD4+ and CD8+
T cell responses in vitro [315, 316]. In this study, we synthesized and characte-
rized CaP nanoparticles with regard to their potential use as a vaccination vehicle
against the influenza virus. We prepared multi-shell CaP nanoparticles, using a
multi-step process of subsequent precipitation and functionalization. For a more
detailed description of the synthesis process, refer to Subsection 3.1.1.
The core of the nanoparticles was functionalized and stabilized with CpG. Im-
munogenic peptides of the influenza virus A/PR/8/34 HA: HA512−520 (MHC
Class I) or HA110−120 (MHC Class II) were subsequently adsorbed on the sur-
face of the CpG-functionalized nanoparticles, incrustation in the inner shell (see
Figure 4.39 A). These peptides and CpG molecules were protected from degra-
dation by the addition of a second shell consisting of calcium phosphate. Finally,
the nanoparticles were colloidally stabilized by the repeated addition of CpG. The
final concentrations of immunoactive molecules in the nanoparticle dispersion
were as follows: CpG=65.3 µg mL−1 (10.3 µM) and HA peptide=20.4 µg mL−1.
On average, the hydrodynamic diameter of these triple-shell nanoparticles was
~250 nm and about 150 nm in scanning electron microscopy images. One should
note that in SEM micrographs the nanoparticles appear without the hydration
shell and that single nanoparticles could be distinguished (see Figure 4.39 B).
For intranasal application, the nanoparticles were concentrated by means of
centrifugation and redispersion in pure water in a quarter of the original volume.
As we have previously quantified the number of absorbed CpG and HA molecules
onto the nanoparticles after the purification [315], the concentrations in the final
dispersion estimated to 130.6 µg mL−1 (20.6 µM) of CpG molecules and 40.8 µg
mL−1 of the HA peptide.
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Figure 4.39 Schematic illustration of functionalized calcium phosphate nanopar-
ticles. A: CaP nanoparticles are prepared in multiple steps to a final composition
of three layers of CaP and TLR ligand CpG (CaP/CpG+HA/CaP/CpG). The
core contains the HA peptide HA110−120 or HA512−520. B: Characterization of
triple-shell CaP nanoparticles, functionalized with CpG and HA peptides by dy-
namic light scattering (the average particle diameter is illustrated) and scanning
electron microscopy.
4.2.1.2 Uptake of calcium phosphate nanoparticles by DCs in vitro
We initially aimed to check the biological effect of the functionalized nanoparticles
in vitro by treating dendritic cells (DCs) to induce their maturation. DCs are the
most effective APCs and play a key role in initiating T cell mediated immune
responses. DCs can activate a substantial part of the adaptive immune response
by internalizing and processing Ags through the MHC Class I and II pathways and,
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finally, by presenting antigenic peptides to CD4+ and CD8+ T cells. Therefore,
targeting DCs with a maturation trigger (CpG), combined with Ag (HA) delivery,
is one important goal in the development of new vaccines.
To determine the uptake efficiency of functionalized CaP nanoparticles in vitro
by DCs, we stimulated whole splenocytes with Alexa488-labeled CpG-functionalized
CaP nanoparticles. After 24 h, splenocytes were harvested, and CD11c+ DCs
were analyzed for the presence of fluorescence from internalized Alexa488-labeled
nanoparticles. As seen in Figure 4.40 A, CD11c+ DCs showed a high uptake
efficiency. Nearly 37% of all DCs were positive for Alexa488. To analyze whether
CaP nanoparticles alone possess an adjuvant activity for DC activation, we com-
pared CpG-functionalized CaP nanoparticles to CaP nanoparticles, functionalized
with non-immunogenic control oligonucleotides (Oligo). It was shown that only
CpG-functionalized CaP nanoparticles induced the activation of CD11c+ DCs
with a specific upregulation of the costimulatory molecules like CD80, CD86, and
CD40, and an increased secretion of IL-2, IL-12, and TNF-α (Figure 4.40 B).
Previously, we demonstrated that CaP nanoparticles loaded with an MHC Class
II-restricted HA peptide of the influenza virus strongly induced a virus-specific
CD4+ T cell response in vitro [316]. For a potent antiviral vaccine candidate, it
is essential to prime the induction of both virus-specific CD4+ and CD8+ T cell
immunity. Therefore, we isolated CD11c+ DCs from the spleen and determined
whether these DCs can present internalized Ag on MHC Class II molecules and
cross-present this Ag on MHC Class I molecules after the stimulation with CpG-
and HA512−520 or HA110−120 peptides-functionalized CaP nanoparticles. The stim-
ulation with dissolved CpG and HA peptides were used as control. Stimulated DCs
were then co-cultured with HA-specific CD4+ or CD8+ T cells for 48-72 h, and
afterwards the proliferation of T cells was measured. As depicted in Figure 4.40 C,
functionalized CaP nanoparticles and dissolved control had a comparable effect
on the presentation of HA peptides and induced strong HA-specific CD4+ and
CD8+ T cell responses in vitro. These promising results suggest a great potential
of functionalized CaP nanoparticles for Ag delivery in vivo.
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Figure 4.40 Uptake of calcium phosphate nanoparticles and presentation of
virus-specific Ags in vitro. A: Spleen cells were incubated in vitro with Alexa488-
labeled CaP nanoparticles. After 24 h, the cells were stained for CD11c and an-
alyzed for CD11c+Alexa488+ cells. B: CD11c+ splenic cells were incubated with
CpG functionalized CaP nanoparticles or CaP nanoparticles functionalized with
non-immunogenic oligonucleotides. Expression of CD80, CD86, and CD40 and
cytokine levels of IL-2, IL-12, and TNF-α in cell culture supernatants were ana-
lyzed 24 h later. C: CD11c+ splenic cells were incubated with functionalized CaP
nanoparticles or with soluble CpG and HA512−520 or HA110−120 peptides. After
24 h, DCs were washed and co-cultured with eFluor670-labeled HA-specific CD4+
or CD8+ T cells for 48-72 h. Proliferation was measured by loss of eFluor670 dye
and is indicated as a percentage of proliferating cells. The figure comprises the re-
sults of three independent experiments. Bars represent mean ± SEM. ** p<0.01,
*** p<0.001, ns: not significant.
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4.2.1.3 Induction of potent CD4+ and CD8+ effector T cells with
functionalized calcium phosphate nanoparticles
To test the in vivo vaccination efficiency of CpG/HA512−520 or CpG/HA110−120
functionalized CaP nanoparticles, naive BALB/c mice were immunized intraperi-
toneally (i.p.) three times at intervals of 14 d either with PBS, soluble CpG
and HA512−520/HA110−120 peptides or CpG/HA512−520/HA110−120-functionalized
CaP nanoparticles (Figure 4.41 A). Two weeks after the last immunization, the
percentage of HA-specific CD8+ T cells and IFN-γ production was analyzed in
isolated splenocytes. The number of HA-specific CD8+ T cells detected in mice
immunized with functionalized CaP nanoparticles was significantly higher than
that detected in mice immunized with PBS and, more importantly, than that
immunized with soluble CpG and HA peptides (Figure 4.41 B).
Immunized with CaP nanoparticles, mouse splenocytes were restimulated with
HA512−520 or HA110−120 peptide. This restimulation resulted in the induction
of IFN-γ-producing CD4+ and CD8+ T cells (Figure 4.41 C). In contrast, the
restimulation of immunized with soluble CpG and HA peptides, mouse splenocytes
induced a significantly lower IFN-γ response. It is to be noted that no humoral
IgG Ab response against HA peptides was detected in any of the immunized
mice (data not shown). These results indicate a much more efficient inducing of
cellular immunity response after the i.p. immunization with functionalized CaP
nanoparticles compared to soluble factors only.
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Figure 4.41 Immunization protocol and induction of influenza-specific T cell
responses. A: BALB/c mice were immunized three times i.p. with 300 µL
functionalized CaP nanoparticles containing CpG and HA512−520 or HA110−120
peptides, soluble CpG and HA peptides at the same concentrations. Two weeks
after the final immunization, BALB/c mice were sacrificed for cellular analy-
sis. B: Total spleen cells from immunized mice were stained for the presence of
HA-specific CD8+H-2Kd :IYSTVASSL+ T cells (three mice per group). Bars rep-
resent mean ± SEM. C: Splenocytes from immunized BALB/c mice (three mice
per group) were restimulated in vitro with 10 µg mL−1 HA512−520 or HA110−120
peptide. After 24 h, the numbers of IFN-γ-producing CD4+ and CD8+ T cells
were determined by ELISpot in triplicate. Spots were counted and expressed as
spots per splenocyte. The figure illustrates results from one of three independent
experiments. Bars represent mean ± SEM. * p<0.05, *** p<0.001, ns: not
significant.
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4.2.1.4 Acceleration of influenza virus clearance from the lungs by
means of functionalized calcium phosphate nanoparticles
The next step was to determine whether HA-specific CD4+ and CD8+ T cells
induced by i.p. immunization with CaP nanoparticles can exhibit protective ac-
tivity. To this end, we intranasally challenged the immunized mice with a high
dose of influenza virus A/PR/8/34 2 weeks after the third immunization. Seven
days after challenge, viral titers in lungs were determined. Importantly, all mice
immunized with CaP nanoparticles had significantly lower viral titers in the lung
than the PBS group (see Figure 4.42 A). Moreover, 35% of the mice in this group
had completely eliminated the virus by this time. In contrast, immunization with
soluble CpG and HA peptides did not help to clear the virus. It merely resulted
in slightly lower viral titers compared to the PBS control group (Figure 4.42 B).
More interestingly, this accelerated clearance of virus from the lungs of mice im-
munized with CaP nanoparticles was in vivid correlation with an increased number
of HA-specific CD8+ T cells in the spleens of challenged mice (Figure 4.42 B).
However, total IgG concentrations in the serum showed no significant differences
between groups, neither before nor 7 days post infection, indicating a minor effect
of virus-specific T cells on IgG induction (Figure 4.42 C).
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Figure 4.42 Protection of immunized mice against influenza virus replication. A:
14 days after the third immunization, the mice were challenged intranasally with
1,000 PFUs of influenza virus A/PR/8/34. After 7 d, the mice were sacrificed and
lung virus titers were measured by plaque assay; y-axis starts at the influenza virus
detection limit. The figure illustrates results from four independent experiments.
Each data point represents one animal. B: Total spleen cells from influenza-
challenged mice (7 d after challenge) were stained for the presence of HA-specific
CD8+ H-2Kd :IYSTVASSL+ T cells. Each data point represents one animal. C:
IgG concentrations in sera of immunized mice were determined by ELISA 2 weeks
after the final immunization and at day 7 post infection. The figure illustrates
the results of two independent experiments (four mice per group). * p<0.05,
** p<0.01, *** p<0.001, ns: not significant.
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4.2.1.5 Results of intranasal immunization with functionalized calcium
phosphate nanoparticles
The lungs are the major target for invasion of such respiratory pathogens as in-
fluenza virus. Therefore, an efficient protection against virus infection requires
the induction or recruitment of virus-specific CD4+ and CD8+ T cells into the
lung. Therefore, we examined whether the intranasal administration of function-
alized CaP nanoparticles was sufficient to induce mucosal immunity and protec-
tion against influenza virus infection. First, we checked the specific uptake of
nanoparticles by DCs form lung lymph nodes. For this, BALB/c mice were ad-
ministered intranasally with Alexa488-labeled CaP nanoparticles. 4 h later, lung
lymph node cells were stained with anti-CD11c and examined for an Alexa488+
population. In Figure 4.43 one can see that approximately 30% of the CD11c+
DCs were Alexa488 positive. The next step was intranasal immunization of naive
BALB/c mice according to the same immunization protocol as that used for PBS,
soluble CpG, and HA110−120/ HA512−520 peptides or CpG/HA512−520/HA110−120-
functionalized CaP nanoparticles. Two weeks after the last immunization, mice
splenocytes were isolated, restimulated with the corresponding HA peptides, and
analyzed for production of IFN-γ, TNF-α, and IL-2. A higher number of CD4+
and CD8+ T cells producing IFN-γ, IL-2, and TNF-α were detected in the mice
immunized with CaP nanoparticles compared to control groups (Figure 4.43 B
and C).
Furthermore, 7 d after the influenza virus challenge, the viral replication level
in the lungs of mice immunized with CaP nanoparticles was significantly lower
than those treated with PBS (Figure 4.44 A). This decrease was accompanied by
a higher number of HA-specific CD8+ T cells in the lung lymph nodes and the
spleen (Figure 4.44 B).
Although mice represent a good animal model for influenza infection, they
exhibit some differences in viral manifestation compared to humans. Viral repli-
cation in mice is mainly confined to the lower respiratory tract [317,318], whereas
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in humans it is mainly limited to the upper respiratory tract. Consequently, an
influenza infection in mice is more severe than in humans. To simulate the
infection, localized in upper respiratory tract, conscious rather than narcotized
mice were challenged with the influenza virus. Generally, mice infected without
anesthesia showed reduced morbidity 7 d after viral infection. More interestingly,
CpG/HA512−520/HA110−120-functionalized CaP nanoparticles-immunized mice ex-
hibited the highest reduction of the viral load in the lungs, compared to other con-
trol groups (Figure 4.44 C). Furthermore, increased numbers of HA-specific CD8+
T cells indicate an activation of preexisting virus-specific T cells after intranasal
immunization of mice with functionalized CaP nanoparticles (Figure 4.44 D).
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Figure 4.43 Intranasal immunization with functionalized calcium phosphate
nanoparticles prevents influenza virus replication. A: Alexa488-labeled CaP
nanoparticles were administered intranasally to BALB/c mice. After 4 h, lung
lymph node cells were isolated and stained for CD11c. The percentage of
Alexa488+CD11c+ DCs is shown. B: BALB/c mice were immunized intranasally
with 50 µL of CpG/HA512−520-functionalized CaP nanoparticles or soluble CpG
plus HA110−120;512−520 at the same concentrations on days 1, 14, and 28. Spleno-
cytes from CaP nanoparticles-immunized mice were restimulated in vitro with
10 µg mL−1 of the HA512−520 or HA110−120 peptide. After 24 h, the numbers of
IFN-γ-producing CD4+ and CD8+ T cells were determined by ELISpot in tripli-
cate. Two independent experiments (five mice per group) were carried out. Bars
represent mean ± SEM. C: Splenocytes of immunized mice were cultured in the
presence of 10 µg mL−1 of the HA512−520 or HA110−120 peptide. After 48 h,
supernatants were analyzed for indicated cytokines by Luminex technology. The
figure illustrates the results of two independent experiments. Each data point
represents one sample. * p<0.05, ** p<0.01, *** p<0.001, ns: not significant.
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Figure 4.44 Intranasal immunization suppresses virus replication. A: 14 days
after the third immunization, mice were challenged intranasally with 1,000 PFUs
influenza virus A/PR/8/34. After 7 d, mice were sacrificed, and lung virus titers
were measured by plaque assay; y-axis starts at the influenza virus detection limit.
The figure illustrates the results from three independent experiments. B: Lung
lymph node cells and total spleen cells from influenza-challenged mice (7 d after
challenge) were stained for the presence of HA-specific CD8+H-2Kd :IYSTVASSL+
T cells. The figure illustrates the results from three independent experiments. C:
14 days after the third immunization, conscious mice were challenged intranasally
with a 80,000 PFUs of influenza virus A/PR/8/34. Viral RNA was isolated on day
7 post infection from homogenized lungs. Viral copy numbers were determined by
qPCR (five mice per group). The figure comprises the results of two independent
experiments. Bars represent mean ± SEM. D: Lung lymph node cells from
influenza-challenged mice (7 d after challenge) were stained for the presence of
HA-specific CD8+ H-2Kd :IYSTVASSL+ T cells. Each data point represents one
animal. * p<0.05, ** p<0.01, *** p<0.001, ns: not significant.
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4.2.1.6 Results of intramuscular immunization with functionalized
calcium phosphate nanoparticles
Although intranasal immunization represents an effective application route for
inducing potent mucosal immune responses, it is not applicable for most of vac-
cination procedures on human. The predominant route for many viral vaccines
including influenza is intramuscular (i.m.) injection. Thus, our final aim was
to test the efficiency of functionalized CaP nanoparticles for i.m. immuniza-
tion. We vaccinated mice according to the standard immunization protocol, but
by i.m. injection. Two weeks after the last of the three immunizations, con-
scious mice were challenged with the influenza virus. In Figure 4.45, the results
of this experiment are shown. Seven days after infection, only CaP/CpG/HA
nanoparticles-immunized mice showed a viral RNA level in lungs below the de-
tection limit (Figure 4.45 A). Moreover, this accelerated clearance of the virus
from the lungs of mice immunized with CaP nanoparticles was accompanied by
an elevated number of HA-specific CD8+ T cells in the lung lymph nodes of chal-
lenged mice (Figure 4.45 B). In comparison, an i.m. immunization with soluble
HA/CpG did not affect viral clearance.
Overall, these results indicate that MHC Class I and II HA peptides and TLR9
ligand CpG-functionalized CaP nanoparticles administered by various immuniza-
tion routes (intraperitoneal and, more importantly, intranasal and intramuscular),
are able to efficiently deliver antigen to DCs and drive sufficient maturation and
signal transduction in DCs to facilitate antigen processing and presentation, thus
inducing protective antiviral cellular immunity in mice.
Virus-specific CD4+ and CD8+ T cells in the lung are considered to provide
protection against respiratory viruses like influenza. Since the lung is an en-
trance point for this kind of infection, particular attention should be paid to this
organ as a target for mucosal immunization. It has been shown that antigens
administrated by the mucosal route are poorly immunogenic because of the im-
munosuppressive environment, and that they often induce tolerance against viral
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infections [319]. Therefore, it is preferable for mucosal vaccinations to use a de-
livery system that ensure both carrier and adjuvant functions. The functionalized
nanoparticulate carrier, based on calcium phosphate, is easily taken up by cells
and degraded in lysosomes. After release in the cytoplasm, the calcium ions are
rapidly pumped out of the cell leaving the intracellular calcium concentration at a
physiologically harmless level [320]. In addition, non-functionalized calcium phos-
phate nanoparticles showed no effect on DCs’ maturation and activation, leaving
this task to immunocompetent adjuvants, which can be efficiently loaded onto
the nanoparticles.
Figure 4.45 Intramuscular immunization with functionalized calcium phosphate
nanoparticles prevents influenza virus replication. A: 14 days after the third i.m.
immunization, conscious mice were challenged intranasally with 80,000 PFUs of
influenza virus A/PR/8/34. Viral RNA was isolated on day 7 post infection from
homogenized lungs. Viral copy numbers were determined by qPCR (five mice per
group). The figure comprises the results of two independent experiments. Bars
represent mean ± SEM. B: Lung lymph node cells from influenza-challenged
mice (7 d after challenge) were stained for the presence of HA-specific CD8+
H-2Kd :IYSTVASSL+ T cells. Each data point represents one animal.
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4.2.1.7 Conclusions
We have demonstrated that biodegradable calcium phosphate nanoparticles, func-
tionalized with influenza virus antigen (HA) and TLR 9 ligand (unmethylated
CpG) and introduced by various immunization routes, can provide an effective
antiviral protection through driving the maturation of DCs and their subsequent
activation and cross-presentation of the antigen to CD4+ and CD8+ T cells. Our
results show that the calcium phosphate nanoparticles represent a perspective al-
ternative and flexible vaccination tool that gives the opportunity to develop novel
and effective vaccine delivery systems.
4.2.2 Functionalized calcium phosphate nanoparticles for
vaccination against the Friend virus
In this study, we introduce CaP nanoparticles loaded with the Toll-like receptor 9
ligand CpG and the viral antigens GagL or gp70 derived from the Friend virus
(FV) as vaccination tool for T cell-mediated immune response against retroviral
infection, and more importantly for therapeutic treatment of chronic retroviral
infection.
4.2.2.1 Synthesis and characterization of functionalized calcium
phosphate nanoparticles
Multi-shell CaP nanoparticles were synthesized by a precipitation method and
subsequent functionalized with TLR9 ligand CpG (63 µM=0.4 mg mL−1) and
Friend virus-specific T cell epitopes from Env-derived glycoprotein 70 (gp70,
1 mg mL−1) and the leader region of Gag (GagL, 1 mg mL−1) (see Subsec-
tion 3.3). Afterwards, another shell of calcium phosphate was attached to protect
the biomolecules from the preliminary degradation, and finally, the nanoparticles
were functionalized with CpG molecules for colloidal stabilization (Figure 4.46 A).
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The final concentrations of molecules in the dispersion of nanoparticles were as
follows: CpG=65.3 µg mL−1, GagL and gp70=20.4 µg mL−1. For a more detailed
description of the synthesis process, refer to Subsection 3.1.1. Scanning elec-
tron microscopy micrographs of the functionalized nanoparticles demonstrated a
spherical shape and high homogeneity of the nanoparticles (Figure 4.46 B).
The obtained nanoparticles were characterized by dynamic light scattering and
nanoparticles tracking analysis to measure the hydrodynamic size. The surface
charge of the functionalized particles is an important physicochemical parameter
of the colloidal stability (Table 4.19). The average size of multi-shell nanopar-
ticles in colloid dispersion was 125-130 nm. A strongly negative zeta potential
(surface charge) of -21 mV, due to the negatively charged CpG molecules on the
surface of the nanoparticles, ensures their stability in aqueous dispersion.
Figure 4.46 A: Schematic illustration of functionalized multi-shell cal-
cium phosphate (CaP) nanoparticles. Multi-shell CaP nanoparticles con-
sist of layers of calcium phosphate and Toll-like receptor ligand CpG
(CaP/CpC+peptides/CaP/CpG). The core contains the antigenic peptides
GagL85−93 or gp70123−141. B: SEM micrographs of calcium phosphate nanopar-
ticles, functionalized with CpG and gp70 and GagL peptides.
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Table 4.19 Colloid-chemical characterization of purified peptide-functionalized
CaP/PEI nanoparticles by DLS and NTA and UV-Vis spectroscopy. PDI: poly-
dispersity index from dynamic light scattering.
Sample PDI Size (DLS)/nm
Size (NTA)
/nm
Zeta
potential /
mV
CaP/CpG/gp70 0.474 293 125 -20
CaP/CpG/GagL 0.253 289 129 -21
4.2.2.2 The induction of virus-specific T cell expansion in vitro and in
vivo with calcium phosphate nanoparticles
The induction of FV-specific T cell proliferation by presenting encapsulated FV
antigen (CD4+ and CD8+ epitope peptides) by targeted DCs on the major his-
tocompatibility complex (MHC) Class I and MHC Class II was analyzed (Fi-
gure 4.47). For that, primary DCs from wild type mice were stimulated with func-
tionalized CaP nanoparticles (CaP/CpG/gp70(GagL)). After 24 h, FV-specific
CD4+ or CD8+ T cells were labeled with the proliferation dye eFluor670 and
co-cultured with CaP nanoparticles-stimulated DCs. 72 h later, the proliferation
of T cells was measured by loss of eFluor670 due to the distribution of the dye
on daughter cell generations. As depicted in Figure 4.47 A and B, functionalized
CaP nanoparticles-treated DCs strongly induced the proliferation of transgenic
FV-specific CD4+ and CD8+ T cells in vitro.
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Figure 4.47 In vitro activation of DCs and FV-specific T cell responses. CD11c+
splenic DCs were incubated with functionalized CaP nanoparticles. After 24 h,
DCs were washed and co-cultured with eFluor670-labeled gp70-specific CD4+(A)
or GagL-specific CD8+ T (B) cells for 72 h. Proliferation was measured by a
loss of eFluor670 dye and was indicated as a percentage of proliferating cells.
Representative histograms of proliferating CD4+ or CD8+ T cells are shown. The
figure comprises results of 2 independent experiments. Representative histograms
are shown. Bars represent mean ± SEM. *** p<0.001.
This is well in line with our results, as we have demonstrated that the nanoparticle-
based uptake of a viral antigen, along with an adjuvant by APCs, is more sufficient
to induce virus-specific CD4+ and CD8+ T cell responses in vitro and in vivo,
compared to the uptake of soluble biomolecules. We used unmethylated Class B
CpG as an adjuvant. CpG binds to TLR9 and is a well-established, safe molecule
with clinical translational potential, as demonstrated by the findings of three
completed clinical trials with CpG as a vaccine adjuvant [321]. CpG can evoke
a range of immunostimulatory effects; it can enhance the activity of lympho-
cytes and APCs, trigger DC maturation, and drive the immune system toward
the TH1 immune response against specific Ags [322]. This finding conforms to
our results that immunization of mice with CaP nanoparticles functionalized with
FV peptides and CpG induced IFN-γ-producing CD4+ and CD8+ effector T cells
and significantly reduced the viral titers in acute and chronic retroviral infection.
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In a recent study, we used poly(I:C) for the treatment of acute retroviral infec-
tion. In FV-infected animals, poly(I:C) treatment improved functional properties
of virus-specific T cells and prevented virus-induced disease [323]. Therefore, it
would be of great interest to test whether the incorporation of poly(I:C) or a
combination of poly(I:C) and CpG into CaP nanoparticles would further improve
the vaccination efficacy against retroviral infection. In general, we showed that
poly(I:C)-functionalized CaP nanoparticles induce the maturation of DCs and T
cells in vitro [313], but we have not yet tested these particles for vaccination.
To analyze the in vivo efficiency of functionalized CaP nanoparticles to induce
FV-specific T cell response, naive FV-susceptible CB6F1 mice were subcuta-
neously immunized twice over a three-week interval either with PBS, soluble
CpG/gp70/GagL, or with CpG/gp70/GagL-functionalized CaP nanoparticles in a
prime-boost immunization (Figure 4.48). Two weeks after the last immunization,
splenocytes of immunized mice were isolated, restimulated with GagL or gp70
peptides, and analyzed for the presence of IFN-γ-producing CD4+ and CD8+
T cells. As demonstrated in Figure 4.48, the number of IFN-γ-producing CD4+
and CD8+ T cells was the highest in mice immunized with functionalized CaP
nanoparticles. These data indicate that immunization with CaP nanoparticles,
functionalized with CpG, gp70, and GagL molecules, primes cellular immunity
leading to the production of antiviral IFN-γ much stronger than immunization
with soluble biomolecules. The applied dose of CpG was relatively low compared
to other vaccine studies [324]. This impressively underlines the importance of
the efficient delivery of the therapeutic agent. Here we could demonstrate that
the CaP nanoparticle system was able to sufficiently induce effective immune
responses even with a low concentration of adjuvants.
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Figure 4.48 Induction of FV-specific T cell responses. FV-susceptible CB6F1
mice were immunized twice over a three-week interval with PBS, CpG/GagL/gp70
or CpG/GagL/gp70-functionalized CaP nanoparticles in a prime-boost immuniza-
tion. Two weeks later, splenocytes from immunized mice were restimulated in
vitro with GagL85−93 or gp70123−141 peptide. After 24 h, the numbers of IFN-
γ-producing CD4+ and CD8+ T cells were determined by ELISpot. The figure
comprises the results of 3 independent experiments. Bars represent mean ± SEM.
** p<0.01; *** p<0.001.
4.2.2.3 Results of prophylactic vaccination with calcium phosphate
nanoparticles
To determine whether the nanoparticle-induced CD4+ and CD8+ T cells response
confer protective immunity, FV-susceptible mice were challenged with a high dose
(2,500 SFFU) of FV 3 weeks after the boost immunization (Figure 4.49 A). After
the challenge, the disease score was monitored by the palpation of spleens, and
spleen sizes were categorized as described before [322]. Remarkably, after infec-
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tion only in the group of mice, immunized with CaP nanoparticles, splenomegaly
was very rare and mild as demonstrated by the spleen weight on day 21 post
infection (Figure 4.49 B and C).
In order to analyze vaccine-mediated control over acute FV replication, viral
loads in plasma and in the spleen were determined on days 10 and 21 post infec-
tion, respectively. In all immunized mice, the mean viral loads were significantly
reduced compared to unimmunized control mice. Importantly, in 80% of mice
vaccinated with functionalized CaP nanoparticles, the virus was not detectable
(<102 FFU), in comparison with 40% in the group of mice vaccinated with CpG/
gp70/GagL (Figure 4.50 D). The viral load in the spleen 21 days post infection
was also reduced in both vaccine groups. However, the immunization with func-
tionalized CaP nanoparticles showed the strongest reduction in the mean viral
loads (Figure 4.50 E). These data clearly demonstrate the high potential of CaP
nanoparticles to induce efficient antiretroviral immunity.
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Figure 4.49 Vaccination with functionalized calcium phosphate nanoparticles
confers protection from FV-induced splenomegaly and reduces viral loads I. A:
FV-susceptible CB6F1 mice were immunized twice over a three-week interval with
PBS, CpG/GagL/gp70 or CpG/GagL/gp70-functionalized CaP nanoparticles in
a prime-boost immunization. Three weeks after boost immunization, mice were
challenged with FV (2500 SFFU). B: Spleens were weighed 21 days post challenge
infection. Spleen weight is depicted in gram (g). C: One representative spleen
per group on day 21 is shown. Median values are indicated by horizontal lines.
The figure comprises results of 2 independent experiments, each with 3-4 mice
per group. * p<0.05; *** p<0.001.
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Figure 4.50 Vaccination with functionalized calcium phosphate nanoparticles
confers protection from FV-induced splenomegaly and reduces viral loads II. D:
Viral loads in the plasma of FV-infected mice were analyzed on day 10 after the
challenge infection. Viremia levels are shown as FFU mL−1. Median values are
indicated by lines. E: On day 21 post challenge infection, viral loads in the spleen
were analyzed. Viral loads are shown as IC/spleen. Median values are indicated
by horizontal lines. The figure comprises results of 2 independent experiments,
each with 3-4 mice per group. * p<0.05; ** p<0.01.
As previously reported, both CD8+ and CD4+ T cells are essential for controlling
the FV infection [325,326]. After deactivation of CD8+ T cells by administration
of anti-CD8 monoclonal antibodies in resistant mice, they fail to control acute
virus replication and develop severe splenomegaly. CD4+ T cells function during
acute retrovirus infection mainly as T helper cells that activate other effector cell
populations of the adaptive immune system [327, 328]. Thus, the depletion of
CD4+ and CD8+ T cells during vaccination led to an abolishment of protection. It
is relevant to use both T cell epitopes for vaccination against retroviral infection.
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4.2.2.4 Results of therapeutic vaccination during chronic viral infection
The aim of therapeutic vaccination is to enhance adaptive immunity during a
chronic infection and to reduce viral load. To test the efficiency of functionalized
CaP nanoparticles in therapeutic vaccination against retroviral infection, resis-
tant C57BL/6 mice were infected with a high dose of FV so that the chronic
infection developed. After the establishment of chronic infection (>6 weeks after
infection), mice were subcutaneously immunized once with either the solution
of CpG/gp70/GagL, or CaP nanoparticles, functionalized with CpG, gp70, and
GagL (Figure 4.53 A). One week after immunization, splenocytes and lymph
node cells were isolated, restimulated with GagL or gp70 peptides and analyzed
for the presence of IFN-γ-producing CD4+ and CD8+ T cells. As depicted in
Figure 4.53 B and C, the highest number of IFN-γ-producing CD4+ and CD8+
T cells was in mice immunized with functionalized CaP nanoparticles, compared
to non-vaccinated (PBS) or CpG/gp70/GagL-treated group.
In addition, a successful reactivation of cytotoxic T cells, which was demon-
strated by a significant increase in the number of totally activated granzyme
B (GzmB) expressing CD4+CD43+GzmB+ and CD8+CD43+GzmB+ T cells (Fi-
gure 4.52 D), was only found in the group of mice immunized with functionalized
CaP nanoparticles. These activated cytotoxic virus-specific T cells are respon-
sible for the reduction of the viral load in chronically retroviral infected mice.
Therefore, the approach of combining virus-specific GagL and gp70 peptides and
immunogenic adjuvant CpG to activation of peptide-specific T cell responses may
find its application for controlling such retroviral infections as HIV [329].
It has recently been shown that regulatory T cells control virus-specific CD8+
T cells during chronic FV infection [330]. Thus, we also determined the number
of regulatory T cells in immunized mice and found that after immunization with
functionalized CaP, their number was significantly decreased in comparison to
non-immunized mice (Figure 4.52 E).
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Figure 4.51 Therapeutic vaccination with functionalized calcium phosphate
nanoparticles reactivates T cell immunity during chronic FV infection I. A:
FV-resistant C57BL/6 mice were infected with 15,000 SFFU FV. Chronically
(>6 weeks) infected mice were vaccinated once with PBS, CpG/GagL/gp70 or
CpG/GagL/gp70-functionalized CaP nanoparticles. 7 days later, splenocytes B
or lymph node cells C from vaccinated mice were restimulated in vitro with GagL
or gp70 peptide. After 24 h, the numbers of IFN-γ-producing CD4+ and CD8+
T cells were determined by ELISpot. The figure illustrates the results of 2 inde-
pendent experiments, each with 5 mice per group. Lines represent mean ± SEM.
* p<0.05; ** p<0.01; *** p<0.001.
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Figure 4.52 Therapeutic vaccination with functionalized calcium phosphate
nanoparticles reactivates T cell immunity during chronic FV infection II. D: The
number of activated cytotoxic CD4+ and CD8+ T cells in the spleen was analyzed
by flow cytometry seven days after therapeutic vaccination. E: The percentage
of CD4+Foxp3+ cells was analyzed by flow cytometry. The figure illustrates the
results of 2 independent experiments, each with 5 mice per group. Lines represent
mean ± SEM. * p<0.05; ** p<0.01.
The results of these in vivo experiments clearly demonstrate the high potential
of the functionalized CaP nanoparticles as vaccine delivery system for therapeutic
immunization against chronic retroviral infections.
Most importantly, a single-shot immunization with CpG/gp70/GagL-functiona-
lized CaP nanoparticles during the chronic infection significantly reduced viral
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loads in the spleen and lymph nodes of FV-infected mice, while the same viral
antigens in soluble form did not (Figure 4.53 A). In addition, the statistical
analysis demonstrates a clear correlation between the percentage of CD8+ effector
T cells and viral load. The higher the number of CD8+ effector T cells detected
in the spleen, the lower was the viral load (Figure 4.53 B). These results suggest
that functionalized CaP nanoparticles are a promising tool to develop an effective
therapeutic vaccines.
Figure 4.53 Therapeutic vaccination with functionalized calcium phosphate
nanoparticles reduces viral loads. A: 7 days after vaccination of chronically in-
fected mice, viral loads in the spleens and peripheral lymph nodes were analyzed.
Viral loads are shown as IC/spleen. The figure illustrates results of 2 indepen-
dent experiments, each with 3-5 mice per group. Lines represent mean values.
B: The percentage of CD8+ effector T cells negatively correlates with the viral
load in the spleen only after immunization with CpG/gp70/GagL-functionalized
CaP nanoparticles. * p<0.05; ** p<0.01.
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4.2.2.5 Results of therapeutic immunization with functionalized
calcium phosphate nanoparticles combined with depletion of
regulatory T cells during chronic viral infection
Regulatory T cells (Tregs) are a subset of CD4+ T lymphocytes with the abil-
ity to suppress the immune system for down-regulation of the immune system
so that no autoimmune disorders occurs. They play a key role in the establish-
ment and/or maintenance of chronic viral infection and constitute a barrier to
efficient vaccination and immunotherapy strategies [331]. The involvement of
regulatory T cells in the development of chronic viral infection was first described
in mice infected with FV [332] and was then extended to other persistent viruses
including HIV [333]. It is becoming increasingly clear that controlling this im-
munosuppressive cell subset would have widespread clinical applications to fight
life-threatening viral diseases. Our results show that a sufficient reactivation of
antiviral T cell immune response with an adequate vaccination vehicle such as
CaP nanoparticles can overcome the suppressive barrier of Tregs and lead to a
significant reactivation of T cell immunity.
It has been shown recently that transient depletion of regulatory T cells during a
chronic phase of retroviral infection helps exhausted CD8+ T cells to regain their
antiviral function. We aimed to check whether the depletion of regulatory T cells
before immunization could improve the efficacy of functionalized CaP nanoparti-
cles. For this experiment, we used DEREG mice in which regulatory T cells were
selectively eliminated by the injection of diphtheria toxin (DT) to establish chronic
FV infection. 6 weeks after infection, the mice were treated with DT 4 and 2
days before as well as 2 and 4 days after the immunization with CpG/gp70/GagL-
functionalized CaP nanoparticles (Figure 4.54 A). This resulted in more than 95%
depletion of regulatory T cells (Figure 4.54 B). 7 days after the immunization,
isolated splenocytes were restimulated with GagL or gp70 peptides and analyzed
for the number of IFN-γ-producing CD4+ and CD8+ T cells. Interestingly, the
combination of regulatory T cells depletion and immunization had further ele-
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vated the number of IFN-γ producing CD4+ and CD8+ T cells (Figure 4.54 C). In
addition, as shown in Figure 4.55 D, the strongest increase in the frequency of to-
tal activated cytotoxic CD4+CD43+GzmB+ and CD8+CD43+GzmB+ T cells was
observed under the combination of regulatory T cell depletion and immunization
with CpG/gp70/GagL-functionalized CaP nanoparticles. Although single-shot
immunization with functionalized CaP nanoparticles during the chronic state of
FV infection already significantly reduced viral loads in the spleen, the additional
depletion of regulatory T cells during the immunization process further enhanced
this effect (Figure 4.55 E).
The combination of depletion of regulatory T cells and therapeutic immuniza-
tion with functionalized CaP nanoparticles of chronically infected mice resulted
in the lowest viral loads in the spleen of all other subsets tested in this study.
Consequently, our findings support the statement that the modulation of this
immunosuppressive cell subset is an important part of a successful antiviral ther-
apeutic vaccination.
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Figure 4.54 Transient depletion of regulatory T cells enhances the viral clearance
after therapeutic calcium phosphate nanoparticle vaccination I. A: Transgenic
DEREG mice on C57BL6 background were chronically infected with FV (>6
weeks). Regulatory T cells were depleted by peritoneal injection of diphtheria
toxin (DT) on day 4 and 2 prior to and on day 2 and 4 after vaccination. B:
The depletion of regulatory T cells is depicted by representative flow cytometry
plots. C: 7 days later, splenocytes from vaccinated mice were restimulated in
vitro with GagL or gp70 peptide. The numbers of IFN-γ-producing CD4+ and
CD8+ T cells were determined by ELISpot. * p<0.05; ** p<0.005.
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Figure 4.55 Transient depletion of regulatory T cells enhances the viral clearance
after therapeutic calcium phosphate nanoparticle vaccination II. D: The number
of activated cytotoxic CD4+ and CD8+ T cells in the spleen was analyzed by flow
cytometry 7 days after the therapeutic vaccination. E: Viral loads in the spleens
of DEREG mice were analyzed 7 days after the vaccination. Viral loads are shown
as IC/spleen. The figure illustrates the results of 3 independent experiments, each
with 4 mice per group. Bars represent mean ± SEM. * p<0.05; ** p<0.005;
*** p<0.0005.
4.2.2.6 Conclusions
In summary, we demonstrated that immunization with antigen/adjuvant-functio-
nalized CaP nanoparticles can efficiently induce the maturation of DCs and the
subsequent activation and proliferation of virus-specific CD4+ and CD8+ T cell
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response against acute as well as chronic retroviral infection on the FV infection
model in mice. Furthermore, therapeutic single-shot immunization with func-
tionalized CaP nanoparticles significantly reduced the viral loads. We have also
demonstrated that the depletion of regulatory T cells during the therapeutic vac-
cination can significantly improve the treatment of chronic retroviral infection.
4.2.3 Summary
The data reported in this section clearly demonstrate the high potential of antigen/-
adjuvant-functionalized CaP nanoparticles for the induction of protective antivi-
ral immunity. Our results show that calcium phosphate nanoparticles represent
a perspective alternative and flexible vaccination tool that allows controlled and
accessible loading of various immunoactive molecules, thus giving the opportunity
to develop flexible and effective vaccine delivery systems.
Owing to their comparable size and controlled composition (i.e. functionaliza-
tion with different adjuvants and viral epitopes), nanoparticles can mimic the virus
particles while at the same time avoiding side effects that are associated with the
application of live or attenuated viruses for active immunization. They represent
a powerful and novel tool for developing vaccines against various life-threatening
infectious diseases.
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In this work, the synthesis, characterization, and application possibilities of cal-
cium phosphate nanoparticles functionalized with various biological and synthetic
molecules in bio- and nanomedicine were investigated. Nanoparticles stabilized
with different polyelectrolytes (PEI, CMC, or nucleic acids) and loaded with
peptides, proteins, oligonucleotides, nucleic acids, porphyrins, polymers, and
other molecules were synthesized and characterized with different physicochemi-
cal methods. The number of fluorescently labeled cargo molecules adsorbed onto
the surface of the nanoparticles were determined by UV-Vis spectroscopy.
In order to study the cellular uptake of cargo-loaded calcium phosphate nanopar-
ticles, in vitro experiments on HeLa, MG-63, THP-1 and hMSC cells were carried
out. Light and fluorescence microscopy as well as CLSM imaging of the cells
showed a high level of calcium phosphate nanoparticle internalization, regardless
of the type of cargo molecule present in the nanoparticles. In contrast, dissolved
molecules alone were usually not able to penetrate the cell membrane. Moreover,
by using different inhibitors of endocytotic pathways on MG-63 cell line, it was ob-
served that nanoparticles were taken up by caveolin-mediated endocytosis. Free
protein molecules (HTRA1), however, used the routes other than endocytosis,
which are yet to be determined.
It was also investigated how the biological milieu influenced the activity of
enzyme-inhibiting polymer on the example of lysozyme. Calcium phosphate
nanoparticles, functionalized with lysozyme-inhibiting polymer, were taken up by
THP-1 cell line within 3 h of incubation as it was demonstrated by confocal laser
scanning microscopy of the treated cells. Nevertheless, the expected significant
inhibitory effect of the polymer inside the living cells, as well as in the cell culture
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medium, was absent. The experiments in phosphate buffer, cell culture medium
with and without FCS, with free polymer and lysozyme showed a dramatic impact
of the experimental conditions on the effectiveness of the lysozyme-inhibitor poly-
mer. The inhibitory effect of the polymer was clearly shown in phosphate buffer
solution in a dose-dependent manner. In the presence of the cell culture medium
containing various biological molecules, the inhibition of lysozyme decreased es-
sentially and could be detected only at the highest concentration of polymer, and
only up to 40%. Furthermore, when the cell culture medium was supplemented
with 10% of FCS, no inhibitory effect was found. This may serve as evidence
for the low specificity of the inhibitory polymer to target molecule. The polymer
molecules interacted with other biomolecules contained in large quantities in cell
culture media.
Another set of experiments was dedicated to the investigation of calcium phos-
phate nanoparticles as potent vaccination tool. The ability of nanoparticles,
loaded with immunoactive molecules like CpG, influenza virus hemagglutinin,
and Friend virus-derived proteins to stimulate the immune response, were tested
in vitro on antigen-presenting cells (DCs) and CD4+ and CD8+ T cells. These
functionalized nanoparticles performed significantly effectively compared to con-
trol groups, driving the maturation of DCs and subsequent promotion of the pro-
liferation of virus-specific CD4+ and CD8+ T cells. Furthermore, in vivo studies
with immunization of mice against influenza virus and Friend virus, as a retroviral
mouse model, showed that the nanoparticles were able to activate the immune
response and helped to clear the viral load in infected mice better than in control
groups where immunoactive molecules were injected in a soluble form.
Summarizing, one can say that calcium phosphate-based nanoparticles can serve
as an effective and biocompatible carrier system that can be used for many ap-
plications in bio- and nanomedicine.
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5.1 Zusammenfassung
In dieser Arbeit wurden Calciumphosphat-Nanopartikel synthetisiert, mit ver-
schiedenen biologischen und synthetischen Molekülen funktionalisiert und hin-
sichtlich potenzieller Anwendungsmöglichkeiten in Bio- und Nanomedizin unter-
sucht. Die Nanopartikel wurden mit unterschiedlichen Polyelektrolyten (PEI,
CMC oder DNA) stabilisiert und mit Peptiden, Proteinen, Oligonukleotiden,
Nukleinsäuren, Polymeren und anderen Molekülen beladen. Danach wurden
die Partikel mittels unterschiedlichen physikalisch-chemischen Methoden charak-
terisiert. Die Menge an fluoreszenzmarkierten Molekülen, die auf der Oberfläche
der Nanopartikel adsorbiert waren, wurde mit UV-Vis-Spektroskopie bestimmt.
Um die zelluläre Aufnahme von beladenen Calciumphosphat-Nanopartikeln zu
untersuchen, wurden in vitro-Versuche an HeLa, MG-63, THP-1 und hMSC-
Zellen durchgeführt. Licht- und Fluoreszenz-Mikroskopie sowie CLSM der Zellen
zeigten eine effiziente Internalisierung von Molekülen zusammen mit den Calcium-
phosphat-Nanopartikeln. Im Gegensatz dazu waren gelöste Moleküle allein im All-
gemeinen nicht in der Lage, die Zellmembran zu durchdringen. Darüber hinaus
wurde durch die Verwendung verschiedener Inhibitoren an MG-63-Zellen fest-
gestellt, dass die Nanopartikel durch Caveolin-vermittelte Endozytose aufgenom-
men wurden. Freie HTRA1-Proteinmoleküle hingegen gelangten durch die an-
deren Aufnahmewege in die Zellen, die noch zu bestimmen sind.
Außerdem wurde am Beispiel des Lysozyms untersucht, wie das biologische
Milieu die Aktivität eines enzymhemmenden Polymers beeinflusst. Calciumphos-
phat-Nanopartikel, wurden mit Lysozym-inhibierendem Polymer funktionalisiert.
Nach 3 h Inkubation wurden sie von THP-1 Zellen aufgenommen, wie es auf
CLSM-Aufnahmen von behandelten Zellen zu sehen war. Dennoch war die er-
wartete signifikante Hemmwirkung des Polymers sowohl innerhalb der lebenden
Zelle als auch im Zellkulturmedium nicht vorhanden. Die durchgeführten Experi-
mente in Phosphatpuffer, Zellkulturmedium mit und ohne FCS, mit freiem Poly-
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mer und Lysozym, und in Abwesenheit von Zellen sowie Nanopartikeln deuteten
auf einen grundlegenden Einfluss der experimentellen Bedingungen hin. Die hem-
mende Wirkung des Polymers konnte im Fall der Phosphatpufferlösung in dosisab-
hängiger Weise deutlich festgestellt werden. Im Vergleich dazu konnte die Hem-
mung von Lysozym im Zellmedium nur bei der höchsten Polymer-Konzentration
und nur bis zu 40% festgestellt werden. Außerdem ging die hemmende Wirkung
gänzlich verloren, wenn das Zellkulturmedium mit 10% FCS ergänzt wurde. Dies
könnte auf eine geringe Spezifität der hemmenden Polymermoleküle hindeuten,
die offenbar mit anderen Biomolekülen, die in großen Mengen in biologischen
Lösungen wie dem Zellkulturmedium enthalten sind, in Wechselwirkung treten
könnten.
Eine weitere Reihe von Experimenten wurde der Untersuchung der Calcium-
phosphat-Nanopartikel als potenziellem neuartigem Impfsystem gewidmet. Die
Fähigkeit von Nanopartikeln, die mit immunoaktiven Molekülen wie CpG, Influenza-
virus-Hämagglutinin oder von Friend Virus-abgeleiteten Proteinen beladen wur-
den, um eine Immunantwort zu stimulieren, wurden zunächst in vitro auf Antigen-
präsentierenden dendritischen Zellen (DCs), CD4+ und CD8+ T-Zellen getestet.
Diese funktionalisierten Nanopartikel riefen im Vergleich zu den Kontrollgruppen
eine signifikant höhere Reifung der DCs hervor. Dadurch wurde die Proliferation
von Virus-spezifischen CD4+ und CD8+ T-Zellen effektiv stimuliert. Zusätzlich
zeigten die in vivo-Studien zur Immunisierung von Mäusen gegen Influenza-Virus
und Friend-Virus (ein Retrovirus-Modell), dass die Nanopartikel eine Immunant-
wort aktivieren konnten und dazu beigetragen haben, die Viruslast in infizierten
Mäusen deutlich zu verringern. Die signifikante Verbesserung der Immunantwort
im Vergleich zur Immunisierung nur mit den löslichen immunaktiven Molekülen
wurde nachgewiesen.
Zusammenfassend konnte festgestellt werden, dass dieses auf Calciumphosphat-
Nanopartikeln basierende Trägersystem vielseitige Anwendungsmöglichkeiten für
Bio- und Nanomedizin bieten kann.
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